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SUMMARY 
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in 
the world. The disease spectrum of NAFLD extends from steatosis (types 1,2) to non-
alcoholic steatohepatitis (NASH) with inflammation (types 3,4). The aims of the study 
were 1) to analytically validate high-throughput real time polymerase chain reaction (RT-
PCR) assays for three selected single nucleotide polymorphisms (SNPs), FTO 
rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 
(Pro12Ala, 34 C>G), and 2) to perform genotype-phenotype association studies in 
relation to biochemical abnormalities, disease severity and age of onset.  
A total of 119 patients with fatty liver identified on ultrasound, including 88 histologically 
confirmed NAFLD patients, and 166 control individuals were genotyped for the three 
selected SNPs. RT-PCR validated against direct sequencing as the gold standard was 
used for detection of genetic variation. All three SNPs were in Hardy Weinberg 
equilibrium in the study population, except for a deviation in genotype distribution 
detected for PPARγ rs1801282 in the NAFLD patient subgroup (p<0.001). After 
adjustment for age and gender, the risk-associated FTO rs9939609 A-allele was 
detected at a significantly higher frequency in the Caucasian compared with Coloured 
patients (p=0.005). The opposite was detected for the risk-associated TNF-α rs1800629 
A-allele, which occurred at a significantly higher frequency in the Coloured compared 
with Caucasian NAFLD patients (p=0.034).  
The onset of fatty liver disease symptoms was on average 5 years younger in the 
presence of each risk-associated TNF-α rs1800629 A-allele (p=0.028). When considered 
in the context of an inferred genotype risk score ranging from 0-6, disease onset 
occurred on average 3 years earlier (p=0.008) in the presence of each risk-associated 
FTO A-allele, TNF-α A-allele or PPARγ C-allele. After adjustment for age, gender and 
race, no differences in genotype distribution or allele frequencies were observed 
between histologically confirmed NAFLD (types 1,2) and NASH (types 3,4) patients, 
while the minor allele frequency for the TNF-α rs1800629 was significantly higher in the 
total NAFLD (types 1-4) (p=0.047) as well as NASH subgroup (NAFLD types 3,4) 
(p=0.030) compared with obese patients without a histologically confirmed NAFLD 
diagnosis. A significant correlation was furthermore observed between the number of 
TNF-α rs1800629 A-alleles and increasing CRP levels (p=0.029), with a favourable 
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reduced effect  in the presence of low- to moderate alcohol intake. The average waist 
circumference of physically active NAFLD patients was 12% lower than in physically 
inactive patients (p=0.004).  
In view of the results presented in this study, the inclusion of the selected SNPs, and in 
particular the pro-inflammatory TNF-α rs1800629 polymorphism, may be considered as 
part of a comprehensive cardiovascular risk evaluation of NAFLD patients. Ultimately, 
early detection of patients with fatty liver disease symptoms and effective intervention 
based on the underlying disease mechanism may prevent progression from NAFLD to 
NASH, shown to be an independent risk factor for cardiovascular diseases. 
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Opsomming 
Nie-alkoholiese lewervervetting (NALV) is die mees algemene kroniese lewersiekte in 
die wêreld. Die siektespektrum van NALV strek van steatose (vervette lewer tipes 1,2) 
tot steatohepatitis met inflammasie (NASH tipes 3,4). Die doel van die studie was 1) om 
analities die hoë omset polimerase kettingreaksie (RT-PKR) metode te valideer vir die 
geselekteerde enkel nukleotied polimorfismes (ENPs) FTO rs9939609 (intron 1 T>A), 
TNF-α rs1800629 (-308 G>A) en PPARγ rs1801282 (Pro12Ala, 34 C>G), en 2) om 
genotipe-fenotipe assosiasie studies uit te voer ten opsigte van relevante biochemiese 
abnormaliteite, graad van die siekte en aanvangsouderdom. 
’n Totaal van 119 pasiënte met vervette lewers is geïdentifiseer met behulp van 
ultraklank, insluited 88 histologies-bevestigde NALV pasiënte, en 166 kontrole individue. 
Hierdie pasiënte is gegenotipeer vir die 3 geselekteerde ENP’s. RT-PKR gevalideer met 
direkte DNA volgorde bepaling as die goue standaard, is gebruik vir opsporing van 
genetiese variasie. Al die ENP’s was in Hardy Weinberg ekwilibrium in die studie 
populasie, behalwe vir ’n afwyking in genotipe verspreiding waargeneem vir PPARγ in 
die NALV subgroep (p<0.001). Nadat aanpassings gemaak is vir ouderdom en geslag, is 
die risiko-geassosieerde FTO rs9939609 A-alleel waargeneem teen ’n betekenisvol hoër 
frekwensie in die Kaukasiese pasiënte in vergelyking met Kleurling pasiënte (p=0.005). 
Die teenoorgestelde is waargeneem vir die risiko-geassosieerde TNF-α rs1800629 A-
alleel wat voorgekom het teen ’n betekenisvol hoër frekwensie in die Kleurling NALV 
pasiënte, in vergelyking met Kaukasiese NALV pasiënte (p=0.034). 
Die aanvang van NALV was gemiddeld 5 jaar vroeër in die teenwoordigheid van elke 
risiko-geassosieerde TNF-α rs1800629 A-alleel (p=0.028). Met inagneming van ’n 
genotipe risiko telling tussen 0–6, het aanvang van siekte gemiddeld 3 jaar vroeër 
voorgekom (p=0.008) in die teenwoordigheid van elke toenemende risiko-geassosieerde 
FTO A-alleel, TNF-α A-alleel en PPARγ C-alleel. Nadat aanpassings gemaak is vir 
ouderdom, geslag en ras, is geen verskille waargeneem in genotipe verspreiding of 
alleel frekwensies tussen histologies bevestigde NALV (tipes 1,2) en NASH (tipes 3,4) 
pasiënte nie, terwyl die minor alleel telling vir die TNF-α rs1800629 betekenisvol hoër 
was in die totale NALV (tipes 1–4) (p=0.047) asook die NASH subgroep (NALV tipes 
3,4) (p=0.03) in vergelyking met vetsugtige pasiënte sonder ’n histologies bevestigde 
diagnose. ‘n Statisties beteknisvolle korrelasie is verder waargeneem tussen die aantal 
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TNF-α rs1800629 A-allele en toenemende CRP vlakke (p=0.029), met n gunstige 
verlaagde effek in die teenwoordigheid van lae alcohol gebruik. Die gemiddelde 
middellyf-omtrek van fisies aktiewe NALV pasiënte was 12% minder as fisies onaktiewe 
pasiente (p=0.004).  
Na aanleiding van die resultate van hierdie studie behoort insluiting van geselekteerde 
ENP’s, en in besonder die pro-inflammatoriese TNF-α rs1800629 polimorfisme, as deel 
van ’n omvattende kardiovaskulere risiko evaluasie oorweeg te word. Aan die einde van 
die dag mag vroeë identifikasie van NALV pasiente en effektieve intervensie gebasseer 
op die onderliggende siekte meganisme, vordering tot NASH verhoed wat getoon is om 
’n onafhanklike risiko faktor vir kardiovaskulêre siekte te wees. 
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1.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a clinical histo-pathological disease with 
histological features that resemble alcohol-induced liver disease, but manifests when fat 
is deposited (steatosis) in the liver without excessive alcohol consumption. The 
histological spectrum of NAFLD ranges from fat that accumulates in hepatocytes without 
inflammation (hepatic steatosis) or severe fibrosis to complex hepatic steatosis, with 
concomitant inflammation (steatohepatitis). 
NAFLD is well known to progress to serious liver related cardiovascular diseases 
(carotid artery wall thickening, vasodilation), especially in type 2 diabetic individuals 
(Targher et al. 2007; Neuschwander-Tetri et al. 2003). Obesity, diabetes and insulin 
resistance (IR) are the main contributing risk factors for more advanced forms of liver 
diseases. According to Marchesini et al. (2003) 70-80% of individuals with NAFLD have 
insulin resistance, obesity and/or diabetes as confirmed by Ratziu et al. (2010). 
NAFLD is the most common cause of liver disease in westernised countries, affecting 
almost 33% of the general population and up to 75% of specific sub-groups such as 
obese individuals. The clinical significance of NAFLD is emphasised by the fact that a 
considerable proportion of patients (20%-30%) progress to non-alcoholic steatohepatitis 
NASH (Petta et al. 2009). The pathogenesis of NAFLD has not been fully elucidated, as 
many risk factors contribute to the development or predisposition of NAFLD. The most 
extensively supported theory implicates insulin resistance (IR) as the key biological 
mechanism involved in the development of hepatic steatosis.  
Other risk factors contributing to the pathogenesis of NAFLD are the metabolic 
syndrome (visceral obesity, hypertension, dyslipidaemia and elevated plasma glucose 
concentration), oxidative stress, cell injury, cytokines/adipokines, fibrogenesis, hepatic 
iron accumulation, environmental carcinogens and a genetic predisposition.  
The clinical characteristics of NAFLD have recently been described for the first time in 
the South African population (Kruger et al. 2010). The study population included 111 
patients with liver biopsy-confirmed NAFLD stage 1 and 2, of which 37% had NASH and 
17% advanced fibrosis (stage 3 and 4). Insulin resistance was identified as a universal 
factor in these NAFLD patients studied in the Western Cape area of South Africa. 
Patients with NASH showed significantly higher mean serum cholesterol and triglyceride 
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levels compared with those with fatty liver only. The aspartate aminotransferase to 
platelet ratio index (APRI) was furthermore found to be significantly increased in NAFLD 
patients with advanced fibrosis compared to those with no/mild fibrosis (Kruger et al. 
2011). Use of APRI in a new algorithm for detection of advanced fibrosis was therefore 
proposed, to ultimately replace invasive histopathologic diagnosis based on liver biopsy. 
Recently, a significant increase in alanine transaminase (ALT) levels was detected in a 
subgroup of South African patients with NASH who tested positive for the iron-related 
H63D (Histidine position 63 ) and C282Y (Cysteine position 282 ) mutations in the High 
Iron Fe haemochromatosis (HFE) gene (Fisher, 2011). This finding raised the possibility 
that assessment of APRI in conjunction with clinically useful genetic risk factors may 
facilitate the prevention of cumulative risk in NAFLD patients. Deleterious mutations in 
the HFE gene are associated with alterations in inflammatory responses, oxidative 
stress, impairment of glucose metabolism and in its most severe form and loss of iron 
homeostasis, the preventable genetic disorder hereditary haemochromatosis (HH). 
Since the implementation of a routine diagnostic service for HH more than 10 years ago, 
the use of genetic testing in conjunction with serum iron studies have largely replaced 
the need for liver biopsies to diagnose HH in the local population (Kotze et al. 2004, 
2009). HFE genotyping combined with measurement of ferritin, glucose and serum iron 
studies also facilitates discrimination between NAFLD and HH, which is complicated in 
the presence of diabetes shown to be an independent risk factor for development of 
hepatic fibrosis in HH patients (Wood et al. 2012). Effective management of type II 
diabetes, found to be directly related to alterations in iron status, inflammation and 
oxidative stress in patients with HH or NAFLD, is important to reduce the risk of liver 
injury and fibrosis in both conditions. Increased iron load associated with the -308 TNF-α 
variant warrants further studies to determine possible interaction with the HFE gene 
(Fargion et al. 2001a; Krayenbuehl et al. 2006) in relation to insulin resistance and 
inflammation in patients with NASH. 
The close association between the prevalence of insulin resistance and the occurrence 
of steatohepatitis in NAFLD patients may have a genetic basis (Tilg and Moschen, 
2011). Aller et al. (2010) reported that more than 80% of NAFLD patients with a 
functional single nucleotide polymorphism (SNP) at nucleotide position -308 in the 
promoter region of the tumour necrosis factor-alpha (TNF-α) gene exhibit inflammatory 
liver disease (NASH), whereas in the not detected (wild-type) group only 19.7% of 
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patients developed NASH. Weight-reduction can be considered an effective anti-
inflammatory strategy since a marked reduction of TNF-α expression in hepatic and 
adipose tissue were observed after extensive weight loss (Moschen et al. 2010).This 
could be the first step of implementing an intervention strategy based on the detection of 
clinically useful polymorphisms in the TNF-α gene associated with the development of 
NASH or other typical NASH associated factors, such as insulin resistance. mRNA 
expression levels of the TNF-α gene was found to correlate significantly with the 
presence of NASH in South African NAFLD patients (Kruger, 2008), which support the 
role of TNF-α in the disease process.  
Insulin resistance and type 2 diabetes develop when there is an imbalance between 
conditions promoting excessive fatty acid synthesis (e.g. dietary, genetic, hormonal, and 
exercise) combined with deficient fatty acid oxidation (Wood, 2004). Peroxisome 
proliferator-activated receptor  (PPAR), an important transcription factor, is a critical 
regulator of adipogenesis, insulin sensitivity and lipid metabolism (Yen et al. 1997; 
Gurnell et al. 2003). The missense mutation at codon 12 of the PPAR gene results in a 
reduction of PPARγ activity. This risk associated allele occurs at a high frequency (~85% 
in Caucasians) in the general population with a modest effect translating into a large 
population-attributable risk (Lohmueller et al. 2003). PPARγ is the molecular target for 
insulin sensitizing agents like the thiazolidinedione’s, a class of anti-diabetic drugs 
improving insulin sensitivity (Gawrieh et al. 2012). In a meta-analysis study of more than 
3000 individuals, Altshuler et al. (2000) concluded that the proline variant increases the 
risk of diabetes 1.25 fold and accounts for to the development of type 2 diabetes in up to 
25% of the general population. The interaction between the PPARγ variant and smoking 
indicated that both factors exhibited a synergistic effect on the development of NAFLD 
(Yang et al. 2012). The interaction between these two independent risk factors 
underlines the importance of genetic and environmental factors contributing to the 
development and progression of NAFLD (Day, 2006). 
Enhanced oxidative stress is associated with reactive oxygenated species (ROS) 
induced lipid peroxidation causing liver cell necrosis, apoptosis and immunological 
dysfunction that could progress to hepatic fibrogenesis (Byrne, 2010). Voluminous fatty 
acids and not enough fatty acid oxidation seem to be critical to the development of 
insulin resistance and eventually type 2 diabetes. There is also broad agreement that 
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long-chain -3 fatty acids in the diet are highly beneficial, by opposing the actions of 
insulin through various mechanisms that may directly suppress fatty acid synthesis and 
promote fatty acid oxidation (Clarke, 2001). Genetic variation involved in fatty acid 
metabolism (PPAR gene) and inflammation (TNF- gene) are important in this context. 
Information on gene-gene and gene-environment interactions is needed in a 
translational context to understand the health impact and implications of SNPs in 
metabolic associated disorders such as NAFLD.  
The common form of obesity is a multifactorial trait thought to develop from an intricate 
interplay of genetic and environmental factors. Therefore, the occurrence of gene-gene 
and gene-environment interactions make it difficult to clearly elucidate the role of specific 
genetic variants in obesity related risk (Marti et al. 2004). Genome wide association 
study’s (GWAS) for type 2 diabetes susceptibility discovered the fat mass and obesity-
associated gene (FTO) (Frayling et al. 2007). Simultaneously other research studies 
reported that the FTO gene was strongly associated with obesity related traits (Dina et 
al. 2007; Scuteri et al. 2007). FTO is highly expressed in the hypothalamus, a region in 
the brain involved in the regulation of energy homeostasis. FTO risk variants appear to 
promote the development of obesity by increasing energy intake through its influence on 
appetite-regulating regions of the hypothalamus. Variation in the FTO gene (intron 1) is 
associated with obesity in both children and adults.  
To the best of our knowledge FTO variation in individuals with NAFLD has never been 
genotyped before. Since obesity and type 2 diabetes are key contributors to the 
metabolic syndrome and possible parallel risk factors for the development of more 
advanced forms of liver disease, it is highly likely that genetic variation in FTO could be 
associated with the risk of developing NASH.  
The underlying mechanism and pathogenesis of NAFLD remains elusive. At present, 
treatment is focused on managing underlying metabolic risk factors as there is no 
pharmacotherapy available for effective treatment of this condition. Lifestyle intervention 
to achieve weight loss and increase exercise is persistently associated with improved 
liver histology (Cheung and Sanyal, 2009). Family members of children with NAFLD are 
considered at high risk for NAFLD. Data provided by Schwimmer et al. (2009) suggest 
that familial factors are a major determinant for the development of NAFLD. Risk factors 
vary between populations depending on modifier genes and lifestyle related exposures. 
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The influence of low-to-moderate alcohol consumption in patients with NAFLD remains a 
controversial subject. In a study performed by Cotrim et al. (2009), 132 patients 
undergoing liver biopsy during bariatric surgery were divided into three groups: 1) 
alcohol intake greater than 20 g/day and less than 40 g/day; 2) alcohol intake less than 
20 g/day, and 3) no alcohol intake. The presence of insulin resistance was similar in the 
groups with moderate and no alcohol consumption (81.3 and 78.7%) but significantly 
less in the light consumption group (54%, P<0.05). According to Dunn et al. (2012) 
moderate alcohol consumption is associated with a decreased prevalence of 
steatohepatitis and a reduced risk of coronary heart disease (CHD) mortality with 
metabolic related risk factors in patients with NAFLD. Addressing the challenge of 
understanding the underlying mechanisms or disease processes provides an opportunity 
to translate new genetic knowledge into therapeutic intervention strategies. 
Therefore examining the complex relations between genes and environment in the 
development and progression of NAFLD will give us a better understanding of potentially 
modifiable risk factors underlying the disease phenotype. Figure 1 shows the histological 
spectrum of NAFLD ranging from fat that accumulates in hepatocytes without 
inflammation (hepatic steatosis) or the development of complex hepatic steatosis to 
severe fibrosis (scarring), with concomitant inflammation (steatohepatitis). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Histological changes/stages of liver disease  
Fatty/Non-fatty Liver Disease 
Fat 
Normal Steatosis 
Steatohepatitis Cirrhosis 
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A central feature in the pathogenesis of NAFLD, both histologically and metabolically, 
relate to the accumulation of triacylglycerol in the liver (Donnelly et al. 2005). Plasma 
non-esterified fatty acids that flow to the liver in the fasted state, delivers the bulk of fatty 
acids to the liver. Newly (de novo) synthesised fatty acids (lipogenesis) derived from 
acetyl-co-enzyme A deliver the remaining Free fatty acid (FFA) pool to the liver in the 
form of very low density lipoproteins (VLDLs). Hepatic steatosis is the clinical 
manifestation of excessive triglyceride accumulation in the liver. The overall distribution 
of hepatic steatosis in an urbanized American population revealed that 45% of 
Hispanics, followed by 33% European-Americans and 24% African-Americans 
developed hepatic steatosis (Browning et al. 2004). 
The prevalence of hepatic steatosis in diabetic individuals as reported by Wlliamson et 
al. (2011) was 56.9%. This was considerably lower when compared to a large Italian 
population study of type 2 diabetic patients, in which 85.3% of patients presented hepatic 
steatosis (Targher et al. 2007). 
1.2. NAFLD and Insulin Resistance 
Insulin resistance (IR) is a patho-physiological condition, where the naturally produced 
hormone insulin becomes less effective at reducing blood glucose levels. The plasma 
glucose concentration is regulated by numerous hormones, insulin being the most 
important one. When glucose levels are high insulin is released into the blood stream to 
stimulate the following actions: 
• Glucose uptake 
• Inhibition of lipolysis 
• Inhibition of fatty acid oxidation 
• Inhibition of glycogen breakdown 
The opposite apply when glucagon is released. Blood glucose levels rise and fall to meet 
the body’s needs. The liver plays a central role in regulating blood glucose levels. 
Glucose is released by the liver from the breakdown of glycogen or from intermediates of 
carbohydrate, protein and fat metabolism. The liver receives glucose-rich blood from the 
digestive tract by means of the portal vein. Blood glucose levels beyond the normal 
range cause adverse health effects. Risk factors that contribute to insulin resistance are 
grouped as genetic risk factors for example PPARγ mutation, Insulin receptor mutations, 
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physiological factors (age, obesity, hypertension, and hypertriglyceridemia), pathology 
abnormalities (metabolic syndrome, liver pathologies, infections, haemochromatosis, and 
hypercortisolism) and environmental risk factors (diet and lifestyle). Insulin resistance 
plays a key role in the development of hepatic steatosis and potentially steatohepatitis 
(Cullan and Redlich, 1997; Willner et al. 2001; Chitturi et al. 2002; Williamson et al. 
2011).  
NASH is more prevalent in patients with metabolic disorders as opposed to other 
associations such as drug toxicity, lipodystrophy and inherited disorders (Chitturi et al. 
2001). Peripheral insulin resistance is frequently observed in obese and type 2 diabetic 
patients with NAFLD, however it also has been reported in patients with NASH who are 
not obese or diabetic (Marchesini et al. 2001; Kim et al. 2004).  
Insulin resistance is a significant predictor of NAFLD and metabolic associated disorders 
(hypertriglyceridemia and hyperuricemia). Regardless of the strong association, not all 
patients with NASH exhibit insulin resistance. This suggests that NASH could be a 
heterogeneous disorder with more than one attributed cause. The genetic origin for 
insulin resistance associated with NASH remains elusive.  
Excessive abdominal fat accumulation both visceral and intrahepatic correlates with 
abnormalities in glucose and lipid metabolism. FFA levels and intrahepatic fat are 
associated with hepatic IR (Gastaldelli et al. 2007). The inability of insulin in non-diabetic 
NAFLD patients to suppress endogenous glucose production was demonstrated by 
Seppala-lindroos et al. (2002). This study revealed that the amount of insulin required for 
normalized glycaemic control correlated with liver fat content in NAFLD patients 
(Bugianesi et al. 2005; Kelley et al. 2003; Seppala-lindroos et al. 2002).  
Alterations in the transcriptional activity of the transcription factor peroxisome 
proliferator-activated receptor gamma co-activator 1α (PPARγ-1α) showed a strong 
association with the insulin resistance phenotype and the manifestation of NAFLD 
(Sookoian et al. 2010). A study conducted by Carulli et al. (2009) revealed that 
interleukin 6 (IL-6) polymorphisms could be used as markers for insulin resistance and 
inflammation. Despite recent advances in the understanding of metabolic and 
inflammatory pathways the complex interplay between genetic and environmental factors 
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involved in NAFLD is not yet fully understood. A study by Petersen et al. (2010) found 
that APOC3 (apolipoprotein class III) were associated with NAFLD and IR.  
Treating NAFLD patients with rosiglitazone improved their insulin sensitivity and reduced 
the inflammation rate (Ryan et al. 2003). Thiazolidinedione anti-diabetic drug treatment 
significantly improved steatosis and necro-inflammation in patients with NASH and 
insulin resistance (Gastaldelli et al. 2009). Thiazolidinedione’s activate PPARγ by binding 
to its receptor; this causes up-regulation of PPARγ transcription factors that decreases 
IR. This gives emphasis to the beneficial effects of glucose-sensitizing medications in 
NAFLD patients.  
Patients exhibiting NAFLD with glucose intolerance were significantly more insulin 
resistant when compared to glucose intolerant patients without a fatty liver (Kelley et al. 
2003; Facchini et al. 2002). Lipid metabolism is altered by the resistance to the action of 
insulin. This enhances peripheral lipolysis, triglyceride synthesis and hepatic uptake of 
free fatty acids (Sanyal et al. 2001). The accumulation of triglycerides in hepatocytes 
cause a preferential shift from carbohydrates to free fatty acid beta-oxidation, an 
occurrence observed in insulin resistant individuals. This may explain the increased FFA 
levels observed in NAFLD patients with type 2 diabetes as opposed to type 2 diabetics 
without NAFLD (Kelley et al. 2003).   
Undoubted epidemiological, biochemical, and therapeutic evidence support the principle 
that the primary pathophysiological derangement in most patients with NAFLD is the 
molecular pathways leading to insulin resistance at a cellular level. Genetic studies are 
warranted to further investigate the role of gene-environment interactions in this context. 
1.3. NAFLD and the Metabolic Syndrome  
The metabolic syndrome is a constellation of interconnected metabolic risk factors that 
contribute to the co-occurrence of both cardiovascular disease (CVD) and type-2 
diabetes.  Individuals with metabolic syndrome have a 2-3 fold increase risk of 
developing coronary heart disease (CHD; Kurl et al. 2006) with a considerable greater 
risk of developing diabetes (Sattar et al. 2003; Hanley et al. 2005a). Low grade 
inflammation and the occurrence of thrombosis are strongly associated with the 
metabolic syndrome (Grundy et al. 2005).  
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The international diabetes federation (IDF) consensus worldwide definition of the 
metabolic syndrome (Anderson et al, 2001; Bonora et al, 1998; Carr et al. 2004, 
Nakamura et al. 1994) define a person as having this condition when they have central 
obesity (waist circumference ≥ 94 cm for European men and ≥ 80 cm for European 
women, the values differ with respect to other ethnicities) with the addition of any two of 
the following factors: 
 Raised triglyceride levels (≥1.7 mmol/L); 
 Reduced high density lipoprotein (HDL) cholesterol levels (<1.03 mmo/L in males 
and <1.29 mmol/L in females); 
 Hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood 
pressure ≥ 85 mmHg; 
 Elevated fasting plasma glucose levels (≥5.6 mmol/L). 
The IDF consensus group has highlighted additional metabolic criteria that appear to be 
related to the metabolic syndrome. This could be included in research studies to 
augment the predictive power of additional factors in CVD and diabetes. The platinum 
standard definition of the IDF consensus group includes the following: 
 Body fat distribution determined by adipose tissue biomarkers: leptin, adiponectin 
and Liver fat content; 
 Atherogenic dyslipidemia determined by apolipoprotein B and small Low-density 
lipoprotein particles; 
 Dysglycaemia determined by the oral glucose tolerant test (OGTT); 
 Insulin resistance determined by fasting/pro-insulin, homeostasis model 
assessment HOMA-IR, insulin resistance by Berman minimal model, elevated 
free fatty acids; 
 Vascular dysregulation (endothelial dysfunction and/or microalbuminuria); 
 Pro-inflammatory state (elevated C-reactive protein, increased inflammatory 
cytokines; (eg.TNF-α) and decrease in adiponectin plasma levels); 
 Prothrombotic state (fibrinolytic factors and/or clotting factors); 
 Hormonal factors (pituitary-adrenal axis). 
The pathogenesis of the metabolic syndrome with each of its components is complex 
and not fully understood; however central obesity and insulin resistance are the major 
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causative factors of the disease. NAFLD is considered the hepatic manifestation of the 
metabolic syndrome (Wild et al. 2004; Dunstan et al. 2002). 
In a study done by Marchesini et al. (2003) the prevalence of metabolic syndrome 
increased dramatically from 18% in normal-weight individuals to 67% in obese subjects 
as assessed by body mass index (BMI). Insulin resistance as assessed by the HOMA-IR 
model was significantly associated with metabolic syndrome (odds ratio 2.5, CI 95% and 
P<0.001 significance). The metabolic syndrome was significantly more prevalent in 
patients with NASH (88%) compared to those with a fatty liver alone (53%). Logistic 
regression analysis demonstrated that the presence of metabolic syndrome imposed a 
high risk of NASH development among NAFLD subjects (odds ratio 3.2, CI 95% and 
P<0.03 significance) (Marchesini et al. 2003).  
The frequency of obesity as a component of the metabolic syndrome in patients with 
NASH has been reported in about 69% to 100% of patients (Bacon et al. 1994; Pinto et 
al. 1996; Sattar et al. 2003; Seppa-Lindroos et al. 2002; Targer et al. 2007). In addition 
the frequency of type 2 diabetes mellitus as a complication of obesity has been reported 
in 34% to 75% of patients with NASH (Hamaguchi et al. 2005; Mulcahy, 2003; Ong et al. 
2005; Pinto et al. 1996). Insulin resistance unifies NAFLD and the metabolic syndrome 
by the clustering of metabolic related risk factors and alterations observed in insulin 
resistant pathways concomitant with metabolic syndrome. This may provide the 
molecular and biochemical basis for the link with NAFLD and insulin resistance. Insulin 
resistance contributes to steatosis by enhancing free fatty acid efflux from adipose tissue 
to the liver causing abnormalities of lipid storage (Lewis et al. 2002). Lipid peroxidation in 
insulin resistance subjects may activate inflammatory cytokines, promoting the 
progression of steatosis to nonalcoholic steatohepatitis translating into liver fibrosis 
(Angelico et al. 2005). 
1.3.1. Clinical diagnosis of NAFLD 
Most patients exhibiting NAFLD are asymptomatic; however right upper abdominal 
discomfort and fatigue urge patients to seek medical attention (Bacon et al. 1994). The 
most common presentation of NAFLD is elevated liver enzymes (aminotransferases) 
detected by routine laboratory screening methods while serum ferritin is an independent 
predictor of histological severe fibrosis in patients with NAFLD (Kowdley et al. 2012). 
Liver markers that present as a consequence of liver injury are aspartate-
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aminotransferases (AST) and alanine-aminotransferase (ALT) (Mulhall et al. 2002). It is 
important to note that normal serum aminotransferases values do not exclude the 
presence of abnormal liver histological features as illustrated by Mofrad et al. (2003). 
Other laboratory tests include cholestatic enzymes (Alkaline Phosphatases) and gamma 
glutamyl transferase (GGT), cholesterol, triglycerides and determination of insulin 
resistance using the homeostasis model assessment (HOMA) or the quantitative insulin 
sensitivity check index (QUICKI).  
Features of metabolic syndrome with the exclusion of alcohol consumption form part of 
the initial diagnostic process of NAFLD. The definitive diagnosis of NAFLD is through 
liver biopsy, a technique not applicable for large epidemiological studies (Hanley et al. 
2005b). Modern imaging systems that include ultrasound, magnetic resonance imaging, 
computerized tomography and spectroscopy are regularly used as a diagnostic tool to 
screen for NAFLD. However, these techniques can only accurately identify steatosis and 
cirrhosis while fibrosis and necro-inflammation may remain undetected by these 
instruments (Aubè et al. 2007; Friedrich et al. 2010).  
A combination of different screening methods and laboratory tests could be used to 
develop a specific algorithm to identify patients with NAFLD/NASH and to potentially 
avoid the need of liver biopsies for definitive diagnoses. One example is the aspartate 
aminotransferase to platelet ratio index (APRI) that was evaluated and implemented as a 
marker for advanced fibrosis in South African NAFLD/NASH patients to avoid the need 
of liver biopsies (Kruger et al. 2011). 
1.3.2. Genetic testing for NAFLD 
Excessive alcohol consumption may translate into alcoholic liver disease (ALD) in 
parallel with metabolic syndrome related NAFLD; both of which are recognised as the 
most common causes of liver disease worldwide. Since the majority of heavy drinkers 
with concomitant obesity/insulin resistance develop steatosis and only a minority 
progress to develop steatohepatitis, fibrosis and/or cirrhosis, subtle inter-individual 
genetic variation interacting with environmental factors could determine the disease 
phenotype and progression to NAFLD. Upon completion of the human genome project in 
2003 new insights into the role of genetic contributing factors relating to inter-individual 
variability translated into better patient care, with particular focus on the mechanistic 
pathogenesis of complex diseases such as NAFLD (Anstee et al. 2011). Understanding 
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the pathogenesis and genetic modifiers of progressive NAFLD combined with 
biochemical and immunological markers of liver injury could provide a new model to 
approach risk management of NAFLD patients. Kotze et al. (2009) established such an 
approach termed pathology supported genetic testing (PSGT) for incorporation of low-
penetrance functional SNPs that are not sufficient to explain the phenotype into a 
intervention plan for complex diseases such as CVD, HH and NAFLD.  
This approach to risk management requires selection of candidate genes based on both 
disease association and mechanism. Since selection of only a limited number of known 
candidate genes could underscore the potential role of other genes that may influence 
disease susceptibility, it is important to view any genetic findings as one component of 
multiple factors that may contribute to obesity and insulin resistance in NAFLD, as the 
focus of the current study. For this reason functional SNPs in the FTO, TNF-α and 
PPARγ genes were selected for analyses based on existing knowledge reported in the 
scientific literature.  
1.4. Fat mass and obesity associated gene (FTO_MIM ID* 612938) 
The FTO gene was first discovered by Peters et al. (1999) through exon trapping. It is 
widely expressed in a variety of human tissues, including the brain, pancreatic islets and 
the liver. Ubiquitous expression of FTO was found in all human embryo and adult tissues 
examined in a study by Boissel et al. (2009). The molecular mass of the 502 amino acid 
FTO protein is 58 kD. Bioinformatic analysis of FTO showed that FTO shared mutual 
sequence motifs with iron- and 2-oxoglutarate (2OG)-dependent oxygenases, highly 
expressed in the brain. FTO is localised to the nucleus, catalysing 2OG to produce 
succinate, formaldehyde and carbon dioxide, by-products of nucleic acid de-methylation 
(Gerken et al. 2007). FTO mRNA is mostly abundant in the brains of mice, particularly in 
the hypothalamic nuclei, the region that regulates feeding and fasting. This could explain 
the association between variation in the FTO gene and obesity.  
Molecular Genetics  
The T to A base change (rs9939609) in the first intron of the FTO gene is located on 
chromosome 16 q12.2. It causes an increase in gene transcription, especially in the 
region where the sequence is strongly conserved as demonstrated by in vitro primer 
extension studies (Frayling et al. 2007). The fat mass and obesity associated protein 
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coded by the FTO gene is also known as alpha-ketoglutarate-dependent dioxygenase 
FTO. The conserved amino acid sequence of the transcribed FTO protein is highly 
homologous with AlkB (alkylation) an enzyme that oxidatively de-methylates DNA 
(Gerken et al. 2007). Although there is a 50% chance of passing on the faulty gene in a 
family, variation in the FTO gene does not cause obesity in the absence of other genetic 
and environmental factors that may lead to cumulative risk. 
Molecular genetic research led to the identification of numerous obesity and diabetic 
related genes involved in the predisposition of pancreatic B-cell function. FTO is one of 
the most common and extensively studied loci associated with both obesity and type 2 
diabetes. Other genes include [Insulin receptor substrate-1(IRS1), Ectonucleotide 
pyrophosphate/phosphodiesterase-1 (ENPP1) and Gastric inhibitory polypeptide 
receptor (GIPR)] (Meyre, 2012). Genome wide association studies of type 2 diabetes 
confirmed FTO as a diabetes susceptibility locus (Frayling et al. 2007; Scott et al. 2007; 
Zeggini et al. 2007). 
The strong association between the FTO intronic variant (rs9939609) and type 2 
diabetes observed in 3757 type 2 diabetic patients in the UK (OR 1.09-1.23, p= 9 x 10-6) 
was obliterated after the adjustment for BMI (OR 0.96-1.10, p=0.44) (Frayling et al. 
2007). However, more recently Hertel et al. (2011) reported that the association of FTO 
with type 2 diabetes was independent of its effect on BMI. A meta-analysis of 20 686 
non-diabetic individuals prospectively followed for more than 10 years revealed that 3 
153 patients developed type 2 diabetes and that this incident risk was strongly 
associated with the FTO polymorphism (OR 1.10-1.22, p= 3.2 x 10-8). After adjustment of 
age, sex and further adjustment of BMI during the follow up, the association of 
rs9939609 with the incident risk of type 2 diabetes was attenuated. The FTO minor allele 
increases BMI by 0.26 kg/m2 in South Asians and 0.39 kg/m2 in white Europeans. The 
heterogeneity may be due to the fact that BMI (kg/m2) in Asians does not represent the 
same adiposity phenotype as in individuals of European decent (Li et al. 2012). 
Spontaneous cortical activity in lean individuals is increased through insulin; however in 
obese individuals this effect is absent. Cerebrocortical insulin resistance prevents normal 
body weight regulation, because insulin is needed as an adiposity- and satiety signal 
(Tschritter et al. 2007; Shimaoka et al. 2010). The FTO genotypic effect on 
cerebrocortical insulin sensitivity is similar to the effect of increased weight; this implies 
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that variation in FTO contributes to the pathogenesis of obesity. The effect of the risk 
genotype on overall weight, detected in children from age 7 years upwards, has been 
estimated to be approximately increased by 3 kilograms (Freyling et al. 2007).  
The expression of FTO mRNA in pancreatic beta- and alpha cells, liver cells, skeletal 
muscle cells and adipose tissue are modulated by type 2 diabetes status (pathogenesis), 
blood glucose levels, oxidation rate of glucose and treatment with the hypoglycaemic 
drug rosiglitazone (Bravard et al. 2011; Kirkpatrick et al. 2010). A significant increase in 
both FTO mRNA and protein levels were observed in muscle cells of type 2 diabetic 
patients when compared with lean control subjects. This confirms that the 
overexpression of FTO in myotubes and its role in oxidative metabolism, lipogenesis and 
oxidative stress, a constellation of metabolic defects is linked to type 2 diabetes. 
However gene expression studies have demonstrated that FTO expression in human 
islets cells are not associated with BMI (Kirkpatrick et al. 2010). Age may contribute to 
the heterogeneity of the association between FTO and BMI (kg/m2) independent of sex 
(Hardy et al. 2009; Speliotes et al. 2010). 
FTO mRNA is linked to the expression of several other genes involved in 
gluconeogenesis in the liver. TNF, NFKB1 (mRNA in subcutaneous adipose tissue), 
KCNJ11 (mRNA in beta cells); all are involved in glucose regulation. Transcription-
factor-7-like-2 (TCF7L2), a major contributing factor of type 2 diabetes risk, binds to the 
FTO promoter region and may cause overexpression of FTO (Zhou et al. 2012).  
FTO acts as a transcriptional co-activator, enhancing transactivation of 
CCAAT/enhancer binding proteins translating to unmethylated and methylated inhibited 
promoters.  This epigenetic regulatory process was demonstrated by Wu et al. (2010). 
The role of FTO in mechanisms of nucleic acid repair and epigenetic regulation support 
the notion that FTO may be a pleiotropic factor contributing to obesity and type 2 
diabetes (Huang et al. 2011). 
Disease Association  
The FTO A-allele was shown to be significantly associated with higher BMI, higher body 
fat percentage, and higher waist circumference (Dina et al. 2007; Zhou et al. 2012). It 
also positively correlated with other symptoms of the metabolic syndrome, including 
hypertension, higher fasting insulin, glucose, triglycerides and lower HDL-cholesterol 
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levels. The risk of being overweight increased between 1.27 and 1.35 fold with each 
additional risk allele (Frayling et al. 2007). The association with type 2 diabetes has been 
replicated in several populations and its effect is mediated through increased BMI and 
adiposity (Li et al. 2012).  
The occurrence of two copies of the risk-associated A-allele is the strongest common 
genetic predictor of obesity known to date. The A-allele is associated with an 
approximately 30% increase in the risk of developing obesity in the general population 
as a consequence of increased energy intake, especially fat intake, and impaired satiety 
responsiveness (Frayling et al. 2007). The average weight gain by an adult with the A-
allele is 1.2 kg. The T allele is protective against overeating by promoting 
responsiveness to internal signals of satiety. Table 1.1 summarises examples of medical 
conditions associated with genetic variation in the FTO gene. 
Table 1.1. A summary of the disorders that have been associated with FTO gene 
variation 
Associated Disorder References 
Alzheimer’s disease Keller et al. 2011 
Breast and prostate cancer Kaklamani et al. 2011; Lewis et al. 2010 
Cerebrocortical insulin resistance Tschritter et al. 2007 
Endometrial cancer Lurie et al. 2011 
Osteoporosis phenotypes Guo et al. 2011 
Peripheral insulin resistance Shimaoka et al. 2010 
Structural brain atrophy Ho et al. 2010 
Type 2 diabetes Meyre, 2012 
Obesity is related to personality addictive disorders such as alcohol dependence (Barry 
et al. 2009). Low to moderate alcohol consumption may protect obese individuals as well 
as diabetic or cardiovascular patients (O’Keefe et al. 2007). The protective mechanism is 
possibly through the induction of microsomal ethanol-oxidizing systems and both the 
inhibition or secretion of ghrelin, an amino acid produced in the fundus (stomach), 
responsible for food seeking behaviour (Badaoui et al. 2008). Sobczyk-Kopciol et al. 
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(2010) reported an inverse association of the obesity predisposing FTO polymorphism 
(rs9939609) with alcohol consumption and the risk for alcohol dependence.  
Population genetics 
The frequencies of the FTO rs9939609 risk associated A allele for obesity in Western 
and Central Europeans is 46%, in Yorubans 51% and in Chinese individuals 16% (Ho et 
al. 2010). The minor allele (risk allele) frequency of FTO was lower in East-Asians (12-
20%) compared to South-Asians (30-33%). Interestingly, the effect of the variant on 
obesity related risk factors and type 2 diabetes were similar in both groups (Li et al. 
2012). In white Europeans approximately 66% carry at least one risk allele and 18% 
carry both risk alleles. Despite the differences in genetic background, the effect of FTO 
on obesity related traits in East and South Asians were similar to white Europeans.  
Combined effects 
Lifestyle factors modify the genetic risk of obesity associated with variation in the FTO 
gene, particularly in individuals who are both inactive and have a high calorie intake. 
Homozygous individuals (AA) were found to be on average two BMI (kg/m2) units 
heavier compared to physically active homozygous individuals with the same allele 
(Andreasen et al. 2008). In a study by Speakmen et al. (2008) adults with the AT and AA 
genotypes were found to consume between 500 and 1250 kilo Joules (kJ) more each 
day than those carrying the protective TT genotype (equivalent to between 125 and 280 
kilo calories (kC) per day more intake). Results from several studies have shown that 
high physical activity could reduce the effect of FTO on the risk of obesity. A long term 
intervention diet study revealed that a diet rich in monosaturated and polyunsaturated fat 
(Mediterranean diet) especially in AA genotype subjects reduced body weight. This 
supports the notion of a conventional low-fat diet being beneficial for the A allele carriers 
Razquin et al. 2010). In a similar manner, diets with different macronutrient composition 
(i.e. fat, carbohydrate, and protein) and fibre content could also influence appetite and 
satiety and thereby influence the risk. Weight reduction is associated with improved 
plasma glucose and insulin levels in diabetic patients (Shai et al. 2008).  
An interaction between FTO and the apolipoprotein E (ApoE) gene known to be strongly 
associated with Alzheimer’s disease was reported by Keller et al. (2011). Those 
individuals who test positive for both the FTO AA genotype and the E4 allele of the ApoE 
gene had the highest risk for development of Alzheimer’s disease. The finding that the 
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FTO AA-genotype increases the risk of dementia in particular Alzheimer’s disease, 
independently of physical activity, BMI, diabetes and CVD is in line with its association 
with reduced brain volume and impaired verbal fluency in cognitively healthy individuals 
(Benedict et al. 2011; Ho et al. 2010).  
Common SNPs such as FTO are influenced by other parameters including lifestyle 
choices, gender and ethnicity. Their combined effects play an important role in fat 
deposition, obesity prevalence and incidence. The FTO risk allele could be a predictive 
factor for the development of obesity and subsequently type 2 diabetes, and these risk 
factors combined may also contribute to the pathogenesis of NAFLD. To our knowledge 
the FTO rs9939609, intron 1 T>A has not been studied in a South African population and 
have not been investigated in patients with NAFLD.  
1.5. Tumour necrosis factor alpha (TNF-α_MIM ID*191160) 
Tumor necrosis factor alpha (TNF-α), a multifunctional pro-inflammatory cytokine 
secreted mainly by macrophages, plays a key role in immune function. Its effect on 
inflammation, apoptotic cell death, cellular proliferation, tumorgenesis, lipid metabolism, 
coagulation, insulin resistance and endothelial function makes it one of the most 
extensively studied genes to date. 
TNF was originally identified in Mus musculus serum after a Mycobacterium bovis strain 
injection (Pennica et al. 1984; Shirai et al 1985.) It is also known as cachexin and was 
firstly recognised for its ability to lyse tumors. The biologically active form of TNF-α binds 
to either tumor necrosis factor receptor 1 (TNFR1) or tumor necrosis factor receptor 2 
(TNFR2) initiating the immune response (Zhang, 2004). 
Molecular genetics 
The TNF gene maps to chromosome 6p21.3 and contains 4 exons which span 3 
kilobases. The last exon codes for more than 80% of the functional protein. TNF is 
mainly produced as a 212-amino acid transmembrane protein arranged in stable 
homotrimers (Tang et al. 1996). Proteolytic cleavage by the metalloprotease TNF alpha 
converting enzyme yields the soluble form of the homotrimeric cytokine (Black et al. 
1997). The region spanning the TNF cluster in the human major histocompatibility 
complex has been implicated in the susceptibility to numerous diseases, including 
diabetes (Stechova et al. 2012). The nucleotide change (mutation) of guanine to adenine 
Stellenbosch University http://scholar.sun.ac.za
Chapter I 
Review of Literature 
 
19 
 
at position -308, also known as rs1800629 at the TNF-α promoter region forms the three 
common genotypes: not detected (GG), heterozygous (GA) and homozygotes (AA).  
TNF is employed against a variety of pathogens (defence against infection), each 
relating to a specific pattern of risk or benefit. This could favour the diversity of genetic 
and environmental elements controlling or influencing TNF production. The relationship 
between genetic variation of TNF-α and anthropometric variables associated with insulin 
resistance and diabetes were demonstrated as early as 1999 by Zinman et al. (1999).  
TNF-α is an important cytokine regulating factor in insulin pathways, stimulating the 
release of free fatty acids from adipocytes. Several studies have implicated TNF-α gene 
variation, in the development of NASH. The levels of TNF-α was reported higher in 
steatohepatitis subjects when compared to healthy controls. Functional SNPs are 
associated with an increased risk of genetic susceptibility to NAFLD. A frequency of 0.31 
was reported in carriers of the -238 TNF-α polymorphism compared to 0.15 in the control 
group. Patients positive for both the -238 and -308 TNF-α polymorphisms exhibited 
higher insulin resistance, a higher prevalence of impaired glucose tolerance, and a lower 
number of associated risk factors for steatosis (Wang et al. 2011).  
The synthesis of pro-inflammatory cytokines such as TNF-α is an early and important 
marker of liver injury, triggering the production of many immune-modulatory cytokines 
resulting in the recruitment of inflammatory cells to initiate fibrogenesis. The depletion of 
critical important cytokines impairs the liver’s ability to regenerate itself, emphasizing the 
importance of cytokines in liver regeneration (Cressman et al. 1996). 
Chronic low grade inflammation has been implicated in both obese and diabetic patients. 
Enhanced TNF-α expression observed in adipose tissue of obese individuals reduced 
synergistically with weight loss (Tilg and Moschen, 2010). Fatty acids and TNF-α 
molecules stimulate the inhibitory phosphorylation of serine in the insulin receptor. This 
demonstrated the role of TNF-α in the pathogenesis of diabetes and/ or obesity. TNF-α 
antibody administration is beneficial in metabolic inflammation and has been 
demonstrated to improve steatosis (Barbuio et al. 2007). TNF-α expression in 
NASH/NAFLD patients significantly correlated with the degree of fibrosis (Manco et al. 
2007; Wong et al. 2006). Ligands of the peroxisome proliferator receptor gamma 
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(PPARγ), pioglitazone, are able to suppress TNF-α function which positively affect fatty 
liver disease (Musso et al. 2012).  
It is clear from the aforementioned that NAFLD/NASH has a heritable component, 
emphasizing that genetic components may predispose individuals to these traits. NAFLD 
is a syndrome overlapping with obesity related traits and insulin resistance; it seems 
likely that treating or managing these diseases could influence the genetic aspect of the 
syndrome.  
Disease association 
Overproduction of TNF-alpha has been associated with a variety of human diseases, 
including obesity, insulin resistance, hypertension, osteoporosis and cancer. The risk of 
acute kidney allograft rejection was 2.5 times higher among the A-allele carriers 
compared to the GG carriers in patients having transplant surgery (Pawlik et al. 2005). A 
meta-analysis of 2500 participants indicated that carriers of the A-allele were 1.46 times 
higher at risk of developing asthma compared to individuals without the risk allele (Aoki 
et al. 2006). The association between rs1800629 and the risk of chronic obstructive 
pulmonary disease was statistically significant in the Asian population (Zhang et al. 
2011). It was proposed that TNF-α could be a modifying gene for diabetes; especially in 
type 2 diabetic patients from families with a history of both type 1 and type 2 diabetes. 
The -308 G>A TNF-α variant was associated with an insulin deficient phenotype in type 
2 diabetic patients (Li et al. 2003).  
Circulating TNF-α molecules derived from adipose tissue induces the activation of serine 
kinases, which stimulates the transcription of inflammatory genes. These genes 
transcribe for an inflammatory protein within tissues, including the liver and muscles, 
enhancing inflammation and insulin resistance (Kelly et al. 2011).  
The significance of the TNF-alpha -308 A-allele in metabolic syndrome was 
demonstrated in a meta-analysis, indicating a 23% increased risk of developing obesity 
compared with controls as well as significantly higher systolic arterial blood pressure and 
plasma insulin levels (Sookoian et al. 2005). TNF promotes the inflammatory response, 
which in turn causes many of the clinical problems associated with autoimmune 
disorders commonly treated by using TNF inhibitors (e.g. infliximab/Remicade, 
adalimumab/Humira, etanercept/Enbrel) (Serio, 2003; Utz et al. 2003). Relevant 
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autoimmune disorders include rheumatoid arthritis (Guis et al. 2007), ankylosing 
spondylitis (Zhu and Yang, 2008), Crohn's disease (Han et al. 2010), psoriasis (Li et al. 
2007) and refractory asthma (Aoki et al. 2006). Furthermore depressive symptoms 
improved in individuals with major depression when TNF-α levels were reduced (Cerri et 
al. 2010). According to Tilg and Moschen, (2011) more than 80% of individuals with the 
heterozygous rs1800629 TNF-α genotype (GA) exhibited inflammatory liver disease 
(NASH), compared to only 19.7% without the risk associated A-allele. The GA genotype 
group demonstrated more liver fibrosis, elevated TNF-α serum levels and a higher rate 
of insulin resistance, leading to the conclusion that variation of TNF-α may predispose 
individuals to develop NASH. Table 1.2 summarises examples of medical conditions 
associated with genetic variation in the TNF-α gene. 
Table 1.2. A summary of disorders that have been associated with TNF-α gene variation 
Associated disorder Reference 
Allograft rejection Pawlik et al. 2005 
Asthma Aoki et al. 2006 
Ankylosing spondylitis Zhu and Yang, 2008 
Chronic obstructive pulmonary disease Zhang et al. 2011 
Crohn’s disease Ferreira et al. 2005; Han et al. 2010 
Graves’ disease Li et al. 2008 
Heart disease Antonicelli et al. 2005 
Hepatocellular carcinoma Jeng et al. 2007 
Leprosy Vejbaesya et al. 2007 
Lymphoma Bel et al. 2007 
Major depression Cerri et al. 2010 
Non-alcoholic steatohepatitis Tilg and Moschen, 2011 
Psoriasis  Li et al. 2007 
Rheumatoid arthritis Guis et al. 2007 
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Population genetics 
The frequency of the -308 TNFα (G>A) SNP varies between different ethnic groups. For 
instance, the minor allele frequency in Chinese individuals is 9%, French and 
Scandinavian 16%, Germans 18% and up to 24% in Australians (Feng et al. 2011). The 
overall frequency of the -308 polymorphism in a NAFLD population group studied by 
Wang et al. (2012) was 14.2% and in the control group 15.6%. The genotype distribution 
of the TNF-α -308 polymorphism in 244 South African women with cervical cancer was 
71% (GG), 26% (GA) and 3% (AA) respectively (Govan et al. 2006). A study conducted 
by Stanczuk et al. (2003) in Zimbabwe reported that 72% (GG) of cervical cancer 
patients tested negative for TNF-α -308, 27% (GA) were heterozygous and 1% 
homozygous (AA) for the risk-associated allele . 
Combined effects 
Macrophages infiltrating adipose tissue, promote the production of cytokines such as 
TNF-α, interleukin 6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1). These 
cytokines contribute to the development of inflammation-induced insulin resistance and 
eventually type 2 diabetes (Gonzalez et al. 2005; Heilbronn and Campbell, 2008). 
Exercise improves both insulin sensitivity and inflammation status in obese individuals 
compared with lean individuals (Kelly et al. 2011). The combined advantage of 
managing both dietary carbohydrate intake (Low-glycaemic index food) and lifestyle 
factors (exercise) were demonstrated in obese individuals, suggesting potential reversal 
of the effects of obesity on inflammation and insulin resistance. Furthermore, lifestyle 
and diet intervention decreased circulating TNF-α, IL-6 and MCP-1 cytokines, 
collectively controlling hyperglycaemia in patients (Hartman et al. 2010). 
Co-existence of the TNF-alpha -308 G>A and IL-6 -174G>C gene variations (A-C allelic 
combination) is a strong predictor for conversion of insulin resistance to type II diabetes. 
When considered separately, only the TNF-alpha -308 A-allele predicted the progression 
to type II diabetes, but the combined effect is much stronger due to gene-gene 
interaction (Haddy et al. 2005).  
In NASH patients elevated hepatocyte apoptosis significantly correlated with disease 
severity, suggesting that apoptotic cells could be a powerful predictor of NASH (Zhang et 
al. 2010). TNF-α is not only involved in the pathogenesis of NAFLD, it also correlates to 
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other components of metabolic syndrome. Its effect on metabolic syndrome is marked 
through changes in lipid metabolism and insulin levels. TNF-α is a marker of systemic 
inflammation during cardiovascular events and a risk factor of metabolic syndrome which 
forms part of a constellation of risk factors contributing to the pathogenesis of NAFLD in 
South African patients (Kruger, 2008).  
1.6. Peroxisome proliferator nuclear receptor gamma (PPARγ_MIM ID* 601487) 
Peroxisome proliferator nuclear receptors, such as peroxisome proliferator-activated 
receptor gamma (PPARγ), induce the proliferation of peroxisomes. These organelles 
contribute to the oxidation of fatty acids and control the expression of multiple targeted 
genes. PPARs serve as unique lipid sensors, activated by both fatty acids and metabolic 
by-products redirecting the metabolism. Although PPARγ is expressed throughout the 
body it is mainly expressed in liver and adipose tissue where it’s involved in adipocyte 
differentiation (Gouda et al. 2010).  
Molecular genetics 
Somatic cell hybridization and linkage analysis mapped the PPARγ gene to chromosome 
position 3p25. The gene contains 9 exons and spans 100 kb producing 2 protein 
isoforms, PPARG1 and PPARG2 with alternative mRNA splicing of the gene (Fajas et al. 
1997; Greene et al. 1995). The unique ligand binding domain of PPARγ mark its mode 
for receptor interaction that translates into distinct pharmacological properties (e.g. 
Rosiglitazone and Thiazolidinedione anti-diabetic drugs). Modulators of PPARγ are 
selective for PPARγ insulin signalling and adipogenic signalling pathways. The C to G 
missense mutation at nucleotide position 34 of the PPARγ gene results in the 
substitution of an alanine for a proline at amino acid position 12 (CCG-Pro to GCG-Ala). 
The proline variant is associated with a reduction in PPARγ activity and differential lipid 
response to dietary fat intake (Gouda et al. 2010). 
Type 2 diabetes develops after years of increased insulin resistance and eventual loss 
and failure of pancreatic beta-cells. The genetic constitution of an individual may 
determine who is likely to develop insulin resistance and type 2 diabetes or who, 
regardless of their diet or lack of exercise, may be resistant to the development of 
diabetes. PPARγ has been identified as a key factor in this process due to its critical role 
in regulation of adipogenesis, insulin sensitivity and lipid metabolism (Gouda et al. 
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2010). The association between the Pro12Ala variant (rs1801282) and diabetes has 
been a major focus of several meta-analysis studies (Altshulder et al. 2000; Gouda et al. 
2010; Ludovico et al. 2007; Vardarli, 2007). Insulin resistance and type 2 diabetes 
associated with this SNP often co-exist with CVD, obesity, dyslipidaemia, non-alcoholic 
hepatic steatosis and metabolic syndrome. 
Disease association 
PPARγ represents an attractive NAFLD candidate gene, because both hepatic lipid 
metabolism and insulin resistance are contributors to the pathogenic phenomena of 
NAFLD (Gawrieh et al. 2012). Moreover, numerous PPARγ agonists have been used in 
therapeutic intervention trials for individuals with NASH, emphasizing the role of PPARγ 
in liver related diseases (Sanyal et al. 2010).  
A major contributor to end stage renal disease in developed countries is diabetic 
nephropathy and PPARγ has been linked to the risk of developing this condition (Liu et 
al, 2010). Enhanced oxidative stress, especially in hyperglycaemic conditions contributes 
to the development and progression of diabetic nephropathy (Forbes et al. 2008). A 
significant association between carriers of the Pro12 variant and diabetic nephropathy 
were made, with a possible synergistic interaction between smoking and the PPARγ 
Pro12 genotype (Liu et al. 2010). Experimental studies of PPARγ agonists showed a 
beneficial effect of PPARγ variants on ulcerative colitis. The Pro12Ala SNP influences 
PPARγ activity, especially in immunocytes and epithelial cells, as a result of this 
susceptibility to inflammatory bowel disease is altered (Zhang et al. 2012). Another study 
indicated a significant association between the Pro12Ala mutation and Crohn’s disease 
(Aoyagi et al. 2010). Cellular and immune dysfunction in combination with environmental 
factors influence the transcription of PPARγ therefore influencing the epithelial cells 
found in patients with ulcerative colitis. Genetic variation in PPARγ alters the 
susceptibility to hepatic steatosis, lobular inflammation and fibrosis in patients with 
histologically advanced NAFLD (Gawrieh et al. 2012). 
The clinical outcome of patients may be affected by the genetic background of the 
individual. To determine whether low-penetrance mutations like the Pro12Ala could 
predispose to NAFLD all known contributing factors need to be considered in 
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conjunction with clinical co-factors. Table 1.3 summarises examples of medical 
conditions associated with genetic variation in the PPARγ gene.  
Table 1.3. A summary of the disorders that have been associated with PPARγ gene 
variation 
Associated Disorder Reference 
Crohns disease Aoyagi et al. 2010 
Diabetes Gawrieh et al. 2012 
Diabetic nephropathy   Lui et al. 2010 
Non-alcoholic fatty liver disease Gawrieh et al. 2012 
Polycystic ovary syndrome Christopoulos et al. 2010 
Ulcerative colitis Zhang et al. 2012 
 
Combined effects 
As previously mentioned, PPARγ controls the expression of several genes involved in 
adipocyte differentiation, lipid storage and insulin sensitivity. PPARγ is also activated by 
fatty acids, thus the effect of fatty acids on glucose metabolism might be mediated 
through the action of PPARγ and therefore could modify its association with fatty acids 
glucose levels and insulin resistance (Yionen et al. 2008).  
Diets rich in polyunsaturated fatty acids (eicosapentaenoic acid) may up regulate the 
expression of PPARγ to a greater extent compared to diets high in saturated fatty acids, 
thereby mediating an individual's physiological response to lipids. An intervention study 
suggested that fish oil supplementation could affect insulin concentrations and serum 
triacylglycerol levels especially in PPARγ genotypic individuals (Lindi et al. 2003).  
Carriers of the Ala12 variant eating a westernised diet have a lower risk of developing 
insulin resistance and diabetes than Pro/Pro homozygotes on the same diet (Hara et al. 
2002). In the presence of this protective allele, intake of a significantly greater amount of 
polyunsaturated and monounsaturated fats than saturated fats exert a beneficial effect 
on weight loss. The possible mechanisms by which fatty acids beneficially mediate 
Stellenbosch University http://scholar.sun.ac.za
Chapter I 
Review of Literature 
 
26 
 
glucose metabolism include lowering of triacylglycerol, free fatty acids levels and 
intramuscular lipids (Pighin et al. 2003).  
Variation in PPARγ is considered to be an important modifier of insulin resistance in 
Caucasian women with polycystic ovary syndrome (PCOS), a common endocrinopathy 
in women of reproductive age. PCOS is characterized by hyperandrogenism and chronic 
anovulation and is associated with hyperinsulinemia, cardiovascular risk and endothelial 
dysfunction (Chrisopoulos et al. 2010). Insulin sensitizing agents such as the 
thiazolidinediones, an agonist for the PPAR receptors, improved ovarian androgen 
biosynthesis and ovulatory function (Orio et al. 2003). Identification of the Pro12Ala 
polymorphism in women with PCOS is associated with an increased body mass index 
(BMI) and attenuation of insulin resistance. Non-diabetic Pro/Ala heterozygous 
Caucasian patients were found to be more insulin sensitive than Pro/Pro homozygotes 
with PCOS, as evidenced by a lower homeostasis model assessment index and lower 
levels of insulin at both the fasting and 2 hour time points during the oral glucose 
tolerance test (Hara et al. 2002). 
One of the first studies to explore a gene-diet interaction with PPARγ was a study 
conducted by Luan et al. (2001). Data from the study suggested that when the dietary 
polyunsaturated fat to saturated fat ratio is low, the mean BMI in Ala carriers is greater 
than in Pro homozygotes and when the ratio is high the opposite is true. PPARγ ligands 
(fatty acids) might be more effective stimulators of adipogenesis especially in Pro12 
individuals. 
The need to include environmental data when assessing low penetrance mutations such 
as the Pro12Ala SNP was illustrated by Robitaille et al. (2003). They found the PPARγ 
Ala12 variant to be associated with a higher BMI, waist circumference, fat mass and a 
greater accumulation of visceral and sub-cutaneous adipose tissue. However, when 
dietary fat and saturated fat was also taken into account, they found that these dietary 
variables were closely associated with components of the metabolic syndrome in 
Pro/Pro homozygotes, but not in Ala carriers. Pro12 individuals are considered to be 
hyper-responders, and are more sensitive and susceptible to environmental stimuli such 
as fat intake. This observation suggests a protective role in individuals that carry the 
Ala12 allele, emphasizing that not every one responds to a high saturated fat diet in the 
same way (inter-individual variability). The PPARγ polymorphism modulates dietary fat 
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intake and components of metabolic syndrome contributes to the pathogenesis of 
NAFLD. 
Population genetics 
According to Paracchini et al. (2005) the frequency of PPARγ 34 C>G minor allele 
ranged from 2% to 18% in the general population The 12Ala allele frequency in 
Caucasian control samples were 12.7% (median) and in East Asians 4.5% (median) 
(Gouda et al. 2010). It is important to denote the specific transcript variant used with its 
unique reference sequence to analyse and interpret the Pro12Ala results obtained. 
According to NCBI (National Centre for Biotechnology Information) the rs1801282 
(Pro12Ala) variant accounts for an amino acid change at position 12. The protein coding 
missense mutation is situated in an exon (ENSP287820). However, depending on the 
specific transcript uploaded and used from NCBI, the risk variant (Pro12Ala) is situated 
in a synonymous coding region. 
The progressive increase in the prevalence of insulin resistance and its related clinical 
manifestations (type 2 diabetes, obesity etc.) have led to the identification of NAFLD and 
its more severe and progressive subtype, NASH, as an emerging disease involving a 
high percentage of individuals maintaining a western type of lifestyle. Recent studies are 
focused on new molecular mediators that may be implicated in the progression of the 
disease, which may identify new molecular targets that could potentially become the 
object of therapeutic interventions. However, further research needs to identify the 
different pathways that lead to inert disease (simple fatty liver) or to progressive disease 
(NASH) and validating the current evidence to establish the most appropriate 
pharmacological and non-pharmacological therapeutic approach in treating individuals 
with liver related diseases.  
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1.7. Aims and Objectives of this study 
The long-term objective of the study is to develop a pathology supported gene-based 
intervention program for improved clinical management of patients with NAFLD/NASH.  
The specific aims were: 
 Analytical validation of high-throughput real-time polymerase chain reaction (RT-
PCR) assays (for selected SNPs in the FTO, TNF-a and PPARg genes) against 
direct sequencing as the gold standard 
 Comparison of genotype distribution and allele frequencies between NAFLD 
patient subgroups and controls 
 Correlation of clinical and biochemical parameters of insulin resistance with 
genotype and environmental factors assessed in NAFLD patients 
 Determination of the potential impact of risk factors incorporated into a genotype 
risk score on age of onset in fatty liver disease patients in relation to NAFLD 
disease severity 
Ultimately, these findings will be incorporated into a comprehensive genetic screening 
assay for patients at increased risk of metabolic associated disorders (e.g. insulin 
resistance, CVD) and liver disease to be performed in conjunction with a medical and 
lifestyle assessment to facilitate the prevention of cumulative risk. 
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2.1. Study Population 
Study participants were recruited at the Gastroenterology Unit of the Department of 
Internal Medicine, (Tygerberg Academic Hospital University of Stellenbosch) and from 
clinicians working at other academic or private hospitals. Participants who fulfilled the 
criteria for fatty liver disease were grouped as steatosis (fatty liver types 1,2) and 
steatohepatitis with inflammation (NASH types 3,4).  
Inclusion criteria 
 Voluntary written informed consenting NAFLD patients. 
 Histologically and ultrasound confirmed features of NAFLD. 
Exclusion criteria 
 Females with a daily intake of alcohol above 20g and males with a daily alcohol intake 
above 30g. 
 Patients with a secondary attributable cause for fatty liver disease; 
- Nutritional ( rapid weight loss, starvation, intestinal bypass surgery) 
- Drugs (Glucocorticoids, Estrogens etc.) 
- Toxins 
- Metabolic (Weber-Christian disease, Wolman’s disease, Acute fatty liver of 
pregnancy, Reye’s disease) 
 Any other histological or blood results suggestive of liver disease; 
- Increased bilirubin  
- Hypoalbuminemia 
- Elevated liver enzymes  
- Hepatitis  
A questionnaire was used to indicate alcohol consumption and other personal 
information (including lifestyle, medications and dietary elements, family history, and 
clinical characteristics). Liver function tests including ALT and AST were used to 
diagnose underlying liver disease. Insulin resistance was determined for each patient by 
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using the homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) 
(fasting insulin [µU/ml] x [fasting glucose {mmol/l}/22.5]). In addition lipid status was 
assessed by measuring the total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides using standard methods. 
DNA samples of 119 patients with fatty liver on ultrasound, of which 88 had 
histologically-confirmed NAFLD (47 Coloured, 35 Caucasian, 5 Black and 1 Indian), 
were obtained as an extension of the parent study performed by Kruger et al. (2010). For 
the purpose of analytical validation of the SNP assays the 31 patients with fatty liver on 
ultrasound only were grouped with the histologically confirmed patients into the “NAFLD 
group”. For the purpose of genotype-phenotype correlations the 31 patients with fatty 
liver on ultrasound only was excluded from the NAFLD patients (types 1-4) for 
comparative analysis and was grouped as “obese”. Within this group 23 patients were 
Coloured, 6 patients Caucasian and 2 patients Black. Hereafter we refer to the 31 
patients with fatty liver on ultrasound (not histologically confirmed) as the obese patient 
group. Reasons for not confirming fatty liver on histology include insufficient clinical 
indication for liver biopsy and exclusion of NAFLD after liver biopsy.  
A specialized data extraction tool was used to retrieve information from an online genetic 
database (http://gknowmix.org) whereby Caucasian control individuals (n=166) for this 
study was selected. Any familial related individuals in the database were excluded using 
their family index number. Individuals with a medical history of insulin resistance, 
diabetes or NAFLD were also excluded from the control group. 
Ethical Approval 
Ethical approval for the research project on NAFLD individuals has been granted in 2004 
by the University of Stellenbosch, under project number N04/02/033 and thereafter 
annually approved until December 2012. In addition, ethical approval has been granted 
for the inclusion of control samples recruited as part of project N09/08/224 focused on 
individuals with and without features of the metabolic syndrome.  
2.2. DNA Extraction 
2.2.1. DNA extraction from Whole Blood using the QIAamp® DNA Blood Midi/Maxi 
kit supplied by QIAGEN (Spin protocol) 
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The QIAamp DNA whole blood protocol was used to extract and purify DNA from 2 ml of 
whole blood that has been treated with EDTA. 
QIAGEN protease stock solution (200 µl) was added with 2 ml of whole blood into the 
bottom of a 15 ml centrifuge tube and mixed briefly by vigorous shaking (vortexing) to 
increase the overall efficacy of the reaction. The protease enzyme will conduct 
proteolysis (protein catabolism) in the blood sample, lysing the cells to release their DNA 
from the nucleus into the solution. Buffer AL (2.4 ml) was added to the 15 ml centrifuge 
tube and mixed thoroughly by inverting the tube 15 times, followed by additional 
vigorous shaking of 1 min to ensure adequate lysis of the sample and to yield a 
homogenous solution.  The homogenous solution was then air incubated on a dry block 
at 70 °C for 10 min to ensure for a maximum DNA yield after lysis. 
Upon removal from the dry block 2 ml of ethanol (96%-100%) was added to the 
homogenised sample in the 15 ml centrifuge tube and mixed by inverting the tube 10 
times, followed by additional vigorous shaking (vortexing). In order to ensure efficient 
binding of the lysate to the QIAamp® Midi spin column, it is essential to mix the sample 
thoroughly after the addition of ethanol. 
One half (~3 ml) of the solution volume was carefully transferred on to the QIAamp® Midi 
spin column and placed back in to the 15 ml centrifuge tube and centrifuged at 1850 x g 
(3000 rpm) for 3 min. When centrifugation was completed the filtrate was discarded and 
the remainder (~3 ml) of the solution were transferred on to the QIAamp® Midi spin 
column and centrifuged at 1850 x g (3000 rpm) for 3 min. The QIAamp® Midi spin 
column was removed after centrifugation and the remaining filtrate discarded. Complete 
removal of the filtrate is necessary to prevent the nozzle of the QIAamp® Midi spin 
column from being submerged in the filtrate, which could reduce the washing efficacy.  
Each column was properly sealed to avoid cross-contamination during centrifugation. 
The column was placed back into the 15 ml centrifuge tube and 2 ml of the wash buffer 
AW1 was added on to the column membrane and centrifuged at 4500 x g (5000 rpm) for 
1 min. Thereafter wash buffer AW2 (2 ml) was added on to the QIAamp® Midi spin 
column and centrifuged at 4500 x g (5000 rpm) for 15 min. The increased centrifugation 
time is essential to remove all traces of Buffer AW2 from the column before elution, as 
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the residual ethanol in the elute may cause inhibition of PCR reactions leading to false-
negative results. 
The QIAamp® Midi spin column was then placed in a clean 15 ml centrifuge collection 
tube and the collection tube containing the filtrate was discarded. Nuclease free water 
(300 µl), equilibrated to room temperature (15-25 °C) was added directly onto the 
membrane of the column and incubated at room temperature for 5 min and centrifuged 
at 4500 x g (5000 rpm) for 2 min.  To obtain maximum concentration, the eluted (300 µl) 
sample was reloaded onto the membrane of the QIAamp® Midi spin column and 
incubated at room temperature (15-25 °C) for 5 min followed by centrifugation at 4500 x 
g (5000 rpm) for 2 min. The DNA solution was placed on a shaker at room temperature 
overnight to ensure proper homogenization of the sample. Thereafter it was stored at 4 
°C for frequent use and the remaining DNA solution stored in aliquots at – 20°C for long 
term use. 
2.2.2. DNA extraction from Saliva samples using the Oragene®-DNA/ saliva Kit 
The following step-by-step protocol was used to purify DNA from 500 µl of Oragene®-
DNA/saliva sample. 
The Oragene®-DNA/saliva sample was mixed thoroughly by inverting the vial several 
times followed by gentle shaking for a few seconds. This was to ensure that the viscous 
saliva sample was properly mixed with the Oragene®-DNA solution. The sample was 
incubated at 50 °C in a water bath for a minimum of 1 hour to ensure that the DNA was 
adequately released and the nucleases permanently inactivated. The mixed Oragene®-
DNA/saliva sample (500 µl) was transferred to a 1.5 ml microcentrifuge tube. A volume 
of 20 µl of Oragene®-DNA purifier (OG-L2P) was added to the microcentrifuge tube and 
mixed by vortexing for 10 seconds. 
The sample was incubated on ice for 10 min to allow for the precipitation of impurities 
and inhibitors. After incubation the vial was centrifuged at room temperature (15-25°C) 
for 5 min at 13 000 rpm (15000 x g), resulting in separation of the DNA containing 
supernatant from the precipitated impurities.  
Glycogen was added to the supernatant to make the pellet more easily visible. The 
supernatant was carefully transferred with a pipet tip into a fresh microcentrifuge tube 
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and the pellet containing the impurities was discarded. An equal amount (500 µl) of 95-
100% ethanol at room temperature (15-25°C) was added to the supernatant and mixed 
gently by inverting the tube 10 times. Thereafter, it was incubated for 10 min at room 
temperature (15-25°C) to allow the DNA to fully precipitate. 
The tube was loaded into a microcentrifuge in a known orientation (ex. hinge of the tube 
pointing away from the centre of the rotor in order to visualize the tiny pellet at the tip of 
the tube below the hinge) and centrifuged at room temperature for 2 min at 13000 rpm 
(15000 x g). The supernatant was carefully removed with a pipet tip and discarded 
without disturbing the DNA pellet. A volume of 250 µl ethanol (70%) was added onto the 
DNA pellet and incubated at room temperature (15-25°C) for 1 min. Upon removal of the 
70% ethanol, 100 µl of DNA buffer (Nuclease Free Water) was added to reconstitute the 
DNA pellet, followed by vortexing for at least 5 seconds. The freshly extracted DNA from 
the Oragene®-DNA/saliva sample was incubated overnight on a shaker at room 
temperature (15-25°C) to ensure homogenization and stored at 4°C for frequent use. 
2.3. DNA Quantification 
A NanoDrop® ND-1000 spectrophotometer (NanoDrop®, Techonologies, USA) with the 
v3.5.2 software package was used to determine the concentration and purity of the DNA 
samples.  
The instrument was turned on followed by selection of the Nucleic Acid analysis option, 
thereafter cleaning of the pedestal and loading of a Nuclease Free Water sample onto 
the pedestal to initialize the instrument. A volume of 2 µl RNase Free water was placed 
on the pedestal to blank (containing all the components of your solution except what is to 
be tested for i.e. DNA) the instrument before making any measurements. Upon 
completion of the blanking process, all the samples were measured and stored. The 
pedestal was cleaned between each measurement with 70% ethanol followed by double 
distilled water. The ratio absorbance reading at 230 nm, 260 nm and 280 nm was used 
to assess the purity of DNA. Purity values for all samples were within the acceptable 
range (260/280 absorbance ratio: 1.6-1.9; 260/230 absorbance ratio : >1.9) indicating 
the absence of contaminants such as proteins, salts or phenols in the sample. Nuclease 
free water was used in the dilution of all the DNA samples to obtain a final concentration 
of 10 ng/µl, as required for Real-Time Polymerase Chain Reaction instruments.  
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2.4. Polymerase Chain Reaction Amplification 
2.4.1. Oligonucleotide Primers 
Oligonucleotide primers were specifically designed to detect genetic variation in the FTO 
(rs9939609, intron 1 T>A), PPARγ (rs1801282, 34 C>G, P12A) and TNF-α (rs1800629, -
308 G>A) genes using the LightCycler® Probe Design Software 2.0 (Version 1.0. R.36) 
package. The genomic reference sequences for FTO (NG_012969.1) PPARγ 
(NG_011749.1) and TNF-α (NG_007462.1) were obtained from the national centre for 
biotechnology information (NCBI, www.ncbi.nlm.nih.gov) database. The primers used in 
the conventional polymerase chain reaction (PCR) method and direct DNA sequencing 
reactions are summarized in table 2.1. 
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Table 2.1. Particulars of the primers used in the conventional PCR experiment and direct DNA sequencing. 
 
Gene 
 
*SNP 
 
Primer 
   
         Nucleotide Sequence (5’ to 3’) 
G/C 
Content 
(%) 
TM 
(°C) 
TA 
(°C) 
SNP 
Position 
Amplicon 
Size (bp) 
FTO rs9939609 
Forward 
        CTGGCTCTTGAATGAAATAGGA 
40.9 52.4 
53.9 
Intron 1 
T>A 
275 
Reverse 
        CTTAAAGTTAATGGCTTCAGGG 
40.9 51.5 
PPARγ rs1801282 
Forward 
CTCCTAATAGGACAGTGCCA 
50.0 53.5 
55 
P12A 
34 C>G 
734 
Reverse 
GCTGAGAGTACTTCAAGAGG 
50.0 52.1 
TNF-α rs1800629 
Forward 
        CCAGCATTATGAGTCTCCG 
52.6 52.7 
56 
-308  
G>A 
742 
 
Reverse 
        GCTTCTCTCCCTCTTAGC 
55.6 51.8 
*Single nucleotide polymorphism 
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2.4.2. PCR Amplification Mixture and Thermal Cycling Conditions. 
Polymerase chain reaction amplification of the various amplicons under investigation 
was performed with the Promega GoTaq® Flexi DNA polymerase PCR kit. Applied 
Biosystems® thermal cyclers (2700, 2720 and 9700) were used to amplify the specific 
region of interest in 25 µl reactions. The reaction mixture consisted of 100 ng/µl template 
DNA, 5 x Colourless Go Taq® flexi buffer (Promega), 0.2 mM dNTP mix (dATP, dTTP, 
dGTP, dCTP) from Fermentas, 1.5 mM MgCl2 (Promega), 0.24 µM of each primer 
(Forward and Reverse) (WhiteHead Scientific) and 1.25 U Go Taq® DNA Polymerase 
(Promega). The Promega PCR reagent mixture was used for all the primer sets under 
investigation. 
The specific PCR conditions (initial denaturation, denaturation, annealing, extension and 
final extension) used to amplify each gene (FTO, PPARγ and TNF-α) are summarised in 
tables 2.2- 2.4.  
Table 2.2. Thermal Cycling Conditions for amplification of FTO. 
Steps Cycles Temperature (°C) Time (min) 
Initial denaturation 1 95 02:00 
Denaturation 
30 
95 00:30 
Annealing 53.9 00:30 
Extension 72 00:30 
Final Extension 1 72 05:00 
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Table 2.3. Thermal Cycling Conditions for amplification of PPARγ. 
Steps Cycles Temperature (°C) Time (min) 
Initial denaturation 1 95 02:00 
Denaturation 
35 
95 00:30 
Annealing 55 00:30 
Extension 72 00:30 
Final Extension 1 72 05:00 
 
Table 2.4. Thermal Cycling Conditions for amplification of TNF-α. 
Steps Cycles Temperature (°C) Time (min) 
Initial denaturation 1 95 02:00 
Denaturation 
40 
95 00:30 
Annealing 56 00:30 
Extension 72 00:30 
Final Extension 1 72 05:00 
 
2.5. Gel Electrophoresis 
PCR products were electrophoresed on a 2.5% (w/v) horizontal agarose gel to determine 
successful amplification. The gel mixture consisted of 2.5g Seakem® LE agarose, 100 ml 
Tris-borate/EDTA (1xTBE) (90 mM Tris-HCl (pH 8.0), 90 mM boric acid (H3BO3), 1 mM 
EDTA (Ethylenediaminetetraacetic Acid) at a pH of 8.0 and 70 µl of 0.01% (v/v) Ethidium 
Bromide (EtBr) that was added to the electrophoretic buffer (1x TBE). The PCR product 
(5 µl) and Ficoll Orange G loading buffer (5 µl) [consisting of 0.02% (w/v) ficoll, 10 mM 
EDTA at pH 7.0] was thoroughly mixed on Para-film and loaded into the wells of the 
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agarose gel. A 100bp molecular size marker from Promega, Wisconsin USA verified 
amplification of the correct fragment size. Electrophoresis of the PCR products was 
conducted at 80 V for one hour in 1 x TBE buffer solution. Visualization of the PCR 
products was accomplished using an ultraviolet light trans-illuminator (GibcoBRL Life 
Technologies, California, USA). 
2.6. DNA Sequencing Analysis 
PCR products obtained for FTO (T>A), PPARγ (C>G) and TNF-α (G>A) were sent to the 
Central DNA Sequencing facility of Stellenbosch University for automated sequencing as 
well as post-PCR clean up. FinchTV Version 1.4.0 (developed by Geospiza Research 
Team) was used to analyze the ABI™ files received from the DNA sequencing facility to 
ultimately generate electropherograms. The application of the software was to view the 
nucleotide sequences of each gene (FTO, PPARγ, TNF-α) and compare it directly to the 
reference sequence as obtained from the NCBI (National Centre for Biotechnology 
Information) database for detection of SNPs.  
The automated sequencing technique consists of a reaction mixture which includes a 
DNA template, nucleotides (dNTPs and ddNTPs), an enzyme and a single primer 
(forward or reverse). Four distinct colours of fluorescence are used to differentiate 
between the four ddNTP (ddATP, ddCTP, ddGTP and ddTTP) molecules. The 
sequential addition of the bases to the 3’-end of the primer sustain the elongation 
process (5’-3’ direction) until the incorporation of a ddNTP. The extension reaction 
requires a hydroxyl group (OH-) on the third carbon of the molecule, but ddNTP 
molecules carry a hydrogen atom instead therefore the extension reaction is terminated.  
Upon completion of the sequencing reaction (either forward or reverse primer) that is 
almost identical to PCR (both forward and reverse primers), gel electrophoreses follow. 
The automated sequencer will detect the colour of the last base (fluorescently labelled) 
through excitation of a laser beam at a specific wavelength (colour dependant). Based 
on the wavelength of light detected by the spectrograph, the light will be separated by a 
specialized charge coupled camera. All the data captured by the sequencer, are 
represented in sequentially determined colour peaks in the form of an analysable 
electropherogram.  
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2.7. Real-Time Polymerase Chain Reaction (RT-PCR) Amplification 
2.7.1. Applied Biosystems® TaqMan® SNP Genotyping Assays 
The ABI™ TaqMan® SNP Genotyping 5’ nuclease technology Assays are standardized 
assays that use two allele-specific TaqMan® Minor Groove Binder (MGB) probes (VIC® 
and FAM™ dye-labelled) and a specific PCR primer pair to detect the single nucleotide 
polymorphism (SNP) of interest. The specific probes and primers uniquely align with the 
template DNA, to provide unmatched specificity. The pre-designed assays in this study 
were used for end-point genotyping by allelic discrimination analysis for SNPs. Two 
different real-time PCR instruments were used i.e. the ABI™ 7900 HT fast real-time PCR 
machine and the Corbett Rotor-Gene™ 6000. The assay employed in this study were 
FTO intron 1 T>A (rs9939609, C_30090620_10), PPARγ Pro12Ala, 34 C>G (rs1801282, 
C_1129864_10) and TNF-α -308 G>A (rs1800629, C_7514879_10). As required by real-
time PCR instruments, the 40x TaqMan® SNP genotyping assay mixture was diluted to 
20x in sterile SABAX water (double distilled water). 
2.7.2. Applied Biosystems® 7900HT 
The ABI™ 7900HT fast real-time PCR system with ABI™ TaqMan® SNP genotyping 
assays was used to genotype large sample quantities obtained during the course of this 
study. The reaction volume (10 µl) consisted of; 10ng/µl template specific DNA (2.0 µl), 5 
µl of universal TaqMan® genotyping master mix (P/N 4371355), 20x TaqMan® SNP 
genotyping assay (0.5 µl) and 2.5 µl SABAX (nuclease-free) water. The amplification run 
was carried out with a three step thermal cycling program starting with an initial hold step 
at 95°C for 10 minutes, followed by 45 cycles of denaturation at 92°C for 15 seconds 
and annealing/extension at 60°C for 1 minute and finally followed by an end-point 
genotyping allelic discrimination scan. 
2.7.3. Corbett Rotor-Gene™ 6000/ QIAGEN Rotor-Gene Q 
The Rotor-Gene™ 6000 series Multiplexing System, 5-Plex HRM model (Corbett 
Research, Australia) was used with the compatible ABI™ TaqMan® SNP genotyping 
assays (C_30090620_10,C_1129864_10 and C_7514879_10) for mutation detection. 
Allelic discrimination and scatter plot analysis data of the fluorescence in each channel 
was obtained during the RT-PCR experiment. A total volume of 10µl per individual 
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reaction used for allelic discrimination consisted of: 5µl TaqMan® universal genotyping 
PCR master mix (P/N 4371355), 10ng/µl template specific DNA (2.0 µl), 20x TaqMan® 
SNP genotyping assay (0.5 µl) and 2.5 µl nuclease-free water. The specific thermal 
cycling program used for amplification was as follows: 45 cycle repeat of the initial hold 
step for 10 minutes at 95°C, denaturation for 15 seconds at 92°C, followed by an 
annealing and final extension step for 1 minute at 60°C set to acquire (VIC®/ yellow and 
FAM™/ green dye) at the end of each cycling step. 
2.8. Statistical Analysis 
Population frequencies of the selected SNPs in the FTO, TNFα and PPARγ genes 
studied were estimated from allele counts. Hardy-Weinberg equilibrium was assessed 
using the exact test. We calculated a risk score for each individual by counting their risk 
alleles (FTO T>A, TNF-α G>A, PPARγ C>G i.e. A-A-C). We also inferred frequencies of 
3-SNP allelic combinations, using the R haplo stats package. Prior to inclusion of the 
genotyping results in the statistical model used for genotype-phenotype association 
studies, potential confounders were identified in the data set and adjusted for in order to 
test for  both single independent and combined allelic effects incorporated into the 
genotype risk score. For descriptive purposes, cross tabulation and frequency tables 
were used to denote occurrences of various qualitative attributes (such as gender, 
ethnicity, diagnostic groups, etc.) whereas the median and interquartile range were used 
to describe quantitative phenotypes (insulin, HOMA-IR, etc.). Log regression models 
were used to compare pairs of groups, while linear regression models were used to 
compare quantitative characteristics between diagnostic and genotypic groups and 
scores. These models were adjusted for possible confounders by including the 
confounders as factors. Log transformations were used when the distributions of 
quantitative traits were not symmetric. All p-values and effect sizes were derived from 
these models. All statistical analyses were done by a qualified biostatistician using 
functions from R software and R packages genetics and R haplo.stats, freely available 
from http://www.r-project.org.   
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3.1. Characteristics of the study population 
Functional SNPs in the FTO (rs9939609, intron 1 T>A), TNF-α (rs1800629, -308 G>A) 
and PPARγ (rs1801282, Pro12Ala C>G) genes (Table 3.1) were evaluated in 119 
patients and 166 control individuals to evaluate the relationship between genetic and 
environmental risk factors as may be reflected by biochemical abnormalities implicated 
in the development or severity of NAFLD. The clinical and biochemical characteristics of 
the study population are summarised in tables 3.2 and 3.3, respectively. Based on the 
assessment of clinical usefulness performed as part of the literature review, the SNPs 
selected for analysis were considered suitable for genotype-phenotype association 
studies in view of their role in inflammation, obesity, insulin resistance and type II 
diabetes. The risk-associated alleles as described in this context are underlined in table 
3.1. 
Table 3.1. Single nucleotide polymorphisms studied and their metabolic associations. 
The risk-associated alleles as previously described in relation to insulin resistance are 
underlined. 
Risk Area Gene Genetic Variation 
Obesity and metabolic syndrome features 
FTO rs9939609, Intron 1 T>A 
Inflammation and insulin resistance TNF-α rs1800629, -308 G>A 
Insulin resistance PPARγ rs1801282, 34 C>G, P12A 
 
DNA samples of the 166 Caucasian control individuals were used to perform analytical 
validation of the high-throughput RT-PCR genotyping method, against direct sequencing 
as the gold standard (Sections 3.2-3.5). Genotyping of the patient study group (n=119) 
was subsequently performed using the standardized RT-PCR assays for the three 
selected SNPs. The patients with a fatty liver (without liver biopsies) were grouped 
separately (n=31) from the 88 histologically confirmed NAFLD patients for comparative 
studies and included 23 Coloured, 6 Caucasian and 2 Black patients. Within the 
histologically confirmed NAFLD patient group 47 patients were Coloured, 35 Caucasian, 
5 Black and 1 Indian. 
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Table 3.2. Description of clinical characteristics in the general Caucasian control individuals, obese patients with fatty liver on ultrasound 
and histologically confirmed NAFLD patients, subdivided into types 1,2 and 3,4 (NASH) [median; (inter quartile range)].  
 
General 
Caucasian 
Controls 
Obese patients  
All NAFLD 
Patients 
(types 1-4) 
Caucasian 
NAFLD  
(types1-4)  
Patients 
Coloured 
NAFLD 
(types 1-4) 
Patients 
NAFLD  
(types 1,2) 
NASH     
(types 3,4) 
N 166 31 88 35 47 45 43 
Male, number 56 (34%) 7 (23%) 28 (32%) 18 (51%) 8 (17%) 16 (36%) 12 (28%) 
Female, number 110 (66%) 24 (77%) 60 (68%) 17 (49%) 39 (83%) 29 (64%) 31 (72%) 
Age (years) 48 (±12) 47 (±12) 53 (±11) 53 (±9) 54 (±11) 53 (±9) 53 (±12) 
BMI (kg/m
2
) 26 (23-29) 37 (33-43) 33 (30-38) 31 (30-34) 34 (31-39) 33 (31-38) 33 (30-38) 
BMI class, number 
     
  
Underweight (<18.4kg/m
2
) 3 (2%) 0  0  0  0  0  0  
Normal (18.5-24.9 kg/m
2
) 64 (39%) 0  4 (5%) 1 (3%) 3 (6%) 2 (4%) 2 (5%) 
Overweight (25-30 kg/m
2
) 61 (37%) 0  17 (19%) 9 (26%) 7 (15%) 8 (18%) 9 (21%) 
Obese (>30 kg/m
2
) 35 (21%) 31 (100%) 67 (76%) 25 (71%) 37 (79%) 35 (78%) 32 (74%) 
Waist circumference (cm) 
91 
(81-99) 
111 
(102-126) 
105 
(100-114) 
109 
(103-113) 
104  
(98-115) 
106 
(99-112) 
104 
(100-115) 
Alcohol consumption, yes  n/a 1 (3%) 13 (15%) 11 (32%) 1 (2%) 6 (14%) 7 (16%) 
Physical activity, yes 115 (70%) 2 (7%) 13 (15%) 8 (24%) 3 (6%) 6 (14%) 7 (17%) 
Smoking, yes  8 (5%) 3 (10%) 21 (24%) 9 (26%) 12 (26%) 13 (29%) 8 (19%) 
Heart Disease, yes n/a 2 (6%) 7 (8%) 5 (14%) 1 (2%) 3 (7%) 4 (9%) 
Family history, yes 
     
  
       Diabetes 30 (18%) 18 (75%) 49 (62%) 14 (52%) 33 (72%) 22 (56%) 27 (68)% 
       Hypertension n/a 13 (54%) 43 (55%) 10 (37%) 31 (69%) 24 (62%) 19 (49)% 
       Cardiovascular disease        n/a 7 (30%) 38 (49%) 15 (58%) 22 (48%) 21 (55%) 17 (42)% 
n/a, not available 
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Table 3.3 Description of biochemical characteristics in the general Caucasian control individuals, obese patients with fatty liver on ultrasound and 
histologically confirmed NAFLD patients, subdivided into types 1,2 and 3,4 (NASH) [median, (inter quartile range)]. 
 
General 
Caucasian 
Controls 
Obese 
Patients 
All NAFLD 
Patients  
(types 1-4) 
Caucasian 
NAFLD 
(types1-4)  
Coloured 
NAFLD 
(types 1-4)  
NAFLD 
(types 1,2) 
NASH 
(types 3,4) 
n 166 31 88 35 47 45 43 
ALT (units/L) 
 
35 (29-51) 47 (32-68) 57 (45-91) 38 (30-56) 38 (28-62) 51 (38-70) 
AST (units/L) 
 
32 (26-51) 34 (27-68) 42 (29-38) 31 (32-50) 33 (24-47) 35 (29-61) 
AST/ALT ratio 
 
0.79 
(0.68-0.95) 
0.77 
(0.65-0.94) 
0.71 
(0.63-0.84) 
0.78 
(0.65-0.99) 
0.79 
(0.66-0.98) 
0.71 
(0.64-0.91) 
C-Reactive Protein (mg/l) 
 
6.8 (5.3-11.5) 7.8 (3.4-10.7) 7.8 (3.4-10.5) 6.6 (3.4-10.7) 8.2 (3.8-12) 6.6 (3.3-11) 
Fasting glucose (mmol/l) 5.0 (4.7-5.2) 5.6 (5.3-7.1) 6.6 (5.3-8.7) 6.4 (5.3-7.4) 8.0 (5.6-9.2) 5.8 (5.1-8.2) 7.8 (5.9-9) 
Insulin concentration (mmol/l) 
 
23 (12-31) 20 (10-28) 19 (10-26) 22 (13-30) 19 (9.8-25) 21 (12-33) 
HOMA-IR 
 
0.3 (0.2-1.3) 1.1 (0.7-1.5) 1.1 (0.7-1.4) 1.2 (0.8-1.7) 1.0 (0.6-1.4) 1.3 (0.8-2) 
HbA1c (%) 5.3 (5.0-5.6) 7.1 (6.0-8.6) 7.1 (6.0-8.9) 6.3 (5.4-8.4) 7.5 (6.5-9.0) 6.5 (5.6-7.4) 7.9 (6.5-9) 
HDL Cholesterol (mmol/l) 1.4 (1.2-1.6) 1.3 (1.0-1.6) 1.2 (1.1-1.4) 1.2 (1.0-1.3) 1.3 (1.1-1.5) 1.2 (1.1-1.4) 1.2 (1.1-2) 
LDL Cholesterol (mmol/l) 3.5 (2.9-4.3) 3.6 (3.1-4.0) 3.5 (2.7-4.1) 3.8 (2.5-4.2) 3.4 (2.8-4.1) 3.5 (2.7-4.1) 3.4 (3-4.1) 
Total Cholesterol (mmol/l) 5.4 (4.8-6.4) 5.3 (4.8-6.3) 5.6 (4.8-6.5) 5.7 (4.8-6.2) 5.6 (4.7-6.6) 5.6 (4.7-6.2) 5.7 (5-6.6) 
Triglycerides (mmol/l) 0.9 (0.7-1.3) 1.4 (1.1-2.1) 1.8 (1.3-2.8) 2.0 (1.4-3.0) 1.8 (1.4-2.5) 1.6 (1.3-2.4) 1.9 (1.4-3) 
Tf Saturation (%) 30 (23-37) 17 (13-21) 19 (12-26) 23 (16-27) 19 (12-25) 15 (11-26) 20 (15-27) 
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3.2. Conventional Sequencing- Agarose Gels and Electropherograms 
The specific amplicons obtained for the FTO (T>A), TNF-α (G>A) and PPARγ (G>C) 
mutations using conventional primers visualized with ethidium Bromide in a 2.5 % 
agarose gel are presented in figures 3.2.1, 3.2.5, 3.2.9 respectively. The sequencing 
results of each genotype in relation to the risk-associated allele when not detected (ND), 
heterozygous (HET) or homozygous (HOM) are presented in electropherograms for one 
of the control samples in figures 3.1.2 (FTO-ND), 3.2.3 (FTO-HET), 3.2.4 (FTO-HOM), 
3.2.6 (TNFα-ND), 3.2.7 (TNFα-HET), 3.2.8 (TNFα-HOM), 3.2.10 (PPARγ-ND), 3.2.11 
(PPARγ-HET) and 3.2.12 (PPARγ-HOM). Forward (sense) and reverse (anti-sense) 
sequencing were carried out for each genotype to emphasize the analytical validity. Only 
the forward sequence is shown as the reverse sequence continually substantiated the 
result obtained. 
 
Figure 3.2.1. A 2.5% (w/v) agarose gel depicting the PCR amplicons synthesised with 
the FTO (rs9939609) primer set visualized with 0.0001% (v/v) Ethidium Bromide. Lane 1 
contains a 100-bp DNA ladder. Lanes 2 to 4 contains amplicons of 275bp and lane 5 
contains the NTC (non-template control) PCR reaction product. 
 
 
 
 
Figure 3.2.2. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the FTO primer set. The red arrow indicates the FTO (intron 
1 T>A) nucleotide (126) mutation position. The “T” highlighted position resembles the TT 
genotype where the risk-associated allele was not detected. 
     1                               2                              3                                 4                               5 
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Figure 3.2.3. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the FTO primer set. The red arrow indicates the FTO (intron 
1 T>A) nucleotide (126) mutation position. The “W” highlighted position resembles a 
heterozygous TA genotype. 
 
 
Figure 3.2.4. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the FTO primer set. The red arrow indicates the FTO (intron 
1 T>A) nucleotide (126) mutation position. The “A” highlighted position resembles a risk-
associated homozygous AA genotype. 
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Figure 3.2.5. A 2.5% (w/v) agarose gel depicting the PCR amplicons synthesised with 
the TNF-α (rs1800629) primer set visualized with 0.0001% (v/v) Ethidium Bromide. Lane 
1 contains a 100-bp DNA ladder. Lanes 2 to 7 contains amplicons of 742bp and lane 8 
contains the NTC (non-template control) PCR reaction product. 
 
Figure 3.2.6. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the TNF-α primer set. The red arrow indicates the TNF-α (-
308 G>A) nucleotide (348) mutation position. The “G” highlighted position resembles the 
GG genotype where the risk-associated allele was not detected. 
 
 
 
 
Figure 3.2.7. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the TNF-α primer set. The red arrow indicates the TNF-α (-
308 G>A) nucleotide (345) mutation position. The “R” highlighted position resembles a 
heterozygous GA genotype. 
      1                  2                   3                   4                  5                   6                   7                   8 
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Figure 3.2.8. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the TNF-α primer set. The red arrow indicates the TNF-α (-
308 G>A) nucleotide (346) mutation position. The “A” highlighted position resembles a 
risk-associated homozygous AA genotype. 
 
Figure 3.2.9. A 2.5% (w/v) agarose gel depicting the PCR amplicons synthesised with 
the PPARγ (rs1801282) primer set visualized with 0.0001% (v/v) Ethidium Bromide. 
Lane 1 contains a 100-bp DNA ladder. Lanes 2 to 4 contains amplicons of 734bp and 
lane 5 contains the NTC (non-template control) PCR reaction product. 
 
Figure 3.2.10. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the PPARγ primer set. The red arrow indicates the PPARγ 
               1                            2                            3                            4                           5                 
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(34 C>G, P12A) nucleotide (217) mutation position. The “G” highlighted position 
resembles the GG genotype where the risk-associated allele was not detected. 
 
 
 
Figure 3.1.11. Electropherogram depicting the forward (sense) sequence reaction of a  
Figure 3.2.11. PCR amplicon obtained with the PPARγ primer set. The red arrow 
indicates the PPARγ (34 C>G, P12A) nucleotide (217) mutation position. The “S” 
highlighted position resembles a heterozygous CG genotype. 
 
 
Figure 3.2.12. Electropherogram depicting the forward (sense) sequence reaction of a 
PCR amplicon obtained with the PPARγ primer set. The red arrow indicates the PPARγ 
(34 C>G, P12A) nucleotide (220) mutation position. The “C” highlighted position 
resembles a risk associated homozygous CC genotype. 
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3.3. RT-PCR Genotyping with the ABI™ 7900HT. 
In this investigation the ABI™ 7900HT Real-Time PCR instrument was used with ABI™ 
TaqMan® SNP Genotyping assays to determine the specific genotypes of the various 
patient and control samples screened in this study. The ABI™ SDS version 2.3 software 
package (Foster City, California, USA) was used as the user interface of the instrument. 
Analytical validation of the assays were achieved using positive control samples with 
known genotypes determined by conventional PCR and DNA sequencing prior to the 
RT-PCR run and 12 non-template controls (NTC, consisting of nuclease-free water as a 
replacement for DNA) in each 96 well plate reaction run.  
Genotyping was achieved in three distinct stages. The first was an amplification run 
during which amplicons were exponentially synthesized and the fluorescence data 
plotted as a graph (∆Rn-unit of fluorescence vs. cycles) using the standard curve (AQ) 
setting of the instrument. The second stage was a post-amplification scan determining 
the allelic discrimination using the SDS software package. The software presents the 
results on an allelic discrimination scatterplot by contrasting the fluorescence data 
obtained from the VIC® and FAM™ reporter dyes. Upon signal normalization and multi 
component analysis the data obtained from a single well is plotted as a single data-point 
on the scatterplot. The allelic discrimination analysis displays the results as an allele Y 
(assay identification and allele) on the y-axis and allele X (assay identification and 
alternate allele) on the x-axis of the graph. Analytical validation and verification of the 
genotyping results obtained concluded the final stage of the process. 
All three assays (FTO rs9939609 intron 1 T>A, TNF-α rs1800629 -308 G>A and PPARγ 
rs1801282 34 C>G P12A) employed on the ABI™ 7900HT were successful in the 
mutation screening, yielding clear amplification of the polymorphic target sequence and 
precise genotyping of each individual sample. Internal control samples loaded on each 
plate verified the DNA sequence data obtained and clear NTC clustering per plate 
corresponds to the absence of contamination during the analytical procedure, ensuring 
the credibility of the results generated during the study. Due to the bulk of genotyping 
results generated from this study only one sample batch of each assay is illustrated in 
this section to exemplify the results obtained through the ABI™ 7900HT RT-PCR 
genotyping system.  
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The investigation of FTO (intron 1 T>A) yielded the amplification graph presented in 
figure 3.3.1. The graph signifies successful amplification and fluorescence acquired by 
the ABI™ TaqMan® SNP genotyping assay. The allelic discrimination scatterplot of FTO 
is depicted in figure 3.3.2 grouping the genotypes of each sample screened with black 
dots representing NTCs, blue dots matching the risk associated not detected, green dots 
equivalent to heterozygotes and red dots indicating the homozygotes. 
The investigation of TNF-α (-308 G>A) yielded the amplification graph presented in 
figure 3.3.3. The graph signifies successful amplification and fluorescence acquired by 
the ABI™ TaqMan® SNP genotyping assay. The allelic discrimination scatterplot of TNF-
α is depicted in figure 3.3.4 grouping the genotypes of each sample screened with black 
dots representing NTCs, blue dots matching absence of the risk allele, green dots 
equivalent to heterozygotes and red dots signifying the less prevalent homozygotes. 
The investigation of PPARγ (P12A, 34 C>G) yielded the amplification graph presented in 
figure 3.3.5. The graph signifies successful amplification and fluorescence acquired by 
the ABI™ TaqMan® SNP Genotyping assay. The allelic discrimination scatterplot of 
PPARγ is depicted in figure 3.3.6 grouping the genotypes of each sample screened with 
black dots representing NTCs, green dots equivalent to heterozygotes and red dots 
indicating the homozygotes. 
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Figure 3.3.1. Distinctive amplification attained using the ABI
™
 
TaqMan
®
 assay for FTO (∆Rn vs numeral cycles). (Abbreviation: 
∆Rn = unit of fluorescence) 
 
Figure 3.3.2. Typical allelic discrimination analysis using the 
ABI
™
 TaqMan
®
 assay for FTO [Allele Y (C_30090620_10-T) vs 
Allele X (C_30090620_10-A)]. Black = NTC (Non template 
control), Blue = Not detected TT, Green = Heterozygous TA, Red 
= Homozygous AA.
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Figure 3.3.3 Distinctive amplification attained using the ABI™ 
TaqMan
®
 assay for TNF-α (∆Rn vs. numeral cycles). (Abbreviation: 
∆Rn = unit of fluorescence). 
Figure 3.3.4 Typical allelic discrimination analysis using the ABI
™
 
TaqMan
®
 assay for TNF-α [Allele Y (C_7514879_10-G) vs. Allele X 
(C_7514879_10-A)]. Black = NTC (Non template control), Blue = 
Not detected GG, Green = Heterozygous GA, Red = Homozygous 
AA. 
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Figure 3.3.6. Typical allelic discrimination analysis using the 
ABI
™
 TaqMan
®
 assay for PPARγ [Allele Y (C_1129864_10-G) 
vs Allele X (C_1129864_10-C)]. Black = NTC (Negative 
template control), Green=Heterozygous CG, Red = 
Homozygous CC, Blue= Not detected GG (absent) 
 
Figure 3.3.5. Distinctive amplification attained using the ABI™ 
TaqMan
®
 assay for PPAR-γ (∆Rn vs numeral cycles). 
(Abbreviation: ∆Rn = unit of fluorescence) 
 
Stellenbosch University http://scholar.sun.ac.za
Chapter III 
   Results 
56 
 
 
3.4 RT-PCR genotyping with the Corbett Rotor-Gene™ 6000/ QIAGEN Rotor-Gene Q 
In this study, the Corbett Rotor-Gene™ 6000 series multiplexing system (5-Plex HRM 
model) with the ABI™ TaqMan® SNP genotyping assays were employed using allelic 
discrimination and scatterplot analysis for amplification and genotyping of the patient and 
control samples. Allelic discrimination analysis was accomplished using the real time 
kinetic data from multiple (2 or more) channels simultaneously to genotype the samples. 
The ABI™ TaqMan® SNP genotyping assays consisted of unlabelled primers specifically 
designed to amplify the target sequence and dual labelled TaqMan® MGB (Minor Groove 
Binding) probes, VIC® and FAM™ used for allelic discrimination detection.  
The dual labelled probes have unique fluorophores acting as fluorescent dyes (VIC® and 
FAM™) which are allele specific to ultimately differentiate between the different alleles of 
each SNP under investigation. The yellow channel sensor was encaged for detection of 
the VIC® fluorescence probe with excitation wavelength of 530 nm and emission 
wavelength of 555 nm and the green sensor channel was employed for the detection of 
the FAM™ fluorescence probe with excitation wavelength 470 nm and emission 
wavelength 510 nm by the Rotor-Gene™ fluorometer. 
A scatterplot analysis was performed using multiple channels (green and yellow) to 
genotype the patient and control samples. The genotypes were determined on the basis 
of regions defined on the scatterplot and the relative expression of the two channels after 
normalization to accentuate the differences in expression between the samples. 
All three assays (FTO intron 1 T>A, TNF-α -308 G>A and PPARγ 34 C>G, P12A) 
employed on the Corbett Rotor-Gene™ 6000 series were successful in the mutation 
screening process, yielding clear amplification of the polymorphic target sequence and 
precise genotyping of each individual sample. Internal control samples were included in 
each run to verify the DNA sequence data obtained. To quantify the data generated 
during each run a threshold was set to exclude small changes of fluorescence, due to 
probe degradation or other effects (NTCs) which do not show true amplification but 
rather a steady line. No amplification was acquired with the non-template controls 
correspond to the absence of contamination during the analytical procedure, ensuring 
the credibility of the results generated during the study.  
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Due to the bulk of genotyping results generated from this study only one sample batch of 
each assay is illustrated in this section to exemplify the results obtained through the 
Corbett Rotor-Gene™ 6000 series multiplexing system. Analytical validation and 
verification of the genotyping results obtained during the investigation concluded the final 
phase of the process. 
The allelic discrimination analysis for the FTO (intron 1 T>A, rs9939609) assay is 
presented in figure 3.4.1 with the legend and genotypes illustrated by table 3.4.1. The 
lines without intermitted circles represent the (T) allele, which is detected by FAM™-
labelled probes, while the lines with the intermitted circles signifies the homozygote (A) 
allele detected by the VIC®-labelled probes. Amplification of both alleles simultaneously 
indicative of significant fluorescence of both dyes represents the heterozygous (T/A) 
genotype. A threshold level (>0.1) was established as a discriminatory parameter during 
analysis to indicate the presence of allele specific fluorescence above the threshold 
setting. 
 
 
Figure 3.4.1. Allelic discrimination analysis of FTO (rs9939609, Intron 1 T>A) using the ABI
™
 
TaqMan
® 
(C_30090620_10) genotyping assay. (Normalized fluorescence vs. number of cycles) 
VIC®-Circles 
FAM™- No Markers  
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In addition to allelic discrimination analysis, scatterplot analysis was also performed to 
further validate the results of the study. Scatterplot analysis was applied using two 
channels simultaneously. Genotype acquisition is based on specific regions found on the 
scatterplot as well as relative expression of amplification of the green (FAM™) and yellow 
(VIC®) channels respectively. Upon normalization the different fold increases of each 
channel and log transformation accentuated the differences in expression of each 
individual sample. 
The scatterplot analysis for the FTO (Intron 1 T>A) assay is presented in figure 3.4.2 
with the legend and genotypes depicted in table 3.4.1. Genotype determinations were 
based on the dual VIC® and FAM™ Minor Groove Binding (MGB) probes.  
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No. Colour Name Genotype FAM
™ 
VIC
® 
1 
 
sample Heterozygous Reaction Reaction 
2 
 
sample Heterozygous Reaction Reaction 
3 
 
sample Heterozygous Reaction Reaction 
4 
 
sample Mutant No Reaction Reaction 
5 
 
sample Heterozygous Reaction Reaction 
6 
 
sample Not detected Reaction No Reaction 
7 
 
sample Not detected Reaction No Reaction 
8 
 
sample Not detected Reaction No Reaction 
9 
 
sample Not detected Reaction No Reaction 
10 
 
sample Mutant No Reaction Reaction 
11 
 
sample Heterozygous Reaction Reaction 
12 
 
sample Heterozygous Reaction Reaction 
13 
 
sample Not detected Reaction No Reaction 
14 
 
sample Heterozygous Reaction Reaction 
15 
 
sample Not detected Reaction No Reaction 
16 
 
sample Mutant No Reaction Reaction 
17 
 
sample Not detected Reaction No Reaction 
18 
 
sample Not detected Reaction No Reaction 
19 
 
sample Not detected Reaction No Reaction 
20 
 
blank None No Reaction No Reaction 
Table 3.4.1. Legend for figure 3.3.1 and 3.3.2, specifying 
genotypes of the samples based on Allelic discrimination data 
and Scatterplot analysis. 
F
A
M
™
 
VIC® 
Figure 3.4.2. Genotypes grouped by scatterplot analysis (FAM™ 
fluorescence vs. VIC
®
 fluorescence) of the ABI
™
 TaqMan
® 
(C_30090620_10) FTO assay. The legend is presented in table 
3.4.1 
 
None Risk-associated-
aassociated  
Not-detected 
ddededetected 
Heterozygous 
60 
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The allelic discrimination analysis for the TNF-α (rs1800629, -308 G>A) assay is 
presented in figure 3.4.3 with the legend and genotypes illustrated by table 3.4.2. The 
lines without intermitted circles represent the (G) allele, which is detected by FAM™-
labelled probes, while the lines with the intermitted circles signifies the homozygote (A) 
allele detected by the VIC®-labelled probes. Amplification of both alleles simultaneously 
indicative of significant fluorescence of both dyes represents the heterozygous (G/A) 
genotype. A threshold level (>0.1) was established as a discriminatory parameter during 
analysis to indicate the presence of allele specific fluorescence above the threshold 
setting. 
 
 
Figure 3.4.3.  Allelic discrimination analysis of TNF-α (rs1800629, -308 G>A) using the ABI
™
 
TaqMan
® 
(C_7514879_10) genotyping assay. (Normalized fluorescence vs. number of cycles) 
 
The scatterplot analysis for the TNF-α (rs1800629, -308 G>A) assay is presented in 
figure 3.4.4 with the legend and genotypes depicted in table 3.4.2. Genotype 
determinations were based on the dual VIC® and FAM™ Minor Groove Binding (MGB) 
probes.  
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No. Colour Name Genotype FAM
™ 
VIC
® 
1 
 
sample Heterozygous Reaction Reaction 
2 
 
sample Heterozygous Reaction Reaction 
3 
 
sample Not detected Reaction No Reaction 
4 
 
sample Heterozygous Reaction Reaction 
5 
 
sample Not detected Reaction No Reaction 
6 
 
sample Heterozygous Reaction Reaction 
7 
 
sample Not detected Reaction No Reaction 
8 
 
sample Not detected Reaction No Reaction 
9 
 
sample Not detected Reaction No Reaction 
10 
 
sample Not detected Reaction No Reaction 
11 
 
sample Heterozygous Reaction Reaction 
12 
 
sample Heterozygous Reaction Reaction 
13 
 
sample Heterozygous Reaction Reaction 
14 
 
sample Heterozygous Reaction Reaction 
15 
 
sample Not detected Reaction No Reaction 
16 
 
sample Not detected Reaction No Reaction 
17 
 
sample Not detected Reaction No Reaction 
18 
 
sample Not detected Reaction No Reaction 
19 
 
sample Not detected Reaction No Reaction 
20 
 
blank None No Reaction No Reaction 
Table 3.4.2. Legend for figure 3.3.3 and 3.3.4, specifying 
genotypes of the samples based on Allelic discrimination data and 
Scatterplot analysis. 
F
A
M
™
 
         VIC® 
Not-detected 
None Risk-associated  
Heterozygous 
Figure 3.4.4. Genotypes grouped by scatterplot analysis 
(FAM™ fluorescence vs. VIC
®
 fluorescence) of the ABI
™
 
TaqMan
® 
(C_7514879_10) TNF-α assay. The legend is 
presented in table 3.4.2. 
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The allelic discrimination analysis for the PPARγ (rs1801282, 34 C>G, P12A) assay is 
presented in figure 3.4.5 with the legend and genotypes illustrated by table 3.4.3. The 
lines without intermitted circles represent the (C) allele, which is detected by FAM™-
labelled probes, while the lines with the intermitted circles signifies the homozygous (G) 
allele detected by the VIC®-labeled probes. Amplification of both alleles simultaneously 
indicates significant fluorescence of both dyes and represents the heterozygous (C/G) 
genotype. A threshold level (>0.05) was established as a discriminatory parameter 
during analysis to indicate the presence of allele specific fluorescence above the 
threshold setting. 
 
 
Figure 3.4.5.  Allelic discrimination analysis of PPARγ (rs1801282, 34 C>G, P12A) using the 
ABI
™
 TaqMan
® 
(C_1129864_10) genotyping assay. (Normalized fluorescence vs. number of 
cycles) 
 
The scatterplot analysis for the PPARγ (rs1801282, 34 C>G, P12A assay is presented in 
figure 3.4.6 with the legend and genotypes depicted in table 3.4.3. Genotype 
determinations were based on the dual VIC® and FAM™ Minor Groove Binding (MGB) 
probes.  
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No. Colour Name Genotype FAM
™ 
VIC
® 
1 
 
sample Heterozygous Reaction Reaction 
2 
 
sample Mutant No Reaction Reaction 
3 
 
sample Mutant No Reaction Reaction 
4 
 
sample Mutant No Reaction Reaction 
5 
 
sample Not Reaction Reaction No Reaction 
6 
 
sample Mutant No Reaction Reaction 
7 
 
sample Mutant No Reaction Reaction 
8 
 
sample Mutant No Reaction Reaction 
9 
 
sample Mutant No Reaction Reaction 
10 
 
sample Mutant No Reaction Reaction 
11 
 
sample Heterozygous Reaction Reaction 
12 
 
sample Mutant No Reaction Reaction 
13 
 
sample Mutant No Reaction Reaction 
14 
 
sample Mutant No Reaction Reaction 
15 
 
sample Mutant No Reaction Reaction 
16 
 
sample Mutant No Reaction Reaction 
17 
 
sample Heterozygous Reaction Reaction 
18 
 
sample Mutant No Reaction Reaction 
19 
 
sample Heterozygous Reaction Reaction 
20 
 
blank None No Reaction No Reaction 
  
  
  
  
  
  
  
  
  
F
A
M
™
 
Table 3.4.3. Legend for figure 3.3.5 and 3.3.6, specifying 
genotypes of the samples based on Allelic discrimination 
data and Scatterplot analysis. 
Not-detected Heterozygous 
Figure 3.4.6. Genotypes grouped by scatterplot analysis (FAM™ 
fluorescence vs. VIC
®
 fluorescence) of the ABI
™
 TaqMan
® 
(C_1129864_10) PPARγ assay. The legend is presented in table 3.4.3 
         VIC® 
Risk-associated  None 
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3.5 Genotype distribution in the general control study population 
The genotype distribution observed for FTO rs9939609 (intron 1 T>A) among the 166 
control samples achieved through application of RT-PCR is summarized in figure 3.5.1. 
 
 
Figure 3.5.1. Genotype distribution of 166 samples obtained using the ABI
™
 TaqMan
®
 FTO 
assay. Among the 166 control samples, the risk-associated FTO A-allele was excluded in 63 
(38%) individuals (not detected TT), one copy detected in 70 (42.2%) individuals (heterozygous 
TA) and two copies of the risk-associated allele detected in 33 (19.9%) individuals (homozygous 
AA). 
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The genotype distribution observed for TNF-α rs1800629 (-308 G>A) among the 166 
control samples achieved through application of RT-PCR is summarized in figure 3.5.2.  
 
 
Figure 3.5.2. Genotype distribution of 166 samples obtained using the ABI
™
 TaqMan
®
 TNF-α 
assay. Among the 166 control samples, the risk-associated TNF-α A-allele was excluded in 119 
(71.7%) individuals (not detected GG), one copy detected in 43 (25.9%) individuals 
(heterozygous GA) and two copies of the risk-associated allele detected in 4 (2.4%) individuals 
(homozygous AA). 
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The genotype distribution observed for PPARγ rs1801282 (Pro12Ala, 34 C>G) among 
the 166 control samples achieved through application of RT-PCR is summarized in 
figure 3.5.3.  
 
 
Figure 3.5.3. Genotype distribution of 166 samples obtained using the ABI
™
 TaqMan
®
 PPARγ 
assay. Among the 166 control samples, the risk-associated PPARγ C-allele was excluded in 5 
(3.0%) individuals (not detected GG), one copy detected in 39 (23.5%) individuals (heterozygous 
GC) and two copies of the risk-associated allele detected in 122 (73.5%) individuals 
(homozygous CC). 
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3.6. Comparative analysis of Allelic and Genotype Distribution 
Following the optimisation of the RT-PCR assays for the FTO rs9939609, TNF-α 
rs1800629 and PPARγ rs1801282 SNPs, a total of 119 patients (31 with fatty liver on 
ultrasound and 88 histologically confirmed NAFLD) were genotyped using the ABI™ 
7900HT and Corbett Rotor-Gene™. Among the 166 general Caucasian control 
individuals all three SNPs were in Hardy Weinberg equilibrium (p>0.05). However, in the 
NAFLD patient group subdivided into Coloured (p=0.005) and Caucasian (p=0.043) 
patients, significant deviation was observed for PPARγ rs1801282 (table 3.6.1) in these 
groups and the total group of 88 histologically confirmed NAFLD patients (p<0.001). This 
is ascribed to over-representation of the PPARγ rs1801282 GG genotype, a finding 
unrelated to the specific allelic risk implication.  
Table 3.6.1. P-values of Hardy Weinberg Equilibrium testing for the FTO rs9939609 
(intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 
C>G) single nucleotide polymorphisms in the study groups. 
Mutations 
General 
Caucasian 
Controls 
 
All NAFLD 
patients 
(types 1-4) 
Obese  
Caucasian 
NAFLD 
(types 1-4) 
patients  
Coloured  
NAFLD 
(types 1-4) 
patients 
 
N 166 88 31 35 47 
FTO rs9939609 0.109 0.077 0.718 0.095 0.495 
TNF-α rs1800629 1,000 0.633 1,000 1,000 1,000 
PPARγ rs1801282 0.360 <0.001 1,000 0.043 0.005 
 
In table 3.6.2 the FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and 
PPARγ rs1801282 (Pro12Ala, 34 C>G) minor allele frequencies and genotype 
distributions are compared between Coloured and Caucasian NAFLD patients single 
and combined, and Caucasian control samples. P-values are given in table 3.6.3. A 
control group for the coloured population was not available for this study.  
Since the allelic distribution of most SNPs vary considerably between ethnic groups, and 
due to possible age and gender effects, statistical comparisons between study groups 
were made within the same ethnic group or after adjustment for ethnicity, age and 
gender. 
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Table 3.6.2. Genotype distribution and minor allele counts and frequencies in the Caucasian control individuals and patient 
subgroups genotyped for the FTO rs9939609 (intron 1 T>A), TNF-α s1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 
34 C>G) single nucleotide polymorphisms. 
SNP 
General 
Caucasian 
Controls 
 Obese  
All NAFLD 
Patients 
(types 1-4) 
Caucasian 
NAFLD 
Patients 
(types 1-4)  
Coloured 
NAFLD 
Patients 
(types 1-4) 
NAFLD 
(types 1,2) 
NASH   
(types 3,4) 
FTO 
     
  
Typed 166 31 88 35 47 45 43 
T/T 63 (0.38) 10 (0.32) 29 (0.33) 7 (0.20) 21 (0.45) 17 (0.38) 12 (0.28) 
T/A 70 (0.42) 14 (0.45) 50 (0.57) 23 (0.66) 23 (0.49) 23 (0.51) 27 (0.63) 
A/A 33 (0.20) 7 (0.23) 9 (0.10) 5 (0.14) 3 (0.06) 5 (0.11) 4 (0.09) 
A 136 (0.41) 28 (0.45) 68 (0.39) 33 (0.47) 29 (0.31) 33 (0.37) 35 (0.41) 
TNF-α 
     
  
Typed 166 31 88 35 47 45 43 
G/G 119 (0.72) 25 (0.81) 67 (0.76) 29 (0.83) 33 (0.70) 34 (0.76) 33 (0.77) 
G/A 43 (0.26) 6 (0.19) 19(0.22) 6 (0.17) 13 (0.28) 11 (0.24) 8 (0.19) 
A/A 4 (0.02) 0 (0.00) 2 (0.02) 0 (0.00) 1 (0.02) 0 (0) 2 (0.05) 
A 51 (0.15) 6 (0.10) 23 (0.13) 6 (0.09) 15 (0.16) 11 (0.12) 12 (0.14) 
PPARγ 
     
  
Typed 166 31 88 35 47 45 43 
C/C 122 (0.73) 30 (0.97) 78 (0.89) 29 (0.83) 43 (0.91) 38 (0.84) 40 (0.93) 
C/G 39 (0.23) 1 (0.03) 6 (0.07) 4 (0.11) 2 (0.04) 4 (0.09) 2 (0.05) 
G/G 5 (0.03) 0 (0.00) 4 (0.05) 2 (0.06) 2 (0.04) 3 (0.07) 1 (0.02) 
G 49 (0.15) 1 (0.02) 14 (0.08) 8 (0.11) 6 (0.06) 10 (0.11) 4 (0.05) 
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After adjustment for age and gender, both the genotype distribution (p=0.018) and allele 
frequencies (p=0.005) of FTO rs9939609 was found to differ significantly between the 
Coloured and Caucasian NAFLD patients (table 3.6.3). The risk-associated FTO 
The differences in minor alleles of the three selected SNPs between the general 
Caucasian controls (21% obese) compared with NAFLD Caucasian patients (71% 
obese) (shown in table 3.6.2 shaded areas), were not statistically significant. The 
observed frequency of the risk-associated TNF-α A-allele (9%) was lower in the 35 
NAFLD patients (AA genotype not detected) than the 166 controls (15%) but the 
difference did not reach statistical significance (p=0.981). When a sub-analysis was 
done comparing the frequency of the risk associated TNF-α A allele Caucasian NAFLD 
patients (n=35) with only those Caucasian controls (n=67) with normal BMI (<25 kg/m2), 
this difference was also not significant (p=0.129). Further investigation was focused on 
genotype-phenotype comparisons between patient subgroups (table 3.6.3) as the 
identification of genetic risk factors that could help to identify patients at high risk of 
progression from fatty liver disease to the more severe NASH (NAFLD types 3,4) 
subtype, represents the most important aspect of this study. 
 
Table 3.6.3 P-values for comparing the genotype and minor allele frequencies for the 
FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 
(Pro12Ala, 34 C>G) single nucleotide polymorphisms between patient subgroups after 
adjusting for age, gender and ethnicity (unless comparison is within an ethnic group). 
 
Typed 
NAFLD 
 (types 1-4) 
patients vs. 
Obese  
NAFLD (types1-
4) Coloured 
patients vs. 
NAFLD (types 1-
4) Caucasian 
patients 
Obese vs. 
NASH (types 
3,4) patients 
NAFLD (types 
1,2) patients vs. 
NASH (types 
3,4) patients 
FTO  
Genotype  0.377 0.018 0.401 0.694 
Allele (A) 0.307 0.005 0.513 0.690 
TNF-α  
Genotype  0.123 0.102 0.073 0.179 
Allele (A) 0.047 0.034 0.030 0.300 
PPARγ  
Genotype  0.387 0.431 0.513 0.352 
Allele (C) 0.263 0.288 0.528 0.152 
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rs9939609 A-allele was detected at a significantly higher frequency in the Caucasian 
than Coloured patients, while the opposite was detected for the risk-associated TNF-α 
rs1800629 A-allele that occurred at a significantly higher frequency in the Coloured 
compared with Caucasian NAFLD patients (p=0.034). No difference in genotype or 
allelic distribution was observed for PPARγ rs1801282, despite the deviation in Hardy 
Weinberg equilibrium found in NAFLD patients only (not controls). After adjustment for 
age, gender and race, no differences in genotype distribution or allele frequencies were 
observed between histologically confirmed NAFLD (types 1,2) and NASH (types 3,4) 
patients, while the minor allele count for the TNF-α rs1800629 was significantly higher in 
NAFLD patients (types 1-4) (p=0.047) and NASH (NAFLD types 3,4) (p=0.03) compared 
with obese patients without a histologically confirmed diagnosis. This finding was in 
accordance with the expectation of increased disease severity ranging in our study 
population from obese to NAFLD (types 1,2) to NASH (NAFLD types 3,4). 
3.7. Allelic effects and risk score assessment 
According to the literature review performed (chapter 1) the minor A-alleles of FTO 
rs9939609 (intron 1 T>A) and TNF-α rs1800629 (-308 G>A), and the common C-allele of 
PPARγ rs1801282 (Pro12Ala, 34 C>G), are the risk associated alleles (underlined) for 
obesity and/or insulin resistance. The inferred frequencies for seven allelic combinations 
(the eighth, A-A-G was not detected) are summarised in table 3.7.1 and depicted in 
figure 3.7.1. The allelic combination A-A-C was significantly more frequent in NAFLD 
types 1,2 patients than in types 3,4 (NASH) patients, while T-A-C was the risk 
combination for NASH types 3,4 compared to the reference combination T-G-G, after 
adjustment for age, gender and race. However, the allelic combinations A-A-C and T-A-
C had the same effects within the obese, NAFLD types 1,2 and NASH types 3,4 groups 
after adjustment for age, gender, race, smoking, alcohol consumption and physical 
activity. 
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Table 3.7.1. Inferred frequencies of allelic combinations for the FTO rs9939609 (intron 1 
T>A), TNF-α s1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) single 
nucleotide polymorphisms. 
Allele combination Obese NAFLD (types 1,2) NASH (types 3,4) 
Typed 31 45 43 
A-A-C 0.05 0.11 0.02 
A-G-C 0.38 0.21 0.37 
A-G-G 0.02 0.05 0.02 
T-A-C 0.05 0.02 0.11 
T-A-G 0.00 0.00 0.01 
T-G-C 0.50 0.55 0.45 
T-G-G 0.00 0.06 0.02 
 
 
 
Figure 3.7.1. Frequencies of the allelic combinations for FTO rs9939609 (intron 1 T>A), 
TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) in the obese, 
NAFLD (types 1,2) and NASH (types 3,4) patient groups. 
 
A risk score was calculated for each individual by counting the risk associated FTO 
rs9939609 A-alleles, the TNF-α rs1800629 A-alleles, and the PPARγ rs1801282 C-
alleles. A minimum risk score of 0 and a maximum of 6 could therefore be obtained for 
each individual. The frequencies of the risk score of the three patient groups subdivided 
into obese, NAFLD (types 1,2) and NASH (NAFLD types 3,4) are summarised in table 
3.7.2 and depicted in figure 3.7.2. No patient had all three risk homozygotes, which 
    Obese                                          NAFLD (types 1,2)                     NASH (types 3,4) 
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would correspond to the highest risk score of 6. A similar risk score was observed in the 
obese (most individuals had a risk score of 3, 42%), NAFLD types 1, 2 (most had a 
score of 2, 36%) and NASH types 3, 4 (most had a score of 3, 53%) groups (table 3.7.2). 
No significant association with an increasing risk score was detected between the obese 
patients, NAFLD types 1,2 and NASH types 3,4 groups after adjusting for age, gender, 
race, smoking, alcohol consumption and physical activity (p=0.454). 
Table 3.7.2. Counts and frequencies of calculated risk allele score of FTO rs9939609 
(intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 
C>G) combined. 
Risk Score  Obese NAFLD (types 1,2) NASH (types 3,4) 
0 0 (0%) 1 (2%) 0 (0%) 
1 0 (0%) 3 (7%) 1 (2%) 
2 9 (29%) 16 (36%) 9 (21%) 
3 13 (42%) 13 (29%) 23 (53%) 
4 7 (23%) 10 (22%) 9 (21%) 
5 2 (6%) 2 (4%) 1 (2%) 
6 0 (0%) 0 (0%) 0 (0%) 
 
 
 
Figure 3.7.2. The frequencies of the calculated risk score (0-6) for FTO rs9939609 
(intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 
C>G) compared between the three patient groups classified according to disease 
    Obese                                           NAFLD (types 1,2)                    NASH (types 3,4) 
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severity from obese to NAFLD types 1, 2 and 3, 4 (NASH). 
In table 3.7.3 age, gender, race and environmental factors including smoking, drinking 
and physical activity were compared between the three patients groups and also 
compared in relation to genetic variation in the FTO (rs9939609, intron 1 T>A), TNF-α 
(rs1800629, -308 G>A) and PPARγ (rs1801282, 34 C>G) genes. Unadjusted p-values 
are shown in table 3.7.3, to assess the need for adjustment of possible confounding 
factors when genotype-phenotype association studies are performed. 
Table 3.7.3. Unadjusted P-values for difference in environmental factors between obese 
and NAFLD types 1,2 and 3,4 (NASH), as well as the association between 
environmental and genetic risk factors in the combined group. 
Characteristic Patient 
groups 
FTO TNFα PPARγ Risk Score Combination 
Age 0.036 0.288 0.028 0.185 0.008 0.057 
Gender 0.477 0.848 0.288 0.756 0.505 0.822 
Race 0.306 0.056 0.163 0.687 0.788 0.003 
Drinker 0.226 0.274 0.617 0.158 0.526 0.020 
Smoker 0.145 0.616 0.542 0.001 0.022 0.009 
Physical activity 0.501 0.582 0.797 0.063 0.683 0.093 
 
Two important age effects were noted. Histologically confirmed NAFLD patients were, on 
average, 6 years older at entry into the study (also documented as the age of disease 
diagnosis) than the obese patient group (p=0.036). Age of onset of fatty liver disease 
was on average 5 years younger in the presence of each risk-associated TNF-α 
rs1800629 A-allele (p=0.028) among the 119 patients included in this study. This age 
effect was not observed on further assessment of the histologically confirmed NAFLD 
group only, after exclusion of the obese group (p=0.230). When considered in the 
context of FTO rs9939609 and PPARγ rs1801282 as part of the risk score (table 3.7.2), 
a 3 year earlier onset of fatty liver disease symptoms was observed with each of the 
three risk-associated (p=0.008) alleles detected. No gender effect was observed (table 
3.7.3), while the race difference could be ascribed to a frequency of 8.8% for the allelic 
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combination T-A-C in Coloureds, while absent in Caucasians. Among alcohol users, 
none had the A-A-C allelic combination (risk-associated genotype in the context of 
insulin resistance according to the literature review), while it was detected in 6.3% of 
non-users (p=0.020). The allelic combinations T-G-G (11.1% vs. 2.5%) and A-G-G (9.8% 
versus none) were much more prevalent in smokers compared to non-smokers 
(p=0.009). The effect of smoking was mainly ascribed to the PPARγ rs1801282 C allele 
detected at a frequency of 79% (38/48) in smokers, compared with 97% (184/188) in 
non-smokers (p=0.001). All 4 patients with the PPARγ rs1801282 GG genotype, were 
smokers, whereas all the non-smokers were either heterozygous or homozygous for the 
risk-associated C-allele. Of smokers, 17% (4) had the PPARγ rs1801282 GG genotype. 
While none of the non-smokers had it. These findings have no obvious clinical 
implication, but confirm the need to adjust for multiple variables when genotype-
phenotype correlations are assessed in the study population. No potential confounding 
effect for physical activity was detected. 
In table 3.7.4 clinical and biochemical factors were summarized for obese patients with 
fatty liver on ultrasound alone and histologically confirmed NAFLD (types 1,2) and NASH 
(NAFLD types 3,4) patients. A significant joint effect of age, gender and race was 
detected for BMI (kg/m2) (p=<0.009), HbA1c levels (p=0.010) and HDL-cholesterol 
(p=0.004) in the combined patient group. BMI was found to be significantly higher in both 
Coloured NAFLD patients (on average 4 kg/m2) and Black NAFLD patients (on average 
8 kg/m2) compared to the Caucasian NAFLD patients (p=0.009) after adjusting for age, 
gender and race. Race also significantly affected HbA1c levels, which were found to be 
increased by 1.32%, on average, in Coloured NAFLD patients compared with Caucasian 
NAFLD patients (p=0.010). HDL-cholesterol was significantly affected by gender 
(p=0.004); on average female patients had a 0.22 mmol/l higher HDL-cholesterol level 
compared to male patients.  
The test of difference between the obese, NAFLD (types 1,2) and NASH (NAFLD types 
3,4) after adjustment for age gender and race did not show a difference in BMI and waist 
circumference between the histologically confirmed NAFLD (types 1,2) and NASH 
(NAFLD types 3,4) patients. However, both NAFLD patient subgroups had a lower BMI 
(on average 4.4 kg/m2 for NASH and 4.2 kg/m2 for NAFLD types 1.2) (p=0.015) and 
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waist circumference (on average 10 cm for NASH and 12 cm for NAFLD types 1.2) 
(p=0.002) compared to the obese patient group (table 3.7.4). 
Significantly higher levels of ALT (on average 23.4 units/L higher) (p=0.031), glucose 
(2.7 mmol/l) (p=0.005), HbA1c (1.54%) (p=0.003), HOMA-IR (1.13 units) (p<0.001) and 
triglyceride (1.33 mmol/l) (p=0.017) were observed in the NASH patient subgroup 
(NAFLD types 3,4) compared with the obese patient subgroup, after adjustment for age, 
gender and race (table 3.7.4). 
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Table 3.7.4. Description (median, interquartile range) and p-values for comparison of clinical and biochemical factors in obese 
patients with fatty liver on ultrasound alone and histologically confirmed NAFLD (types 1,2) and NASH (NAFLD types 3,4) 
patients. 
 
Characteristic Obese 
NAFLD  
(types 1,2) 
NASH  
(types 3,4) 
Joint effect 
of age, 
gender and 
race 
P-values for 
difference between 
groups, adjusted for 
age, gender and race 
N 31 45 43 
  
BMI (kg/m
2
)  37 (33-43) 33 (31-38) 33 (30-38) 0.009 0.015 
Waist circumference (cm) 111 (102-126) 106 (99-112) 104 (100-115) 0.345 0.002 
ALT (units/L) 35 (29-51) 38 (28-62) 51 (38-70) 0.066 0.031 
AST (units/L) 32 (26-51) 33 (23.5-47) 35 (29-60.5) 0.068 0.078 
AST/ALT ratio 0.79 (0.68-0.95) 0.79 (0.66-0.98) 0.71 (0.64-0.91) 0.477 0.420 
C-Reactive Protein (mg/l) 6.8 (5.3-11.5) 8.2 (3.8-11.5) 6.6 (3.3-10.7) 0.183 0.424 
Glucose (mmol/l) 5.6 (5.3-7.1) 5.8 (5.1-8.2) 7.8 (5.9-9.2) 0.155 0.005 
HbA1c (%) 7.1 (6.0-8.6) 6.5 (5.6-7.4) 7.9 (6.5-9.4) 0.010 0.003 
HOMA-IR 0.3 (0.2-1.3) 1.0 (0.6-1.4) 1.3 (0.8-2.1) 0.583 <0.001 
Insulin (mmol/l); 23 (12-31) 18.8 (9.8-24.7) 21.3 (12.0-33.2) 0.690 0.949 
Tf Saturation (%) 17 (13-21) 15 (11-26) 20 (15-27) 0.592 0.224 
Total Cholesterol (mmol/l) 5.3 (4.8-6.3) 5.6 (4.7-6.2) 5.7 (4.8-6.6) 0.315 0.270 
LDL Cholesterol (mmol/l) 3.6 (3.1-4.0) 3.5 (2.7-4.1) 3.4 (2.8-4.1) 0.241 0.949 
HDL Cholesterol (mmol/l) 1.3 (1.0-1.6) 1.2 (1.1-1.4) 1.2 (1.1-1.5) 0.004 0.421 
Triglycerides (mmol/l) 1.4 (1.1-2.1) 1.6 (1.3-2.4) 1.9 (1.4-3.1) 0.478 0.017 
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Table 3.7.5 shows the P-values for difference in clinical characteristics between patient 
groups [obese versus NAFLD (types1,2) versus NASH (types 3,4) (first column)] and 
association with genetic factors, adjusted for age, gender, race, smoking, alcohol 
consumption and physical activity in the combined patient group. When the results 
presented in table 3.7.4 (last column) were re-assessed in the patient groups in relation 
to BMI and waist circumference after adjustment for smoking, alcohol consumption and 
physical activity (in addition to previous adjustment age, gender and race but excluding 
possible genetic effects), only the difference in waist circumference between the patient 
subgroups remained significant. This finding was not caused due to the effect of any of 
these environmental factors, but resulted from reduced statistical power mainly due to 
the fact that information on these variables were not provided for four patients. Waist 
circumference was on average 11.3 cm smaller in NAFLD (types 1,2) and 8.9 cm smaller 
in NASH (NAFLD types 3,4) than obese patients.  
Table 3.7.6 shows P-values for association between clinical and biochemical 
characteristics and also environmental factors in the 119 obese, NAFLD (types 1,2) and 
NASH (types 3,4) patients after adjusting for age, gender and race. The average waist 
circumference of physically inactive patients was 12% increased compared to the active 
patients (p=0.004). Patients who reported low-moderate alcohol intake (below the cut-off 
level for diagnosis of NAFLD) had on average 70% reduced CRP levels compared with 
patients who abstain from alcohol drinking (p=0.038).  
Tables 3.7.7, 3.7.8 and 3.7.9 contains p-values for tests of interaction between 
environmental factors (BMI and waist circumference considered a reflection of the diet, 
physical activity, smoking and alcohol consumption) and genetic factors [FTO rs9939609 
(intron 1 T>A) (table 3.7.7), TNF-α rs1800629 (-308 G>A) (table 3.7.8) and PPARγ 
rs1801282 (Pro12Ala, 34 C>G) (table 3.7.9)] on clinical and biochemical characteristics 
in the total group of 119 obese, NAFLD (types 1,2) and NASH (types 3,4) patients, after 
adjusting for age, gender and race. The nature of the detected significant interactions is 
described next with the interaction between smoking and each of the FTO rs9939609 
and TNF-α rs1800629 alleles on BMI as follows: the allelic effects in non-smokers were 
not significant, while in smokers each risk-associated FTO rs9939609 A-allele and TNF-
α rs1800629 A-allele detected reduced BMI (kg/m2) by 13% and 27%, respectively, 
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compared with patients with two copies of the major SNP alleles (p=0.010). The 
interaction between smoking and FTO rs9939609 in relation to transferrin saturation was 
that the rate of change was not significant in smokers (lower for each risk allele) nor in 
non-smokers (higher), but the difference between the effects was significant (p=0.039). 
In patients who reported low-moderate alcohol intake, each risk-associated FTO A-allele 
increased LDL-cholesterol by 54%, compared to having inherited no A-allele (p=0.002), 
while there was no allelic effect in those who did not report drinking. 
Significant interactions were detected between TNF-α rs1800629 and BMI or waist 
circumference on CRP levels; a significant 6% increase in CRP levels was detected for 
each extra kg/m2 in BMI in the absence of the risk-associated A-allele (GG genotype), 
while CRP levels are reduced by 11% (GA genotype) or 26% (AA genotype), 
respectively for each additional kg/m2 in BMI, compared to patients with the GG 
genotype (p=0.005). For each extra cm in waist circumference, CRP levels were 10% 
(GA genotype) or 21% (AA genotype) reduced compared to patients with the GG 
genotype, for whom waist circumference did not show a significant effect (p=0.003). 
From the data presented (p-values) in table 3.7.9, triglyceride levels of patients 
homozygous for the PPARγ rs1801282 risk-associated C allele decreased by 3% with 
each added unit of BMI (1 kg/m2) and increased by 6% with each added BMI unit in GG 
homozygote patients (p=0.013). There was no effect in PPARγ rs1801282 CG 
heterozygotes. No allelic effect for PPARγ rs1801282 was detected in smokers nor non-
smoking on LDL-cholesterol levels, only the difference between those effects was 
significant (p=0.046). The same was observed for PPARγ rs1801282 in relation to the 
effect of alcohol consumption on AST levels; neither drinking nor abstaining was 
associated with a significant effect and only the difference between those effects was 
significant (p=0.048). Abstaining from alcohol was not associated with a significant allelic 
effect of PPARγ rs1801282 on insulin, while alcohol drinkers showed an increase of 
175% with each G-allele (decrease of 175% with each C-allele). Since this estimate was 
based on data from 1 drinker (AST 67) and three non-drinkers (average AST 29) the 
results should be interpreted with caution. 
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Table 3.7.5 P-values for testing of association between clinical characteristics and patient groups for obese versus NAFLD 
(types1,2) versus NASH (types 3,4) (first column) and genetic factors, after adjusting for age, gender, race, smoking, alcohol 
consumption and physical activity in the combined patient group. 
Clinical characteristics Groups FTO TNFα PPARγ Risk score Combination 
BMI (kg/m
2
) 0.139 0.659 0.346 0.020 0.060 0.027 
Waist circumference (cm) 0.006 0.381 0.043 0.175 0.021 0.063 
ALT (units/L) 0.042 0.246 0.823 0.993 0.360 0.378 
AST (units/L) 0.065 0.136 0.495 0.776 0.130 0.015 
AST/ALT ratio 0.610 0.870 0.536 0.683 0.529 0.977 
C-Reactive Protein (mg/l) 0.913 0.717 0.029 0.598 0.296 0.257 
Glucose, fasting (mmol/l) 0.008 0.468 0.744 0.599 0.676 0.970 
HOMA-IR <0.001 0.348 0.196 0.121 0.476 0.183 
HbA1c (%) 0.007 0.486 0.857 0.786 0.659 0.398 
Insulin concentration (mmol/l) 0.930 0.635 0.731 0.165 0.387 0.406 
Tf Saturation (%) 0.284 0.769 0.960 0.072 0.326 0.191 
Total Cholesterol (mmol/l) 0.339 0.930 0.627 0.345 0.519 0.889 
LDL Cholesterol (mmol/l) 0.879 0.591 0.392 0.457 0.659 0.232 
HDL Cholesterol (mmol/l) 0.384 0.897 0.812 0.695 0.878 0.437 
Triglycerides (mmol/l) 0.052 0.617 0.670 0.553 0.399 0.844 
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Table 3.7.6. P-values for testing of association of clinical and biochemical characteristics with environmental factors, 
(including BMI and WC as a reflection of the diet) in obese, NAFLD (types 1,2) and NASH (NAFLD types 3,4) patients after 
adjusting for age, gender and race. 
Clinical characteristics 
BMI 
Waist 
circumference Physical activity Smoking Drinking 
Body mass index (BMI) (kg/m
2
) - - 0.065 0.098 0.089 
Waist circumference (WC) (cm) - - 0.004 0.765 0.203 
ALT (units/L) 0.003 0.083 0.172 0.511 0.332 
AST (units/L) 0.003 0.102 0.074 0.856 0.512 
AST/ALT ratio 0.469 0.499 0.824 0.152 0.464 
C-Reactive Protein (mg/l) 0.625 0.952 0.675 0.283 0.038 
Glucose, fasting (mmol/l) 0.014 0.147 0.248 0.013 0.452 
HOMA-IR 0.631 0.540 0.754 0.462 0.078 
HbA1c (%) 0.006 0.215 0.339 0.171 0.829 
Insulin concentration (mmol/l) 0.263 0.136 0.875 0.759 0.349 
Tf Saturation (%) 0.001 0.043 0.958 0.124 0.862 
Total Cholesterol (mmol/l) 0.032 0.180 0.723 0.842 0.385 
LDL Cholesterol (mmol/l) 0.107 0.287 0.411 0.785 0.516 
HDL Cholesterol (mmol/l) 0.325 0.711 0.968 0.166 0.708 
Triglycerides (mmol/l) 0.009 0.110 0.999 0.581 0.917 
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Table 3.7.7. P-values for testing of interaction between the FTO rs9939609 A-allele and environmental factors on clinical 
characteristics in 119 obese, NAFLD (types 1,2) and NASH (NAFLD types 3,4) patients after adjusting for age, gender and 
race.  
Clinical characteristics 
BMI 
Waist 
circumference  Physical activity Smoking Drinking 
BMI (kg/m
2
) - - 0.550 0.010 0.302 
Waist circumference (cm) - - 0.753 0.051 0.368 
ALT (units/L) 0.147 0.407 0.749 0.593 0.715 
AST (units/L) 0.569 0.985 0.578 0.435 0.561 
AST/ALT ratio 0.096 0.108 0.808 0.838 0.827 
C-Reactive Protein (mg/l) 0.476 0.278 0.506 0.460 0.897 
Glucose, fasting (mmol/l) 0.298 0.549 0.847 0.075 0.307 
HOMA-IR 0.938 0.766 0.380 0.808 0.448 
HbA1c (%) 0.840 0.440 0.362 0.728 0.405 
Insulin concentration (mmol/l) 0.938 0.594 0.548 0.444 0.274 
Tf Saturation (%) 0.239 0.877 0.218 0.039 0.950 
Total Cholesterol (mmol/l) 0.332 0.764 0.570 0.922 0.063 
LDL Cholesterol (mmol/l) 0.243 0.690 0.704 0.487 0.002 
HDL Cholesterol (mmol/l) 0.112 0.080 0.897 0.841 0.053 
Triglycerides (mmol/l) 0.689 0.745 0.497 0.750 0.539 
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Table 3.7.8. P-values for testing of interaction between TNF-α rs1800629 (-308 G>A) and environmental factors on clinical 
characteristics in 119 obese, NAFLD (types 1,2) and NASH (NAFLD types 3,4) patients after adjusting for age, gender and 
race. 
Clinical characteristics 
BMI 
Waist 
circumference Physical activity Smoking Drinking 
BMI (kg/m
2
) - - 0.293 0.010 0.280 
Waist circumference (cm) - - 0.630 0.051 0.208 
ALT (units/L) 0.924 0.645 0.650 0.427 0.402 
AST (units/L) 0.910 0.682 0.247 0.630 0.484 
AST/ALT ratio 1.000 0.824 0.379 0.487 0.665 
C-Reactive Protein (mg/l) 0.003 0.005 n/a 0.778 0.359 
Glucose, fasting (mmol/l) 0.266 0.213 0.932 0.848 0.252 
HOMA-IR 0.574 0.112 0.151 0.137 0.526 
HbA1c (%) 0.242 0.106 0.312 0.731 0.854 
Insulin concentration (mmol/l) 0.855 0.310 *n/a 0.476 0.947 
Tf Saturation (%) 0.267 0.163 *n/a 0.197 0.545 
Total Cholesterol (mmol/l) 0.732 0.889 0.603 0.158 0.737 
LDL Cholesterol (mmol/l) 0.855 0.430 0.754 0.198 0.096 
HDL Cholesterol (mmol/l) 0.139 0.167 0.143 0.655 0.330 
Triglycerides (mmol/l) 0.712 0.348 0.611 0.272 0.543 
n/a, not available  
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Table 3.7.9. P-values for the interaction between PPARγ rs1801282 (Pro12Ala, 34 C>G) and environmental factors on 
clinical characteristics in 119 obese, NAFLD (types 1,2) and NASH (NAFLD types 3,4) patients after adjusting for age, gender 
and race. 
Clinical characteristics 
BMI 
Waist 
circumference Physical activity Smoking Drinking 
BMI (kg/m
2
) - - 0.713 0.704 0.548 
Waist circumference (cm) - - 0.742 0.425 0.215 
ALT (units/L) 0.726 0.766 0.672 0.803 0.100 
AST (units/L) 0.745 0.675 0.337 0.846 0.048 
AST/ALT ratio 0.285 0.196 0.514 0.463 0.972 
C-Reactive Protein (mg/l) 0.795 0.819 0.645 *n/a n/a 
Glucose, fasting (mmol/l) 0.955 0.996 0.729 0.821 0.640 
HOMA-IR 0.544 0.208 0.743 0.672 0.236 
HbA1c (%) 0.191 0.827 0.555 0.123 0.960 
Insulin concentration (mmol/l) 0.676 0.289 0.876 0.782 0.032 
Tf Saturation (%) 0.286 0.951 0.425 0.396 0.838 
Total Cholesterol (mmol/l) 0.377 0.899 0.076 0.346 0.090 
LDL Cholesterol (mmol/l) 0.860 0.715 0.119 0.046 0.117 
HDL Cholesterol (mmol/l) 0.093 0.287 0.279 0.245 0.315 
Triglycerides (mmol/l) 0.013 0.374 0.167 0.829 0.109 
n/a, not available  
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Age of onset of fatty liver disease was on average 5 years younger in the presence of 
each risk-associated TNF-α rs1800629 A-allele (p=0.028) and 3 years younger when 
incorporated as part of the genotype risk score tested in the total group of 119 patients 
included in this study. Extended statistical analysis to verify these age effects in relation 
to alcohol intake and smoking was subsequently undertaken. Single effects were 
assessed after adjusting for multiple variables, as well as combined effects to determine 
the impact of cumulative risk. 
Table 3.7.10. P-values for assessment of genetic association with age of onset of fatty 
liver disease symptoms in the combined patient group (n=119) according to sets of 
factors including the presence or absence of alcohol consumption or smoking. 
Variables tested Adjusted for P-value 
Alcohol Race, gender 0.095 
TNFα rs1800629 Race, gender, alcohol 0.015 
Genotype risk score Race, gender, alcohol 0.020 
TNFα, race, gender, alcohol* - 0.008 
Risk score, race, gender, alcohol* - 0.009 
Race, gender, alcohol* - 0.059 
Alcohol, risk score Race, gender 0.639 
Smoker Race, gender 0.882 
TNFα rs1800629 Race, gender, smoker 0.766 
Genotype risk score Race, gender, smoker 0.418 
TNFα, race, gender, smoker * - 0.477 
Risk score, race, gender, smoker* - 0.412 
Race, gender, smoker* - 0.363 
Smoker, risk score Race, gender 0.595 
*combined effects of multiple variables were tested to determine cumulative risk 
Further analysis showed that each TNF-α rs1800629 risk-associated A-allele subtracts 
on average 5 years from age in the patient study group, after adjusting for race, gender 
and alcohol consumption (5.5 years, p=0.015). When these factors were combined to 
assess cumulative risk, the association becomes even more significant (p=0.008). For 
each extra risk allele incorporated in the genotype risk score (0-6) for FTO rs9939609 
(intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 
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C>G), 2.6 years are subtracted (figure 3.7.3) after adjusting for race, gender and alcohol 
consumption (p=0.020). Alcohol intake or smoking had no effect on age of onset of fatty 
liver disease symptoms with or without adjusting for confounders.  
 
Figure 3.7.3.Box plots of age of onset of fatty liver disease symptoms in the patient 
study group (n=119) and a genotype risk score for FTO rs9939609 (intron 1 T>A), TNF-α 
rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G). The risk-associated 
alleles as previously described in the literature in relation to obesity and/or insulin 
resistance are underlined.  
The association between age of onset of fatty liver disease symptoms and allelic 
combination for FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and 
PPARγ rs1801282 (Pro12Ala, 34 C>G) in NAFLD types1,2, NAFLD types 3,4 (NASH) 
and obese patients was significant (p=0.039) after adjustment for gender. The modelled 
effect of allelic combination on age of diagnoses is illustrated in figure 3.7.4. 
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Figure 3.7.4. Modelled ages for onset of fatty liver disease symptoms or NAFLD 
diagnosis for all the allelic combinations of FTO rs9939609 (intron 1 T>A), TNF-α 
rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) for males and 
females. 
Gender had an independently significant effect in the joint model of gender and allelic 
combinations (p=0.023). After the adjustment for allelic combination, females were 5.2 
years younger at onset compared to male patients. 
There was no independent significant association between age of diagnosis and PPARγ 
rs1801282 (Pro12Ala, 34 C>G) (p=0.113) even when adjusted for gender (p=0.127). 
However the combination of age and gender was significant (p=0.033) and with each 
risk associated PPARγ rs1801282 C-allele age of onset is reduced by 3.7 years. The 
largest effect on earlier age of onset of fatty liver disease symptoms was exerted by 
TNF-α rs1800629 (-308 G>A), while FTO rs9939609 (intron 1 T>A) was not associated 
with earlier age of onset of disease symptoms or diagnosis. 
 
FTO rs9939609 (T>A)  -  TNF-α rs1800629 (G>A)  -  PPARγ rs1801282 (C>G) 
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Functional SNPs in the FTO (rs9939609, intron 1 T>A), TNF-α (rs1800629, -308 G>A) 
and PPARγ (rs1801282, Pro12Ala, 34 C>G) genes were studied in 166 control 
individuals and 119 NAFLD patients subdivided into obese patients with fatty liver 
identified on ultrasound alone (n=31) and histologically confirmed NAFLD patients 
(n=88). An important objective of the study was to identify genetic determinants of 
disease progression from fatty liver disease to NASH, with a particular focus on the role 
of insulin resistance and inflammation in the disease process. Insulin resistance has 
previously been identified as a central feature of NAFLD in the South African population, 
while obesity was excluded as an independent determinant of disease severity at the 
clinical level by Kruger et al. (2010). This parent study provided a clinically well-
characterised study population for possible confirmation of these findings at the DNA 
level. Functional SNPs in the FTO (rs9939609, intron 1 T>A), TNF-α (rs1800629, -308 
G>A) and PPARγ (rs1801282, Pro12Ala, 34 C>G) genes were selected for evaluation in 
this context, in view of their proven role in inflammation, obesity, insulin resistance 
and/or type II diabetes (Frayling et al. 2007 Gouda et al. 2010; Namvaran et al. 2011; 
Prakash et al. 2012; Sobati et al. 2012; Zhou et al. 2012a).  
The genetic data provided in this study indeed confirmed the central role of insulin 
resistance in the disease process, while obesity was excluded as an independent risk 
factor for development of NAFLD and/or progression to NASH.  The genetic contribution 
of the TNF-α SNP (rs1800629, -308 G>A) was shown to be of particular importance in 
relation to NAFLD. Due to the invasiveness of histopathologic diagnosis based on liver 
biopsy the identification of predictive genetic risk factors represents an important area of 
research to facilitate the prevention of cumulative risk that may lead the development of 
CVD or hepatic fibrosis. Kruger et al. (2011) have demonstrated the clinical usefulness 
of APRI as a non-invasive marker for liver fibrosis to avoid liver biopsy in South African 
patients with NAFLD. However, the undefined nature of hereditary factors impacting on 
disease development and severity in the ethnically diverse South African population 
warrants genetic studies to identify the underlying disease mechanism(s) in clinically well 
characterised NAFLD patients.  
A critical step for implementation of genetic tests is to understand where the additional 
information provided by this technology fits into the context of the current clinico-
pathological prognostication of NAFLD. This study was therefore modelled on a 
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pathology supported genetic testing (PSGT) approach recently described in the context 
of CVD, to identify patient subgroups requiring different treatment strategies (Kotze and 
van Rensburg, 2012). Genetic testing for CVD risk factors provides a prototype for 
complex conditions that frequently share disease mechanisms due in part to overlap 
between genetic risk factors. NAFLD is the hepatic manifestation of the metabolic 
syndrome and is an established CVD risk factor (Neuschwander-Tetri et al. 2003; 
Targher et al. 2007). An important consideration was therefore to extend the CVD 
multigene test developed in South Africa (Kotze et al. 2003, Kotze and Thiart 2003) by 
adding a genetic component related to obesity, insulin resistance and inflammation for 
CVD risk evaluation in patients with symptoms of fatty liver disease. Functional SNPs in 
the FTO (rs9939609, intron 1 T>A), TNF-α (rs1800629, -308 G>A) and PPARγ 
(rs1801282, Pro12Ala C>G) genes were selected for this purpose as discussed below in 
relation to the specific aims defined for this study: 1) to perform analytical validation of 
high-throughput RT-PCR assays for the selected SNPs against direct sequencing as the 
gold standard; 2) compare the genotype distribution and allele frequencies between 
NAFLD patient subgroups and controls; 3) correlate clinical and biochemical parameters 
of insulin resistance with genotype and environmental factors assessed in NAFLD 
patients; and 4) determine the potential impact of risk factors incorporated into a 
genotype risk score on age of onset in fatty liver disease patients in relation to NAFLD 
disease severity. 
4.1. Analytical validation of high-throughput RT-PCR 
DNA samples of the 166 Caucasian control individuals were used to perform analytical 
validation of the high-throughput real time polymerase chain reaction (RT-PCR) 
genotyping method, against direct sequencing as the gold standard. Analytical validation 
of the RT-PCR screening method used was accomplished by comparing pre-sequenced 
positive control samples and including them as internal control samples during each run 
to corroborate the results generated during the screening process.  
Methods currently available to genotype an individual’s DNA include conventional or real 
time PCR using DNA fragment analysis or allele specific oligonucleotide probes, 
conventional DNA sequencing, next generation DNA sequencing, nucleic acid 
hybridization (microarrays/beads), restriction fragment length polymorphism (RFLP) 
analysis, terminal or amplified (t-FLP or AFLP) and multiplex ligation-dependant probe 
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amplification. PCR amplification using fluorescence resonance energy transfer probes 
was applied successfully in this study to genotype DNA samples of the study population 
for FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282, 
(Pro12Ala, 34 C>G). The probes used amplified the specific mutation sites of interest 
and the results obtained were corroborated by direct DNA sequencing. Comparison of 
PCR-based mutation screening methods against direct sequencing as the gold standard 
has proven to be a dependable approach for analytical validation of new genotyping 
assays.  In this study conventional PCR amplification was used in conjunction with DNA 
sequencing to first identify positive and negative controls for the FTO rs9939609 (intron 
1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 G>C) SNPs 
used as internal controls in this study. High-throughput RT-PCR provided a rapid method 
for simultaneous analysis of large numbers of DNA samples in this study. 
The principle of RT-PCR is nearly identical to that of conventional PCR except that the 
reaction mixtures differ. The “real time” reaction mixture used included a fluorescence 
resonance energy transfer probe that binds to the PCR product in a specific head to tail 
manner. The fluorescence data were collected after each amplification cycle. This 
allowed for optimisation of individual samples when compared to positive and negative 
controls resulting in an increased specificity and sensitivity of the individual assays 
performed in the study population.  
The exponential phase of amplification (starting DNA and amplification product) is the 
most useful type of quantification and this forms the basis of RT-PCR. The two common 
methods for detecting RT-PCR products are the intercalating of fluorescent dyes with 
double stranded DNA; and specific DNA probes that are labelled with a reporter dye 
(fluorescent) detected after hybridization of the probe with its complimentary DNA. RT-
PCR using TaqMan® assay in its simplest form is DNA binding to a dye such as SYBR 
Green that intercalates with the double stranded DNA. Fluorescence of the dye is 
detected after excitation; however this binding process of SYBR Green is non-specific. 
Therefore, in order to detect a specific amplicon an oligonucleotide probe labelled with a 
specific reporter molecule was added in the reaction of SYBR Green. When the probe 
binds to its target sequence a signal was generated that is directly proportional to the 
number of molecules. To detect the fluorescence as it proceeds specific thermal cycler 
such as the Applied Biosystems® 7900HT (Brown, 2003) was used. 
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The availability of high quality DNA extracted from blood or saliva was essential to 
successfully genotype (allelic discrimination) the individuals included in this study. The 
quality or quantity of many samples from the original database of NAFLD patients was 
not sufficient and therefore only 88 histologically confirmed NAFLD patients could be 
included in this study. Even though peripheral blood is the preferred source of DNA the 
extraction procedure required to obtain a sample is invasive. A study done by Abraham 
et al. (2012) investigated the feasibility of using saliva extracted DNA in comparison to 
blood-extracted DNA. Their findings suggested that the total DNA yield in saliva were 
lower (mean 24µg) compared to blood (mean 210 µg) after adjusting for the volume 
difference. Protein contamination and the rate of DNA fragmentation measured higher in 
saliva compared to blood. However, when genotyping using TaqMan® assays as we did 
during the allelic discrimination phase of this project, genotype call rates and 
concordance were the same for all the samples assessed. Saliva sample collection is 
less invasive for the patient and more convenient for the clinician and this could 
positively affect participant recruitment for genetic studies and be a viable alternative 
DNA source for high throughput genotyping techniques. Within this study an optimal 
quantity and quality of DNA was obtained, irrespective of the extraction protocol used 
(blood or saliva).  
4.2. Comparison of genotype distribution and allele frequencies between study 
groups 
Following the optimisation of the RT-PCR assays for the FTO rs9939609 (intron 1 T>A), 
TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) SNPs in 166 
Caucasian control individuals, a total of 119 patients were genotyped using the ABI™ 
7900HT and Corbett Rotor-Gene™. Thirty-one patients with a fatty liver detected on 
ultrasound alone were grouped separately for comparative studies from the 88 
histologically confirmed NAFLD patients, including 47 Coloured, 35 Caucasian, 5 Black 
and 1 Indian patient. Within the non-histologically confirmed obese patient group 23 
patients were Coloured, 6 Caucasian and 2 Black. Since genotype distribution and allele 
frequencies of most SNPs vary considerably between ethnic groups, statistical 
comparisons were made within the same ethnic group or after adjustment for ethnicity.  
 
The prevalence of NAFLD/NASH varies greatly among different population groups and 
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raised the question whether this could partly be ascribed to differences in allele 
frequencies of disease-associated SNPs across ethnic groups. The incidence of non-
alcoholic hypertransaminasemia in Japanese individuals was 31 cases per 1000 person-
years (Suzuki et al. 2005) and 29 cases per 100 000 person years in Europeans 
(Hamaguchi et al. 2005). The prevalence of NAFLD in Korean liver transplant donors 
was 51% (Lee et al. 2007) and 20% in American donors (Marcos et al. 2000).The 
prevalence of steatohepatitis and fibrosis in lean autopsied Canadian individuals was 3% 
and 7%, respectively (Wanless and Lentz, 1990). Autopsied cases from Greece revealed 
steatosis in 31% and NASH in 40% of traffic accident deaths, after exclusion of other 
liver diseases (Zois et al. 2010). There is convincing evidence substantiating that genetic 
factors account for considerable variability in the natural history of NAFLD. A family 
clustering study conducted by Wilner et al. (2001) has shown that one fifth of patients 
with NASH have a similarly affected first-degree relative. In a study by Struben et al. 
(2000), coexistence of NASH and cryptogenic cirrhosis was observed in seven out of 
eight families studied. To fully elucidate an accurate global incidence rate for NAFLD 
further research is needed. A variety of diagnostic tools have been used to assess the 
prevalence of NAFLD in the general population, liver biopsies being the gold standard 
method for NASH diagnosis and staging.  
 
For this study a control group for the coloured population was not available for study. All 
three SNPs tested in the 166 South African Caucasian control individuals were in Hardy 
Weinberg equilibrium, while in the NAFLD patient group subdivided into Coloured 
(p=0.005) and Caucasian (p=0.043) patients a significant deviation was observed for 
PPARγ rs1801282. This was caused by over-representation of the PPARγ rs1801282 
GG genotype, an observation that is unrelated to increased or decreased disease risk 
related to the G- or C-allele. PPARγ rs1801282 (Pro12Ala, 34 C>G) groupings were 
found to be in Hardy Weinberg equilibrium in the 31 obese patients, but since this group 
includes both Caucasian and Coloured individuals this finding may not be reliable. Hardy 
Weinberg equilibrium is a mathematical statement that describes genetic balance (allele 
and genotype frequencies) within a population. The genetic characteristics tend to 
remain constant unless outside forces (mutations, immigration, disease state etc.) act to 
change it. 
Comparison of the FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and 
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PPARγ rs1801282 (Pro12Ala, 34 C>G) minor allele frequencies and genotype 
distribution between the different study groups did not show significant differences 
between the general Caucasian controls (21% obese) and Caucasian NAFLD patients 
(71% obese). Although the risk-associated TNF-α A-allele detected in 9% of the 35 
NAFLD patients appeared to be lower than the 15% detected in the 166 controls this 
difference did not reach statistical significance (p=0.981), as was also confirmed in a 
sub-analysis of 67 Caucasian controls with normal BMI (<25 kg/m2).  
The allele frequencies and genotype distribution of FTO rs9939609 (intron 1 T>A), (38% 
TT, 42% TA, 20% AA) in the Caucasian controls were found to be similar to a study of 
4291 Caucasian individuals conducted by Lurie et al. (2011), (36% TT, 47% TA, 17% 
AA). A significant difference in genotype distribution (p=0.018) and allele frequencies 
(p=0.005) for the FTO rs9939609 T>A SNP was identified in NAFLD Coloured patients 
compared with NAFLD Caucasian patients. The minor A-allele was detected at a lower 
frequency in the South African Coloured NAFLD patients compared to the Caucasian 
NAFLD patients. The number of Black NAFLD patients included in the study was too 
small to determine allele frequencies with accuracy. Lombard et al. (2012) reported the 
genotype distribution of FTO rs9939609 (intron 1 T>A) in Black South African 
adolescents from the Birth to Twenty cohort to be 20% TT, 53% TA and 27% AA, with a 
minor allele frequency of 47%. These authors identified a stronger association between 
FTO rs17817449 and obesity in the Black population studied, compared with FTO 
rs9939609 analysed in our study. The minor A-allele of FTO rs9939609 was detected at 
a similar frequency in the NAFLD (types 3,4) group (41%) compared to the NASH 
(NAFLD types 1,2) patient group (37%), with the lowest overall frequency in the 
Coloured NAFLD patient group.  
The FTO rs9939609 A-allele was reported as the risk allele (Li et al. 2012) and is 
considered a predictive factor for the development of obesity and subsequently type II 
diabetes. Failure to confirm the role of this SNP on disease development or progression 
in the context of obesity in our study population corresponds with earlier findings in 
NAFLD patients at the clinical level (Kruger et al. 2010). This may partly be ascribed to 
the fact that the non-histologically confirmed obese patients with fatty liver detected on 
ultrasound only was preselected as being obese. To our knowledge, the FTO rs9939609 
has not previously been studied in South African NAFLD patients, and the allele 
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frequencies and genotype distribution are also reported for the first time in patients with 
fatty liver disease.  
In the case of TNF-α rs180629 (G>A) the allele frequencies and genotype distribution 
(72% GG, 26% GA, 2% AA) in the general Caucasian control samples were found to be 
similar to those previously reported (72% GG, 27% GA, 1% AA) by Paskulin et al. 
(2011). In a study performed by Joffe et al. (2011) in the South African Caucasian 
population comparison of genotype distribution (p=0.345) between normal-weight (55% 
GG, 43% GA, 2% AA) and obese (58% GG, 40% GA, 1% AA) individuals or allele 
frequencies (p=0.453) did not reveal any statistically significant differences for TNF-α 
rs180629. After adjustment for age, gender and race the minor allele count for the TNF-α 
rs1800629 A-allele was significantly higher in NAFLD patients (types 1-4) (p=0.047) and 
NASH (NAFLD types 3,4) (p=0.03) compared with obese patients without a histologically 
confirmed diagnosis (see table 3.6.3). This finding is in accordance with the expectation 
of increased disease severity ranging in our study population from obese to NAFLD 
(types 1,2) to NASH (NAFLD types 3,4) and may be related to an increased risk of 
inflammation known to be associated with NASH (Argo et al. 2011).  
The risk-associated A-allele of TNF-α rs1800629 was present at a significantly higher 
frequency in Coloured NAFLD patients (16%) compared with Caucasian NAFLD patients 
(9%) (p=0.034). This finding may be related to different disease patterns of NAFLD seen 
among ethnic groups. In a diet intervention study performed in the South African Black 
population the frequency of the TNF-α rs1800629 A-allele ranged between 14% to 20% 
in normal weight and obese individuals, respectively (Joffe et al. 2011). The A-allele 
frequency in Chinese individuals was reported to be 9%, French and Scandinavian 16%, 
Germans 18% and in Australians 24% (Feng et al. 2011). The overall frequency of the -
308 TNF-α rs1800629 G>A polymorphism as reported by Wang et al. (2012) within a 
NAFLD population group were similar or slightly lower (14.2%) compared to the control 
group (15.6%). This trend was also observed in our study, as 26% of the Caucasian 
control samples tested positive for the TNF-α rs1800629 polymorphism and 22% of the 
NAFLD types 1-4 patient group. The genotype distribution of TNF-α rs1800629 were 
very similar in the Caucasian control samples and NAFLD Caucasian patient samples. A 
similar TNF-α rs1800629 genotype distribution in 244 South African women with cervical 
cancer (71% GG, 26% GA and 3% AA) was also reported by Govan et al. (2006). 
Stellenbosch University http://scholar.sun.ac.za
Chapter IV 
   Discussion 
 
97 
 
Homozygosity of for the TNF-α AA genotype is relatively rare in the general population 
ranging from 1% as reported by Stanczuk et al. (2003) in Zimbabwean individuals to 5% 
in several other population groups.  
The allele frequencies and genotype distribution (73% CC, 23% CG, 3% GG) of PPARγ 
rs1801282 (Pro12Ala, 34 C>G) in the Caucasian control samples were comparable to 
those observed by Mook-Kanamori et al. (2009) (77% CC, 21% CG, 2% GG). Although 
the difference was not statistically significant, the risk-associated C-allele of PPARγ 
rs1801282 was found to be more prevalent in the NASH (types 3,4) patient group (95%) 
compared to the NAFLD (types 1,2) patient group (89%) as would be expected in 
relation to disease severity. The PPARγ rs1801282 (Pro12Ala, 34 C>G) C-allele 
occurred at a higher frequency in the Coloured NAFLD patients (91%) compared to the 
Caucasian NAFLD patients (83%), but after adjustment for age this difference did not 
reach statistical significance. 
The PPARγ rs1801282 (Pro12Ala, -34 C>G) SNP is located in exon 2 of the PPARγ 
gene, consisting of 9 exons. The SNP arises from a C to G substitution at nucleotide 
position 34 of the NM_015869.4 PPARG transcript-
(http://www.ncbi.nlm.nih.gov/gene/?term=NM_015869.4%20). However, the position of 
the variant may change depending on the specified transcript. For example, one of the 
PPARγ splice variants relates to a SNP that is located in an intronic region, while in 
others the SNP site is allocated to an exonic region (Pro40Ala). Therefore, it is very 
important to specify the splice variant from which the sequence surrounding the 
Pro12Ala was obtained and to provide the correct SNP identity number (whether 
rs1801282 or rs1805192) when designing the genotype assay for functional PPARγ 
rs1801282. 
There is controversy regarding the role of PPARγ rs1801282 (Pro12Ala, 34 C>G) in type 
2 diabetes, obesity and insulin resistance. This is mostly ascribed to the fact that in 
different population groups this SNP acts in the background of other polymorphisms that 
may vary in frequency between ethnic groups and/or exerts its effect in combination with 
different environmental exposures to precipitate certain phenotypes. For example, 12Ala 
(GG genotype) has been associated with decreased BMI, lower insulin, higher insulin 
sensitivity, and higher HDL-cholesterol (Huguenin and Rosa, 2010). In contrast, Passaro 
et al. (2011) associated the variant with increased BMI (kg/m2) and body fat mass. 
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Gouda et al. (2010) showed that in women the 12Ala variant was associated with type 2 
diabetes. Oh et al. (2000), on the other hand, did not find any link between Pro12Ala 
rs1801282 C>G and either diabetes or obesity. The frequency of the Pro12Ala 
polymorphism varies between cohorts from different European countries (Helwig et al. 
2007). The association between insulin resistance and PPARγ rs1801282 may be 
dependent on age as reported by Li et al. (2003). Hasstedt et al. (2001) suggested that 
the variant acts in a recessive manner affecting phenotypes commonly associated with 
insulin resistance syndrome, and this may explain the inconsistent associations reported 
in previous studies.  
The risk-associated PPARγ rs1801282 C-allele contributes to insulin resistance 
(Namvaran et al. 2011; Sanghera et al. 2010) and as NAFLD is considered the hepatic 
manifestation of the metabolic syndrome, individuals homozygote for C-allele may be at 
a higher risk for developing NAFLD or to progress to NASH. The role of PPARγ in the 
development of NAFLD is still not conclusive but point to the direction that NAFLD 
patients are more insulin resistant and have a higher risk allele frequency compared to 
the general population. Since the PPARγ CC genotype is associated with an increased 
risk of type II diabetes it is feasible that evolutionary pressure due to environmental 
hardship could have influenced the survival advantage and spread of this genotype in 
previous generations. Pirie et al. (2010) conducted a study of genetic variation of PPARγ 
in South African subjects of Zulu descent presenting with type 2 diabetes, but the allelic 
distribution did not differ between subjects with or without type 2 diabetes. We also did 
not find any statistically significant differences in genotype distribution or allele 
frequencies between the study groups, despite the fact that the PPARγ rs1801282 allelic 
distribution deviated from Hardy Weinberg equilibrium only in South African NAFLD 
patients.  
4.3. Correlation of clinical and biochemical parameters of insulin resistance and 
inflammation with genotype and environmental factors assessed in NAFLD 
patients 
Subtle genetic variation of FTO rs9939609 T>A, TNF-α rs1800629 G>A and PPARγ 
interacting with environmental factors such as smoking, physical activity and alcohol 
consumption combined with clinical (BMI, waist circumference) and biochemical 
parameters (lipid profile, CRP etc.) may contribute to the disease process as may be 
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reflected by age at diagnosis/onset of disease symptoms and progression from mild 
NAFLD types 1,2 to the more severe NAFLD types 3,4 (NASH). In order to investigate 
these aspects, potential confounding factors was taken into account for comparative 
analyses.  
In this study a significant effect of age, gender and race was detected for BMI (p<0.009), 
HbA1c levels (p=0.010) and HDL-cholesterol (p=0.004) among obese and NAFLD 
patients subdivided into types1,2 and types 3,4 (NASH). BMI kg/m2 was found to be 
significantly higher in both Coloured NAFLD patients and Black NAFLD patients 
compared to the Caucasian NAFLD patients (p=0.009), after adjusting for age, gender 
and race. The impact of obesity varies greatly, even among individuals with a similar 
BMI, it is also a rather crude method of describing the total adiposity because other 
factors such as genetics, gender, age, masculinity, ethnicity and body fat distribution 
(visceral or abdominal) that influence BMI (Stommel et al. 2010). Obesity in NAFLD may 
also vary greatly among NAFLD patients with a similar BMI (Lomonaco et al. 2012). 
Female patients and older individuals have a higher adiposity for any given BMI 
compared to younger male subjects, and obesity early in life significantly predisposes 
individuals to future metabolic related diseases such as CVD and type 2 diabetes (Cusi, 
2012).  
The average plasma glucose concentration over a prolonged period of time may be 
reflected by means of measuring HbA1c levels. In this study race was found to 
significantly affect HbA1c levels, with higher levels detected in Coloured NAFLD patients 
compared with Caucasian NAFLD patients (p=0.010). Since HDL-cholesterol is 
significantly affected by gender (Whakabayashi, 2012) the finding that female patients 
had on average a 0.22 mmol/l higher HDL-cholesterol level compared to male patients 
(p=0.004) could be expected.  
The importance of race as a risk factor for NAFLD was demonstrated by reports that the 
prevalence of NAFLD, hepatic steatosis and concentrated aminotransferase levels are 
the highest in Hispanic individuals followed by Whites, with the lowest rate in African 
Americans (Kalwitz et al. 2008; Williams et al. 2011). The finding of ethnicity as an 
independent risk factor for advanced liver disease in NAFLD patients may explain the 
protective role African Americans have against advanced liver disease. The true 
explanation for ethnic differences in the prevalence of NAFLD in still not fully understood. 
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Differences in visceral adiposity and other characteristics such as adiponectin levels in 
African Americans may be affected by unidentified genetic and environmental factors 
(Wagenknecht et al. 2009). The heritability component of hepatic steatosis is based on 
large family cohort studies is 0.27 (Speliotes et al. 2011). However, this clustering could 
simply be a reflection of the heritability of other risk factors affecting NAFLD such as 
obesity and insulin resistance. Two studies examining ethnic differences in the 
prevalence of NAFLD strongly suggest that susceptibility to NAFLD rather than to its risk 
factors may have a genetic component (Browning et al. 2004; Caldwell et al. 2002). 
The prevalence of NAFLD-related fibrosis consistently increases with age as reported in 
a study by Firth et al. (2009). The 351 histologically confirmed NAFLD patients divided 
into older, middle aged and younger groups showed a significant association between 
the prevalence of NAFLD and fibrosis with increasing age. Older patients have more 
NAFLD related risk factors, such as hypertension, obesity, insulin resistance and 
hyperlipidaemia, which could explain the association between age and the prevalence of 
NAFLD in elderly individuals (Vernon et al. 2011). Advanced age is considered an 
independent risk factor for hepatic steatosis (Ascha et al. 2010; Lee et al. 2007). It is 
important to note that younger NAFLD patients with unexplained liver enzyme elevations 
were associated with hepatic steatosis and higher ALT activity. Since the age range of 
both our control samples and patient sample groups were above 45 years (median), age 
as an independent risk factor is unlikely to affect the comparative analyses performed 
between subgroups in our study group; however, where possible we have adjusted for 
age. 
The idea of gender influencing NAFLD susceptibility lacks empirical support. Initially 
NAFLD was thought to be more common in females (Fan et al. 2005; Singh et al. 2004), 
but a study of 26 527 Asian subjects revealed that the prevalence of NAFLD was higher 
in men (32%) than in women (16%) (Chen et al. 2008). Within our study more females 
was present in both the general Caucasian control group (66%) and NAFLD types 1,2, 
NAFLD types 3,4 and NASH patient (88%) groups compared to the males in each group. 
Some studies reported that male gender is associated with elevated aminotransferase 
levels, hepatic fibrosis, histologically confirmed NASH and overall mortality 
(Papatheodoridis et al. 2007; Kallwitz et al. 2008). The association between female 
gender and NAFLD or fibrosis has only been reported in a few studies (Hashimoto et al. 
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2005; Ong et al. 2005); however one study reported that female gender is an 
independent risk factor for NASH especially in patients with the metabolic syndrome 
(Sorrentino et al. 2004). Female gender may be an important risk factor for earlier 
development of metabolic syndrome features that may cumulate in NAFLD as females 
had a significantly earlier age of onset of disease symptoms which correlated 
significantly with presence of the risk-associated A-C allelic combination of the TNF-α 
rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) SNPs.  
The test of difference between the obese, NAFLD (types 1,2) and NASH (NAFLD types 
3,4) after adjustment for age gender and race did not show a difference in BMI and waist 
circumference between the histologically confirmed NAFLD (types 1,2) and NASH 
(NAFLD types 3,4) patients. However, both NAFLD patient subgroups had a lower BMI 
(on average 4.4 kg/m2 for NASH and 4.2 kg/m2 for NAFLD types 1.2) (p=0.015) and 
waist circumference (on average 10 cm for NASH and 12 cm for NAFLD types 1.2) 
(p=0.002) compared to the obese patient group. This finding is in accordance with the 
selection of patients with BMI above 30 kg/m2 for the obese patient group, in order to 
further investigate the role of obesity in the development/progression of NAFLD. 
Significantly higher levels of ALT (p=0.031) (on average 23.4 units/L higher), glucose 
(2.7 mmol/l higher) (p=0.005), HbA1c (1.54 % higher) (p=0.003), HOMA-IR (1.13 units 
higher) (p<0.001) and triglycerides (p=0.017) (1.33 mmol/l higher) were observed in the 
NASH patient subgroup (NAFLD types 3, 4) compared with the obese patient subgroup, 
after adjustment for age, gender and race. HbA1c (p=0.003), HOMA-IR (p<0.001) and 
triglyceride levels (p=0.017) were also significantly higher in NASH (types 3, 4) 
compared to NAFLD (types 1,2) patients.  
NAFLD is the hepatic manifestation of the metabolic syndrome characterised by 
elevated triglyceride levels, for this reason we expected to find the highest triglyceride 
levels in the NASH types 3,4 patient group. A statistically significant difference was 
earlier observed in the mean serum triglyceride levels when South African patients with 
NAFLD (types 1,2) were compared with NASH (NAFLD types 3,4) patients, while these 
levels did not differ significantly between patients with no/mild fibrosis and those with 
advanced fibrosis (Kruger et al. 2010). These findings implicated dyslipidemia in the 
pathogenesis of NASH, while apparently unrelated to the risk of advanced fibrosis that 
was not investigated in the current study. Even though virtually all the South African 
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patients studied by Kruger et al. (2010) were either overweight or obese, the presence of 
marked obesity did not predict the presence of more advanced liver disease. These 
findings from the parent study suggest that in addition to obesity or insulin resistance as 
a consequence of high BMI, secondary hits involving gene-environment interactions may 
be required to develop NASH and advanced fibrosis after the first signs of fatty liver 
becomes evident on ultrasound. The results presented in this study provide supporting 
evidence for these earlier clinical findings now also at the DNA level.  
After further adjustment for smoking, alcohol consumption and physical activity the 
significant differences in waist circumference and biochemical parameters for ALT 
(p=0.042), glucose (p=0.008), HOMA-IR (p<0.001) and HbA1c (p=0.007) levels detected 
in NASH types 3,4 patients compared to the obese and/or NAFLD (types 1, 2) patients 
remained significant, while the previous associations reported for BMI and triglyceride 
levels disappeared. This finding was mainly ascribed to reduced statistical power with 
inclusion of three more variables adjusted for in the statistical model and small sample 
size. After adjustment for all 6 variables, a statistically significant association between 
the risk-associated TNF-α rs1800629 A-allele and CRP levels (p=0.029) was 
furthermore observed due to a favourable effect of low- to moderate alcohol intake on 
CRP levels. This biochemical marker of inflammation increased significantly (25.7 mg/l) 
with each risk-associated A-allele detected among fatty liver disease patients. The 
favourable effect of low-moderate alcohol intake on CRP-levels in patients with fatty liver 
disease is an important observation. Chronic systemic low grade inflammation increases 
with the degree of obesity and insulin resistance, especially if coronary artery disease is 
also present (Wannamethee et al. 2004). Patients who reported low-moderate alcohol 
intake had on average 70% reduced CRP levels compared with patients who abstained 
from alcohol drinking (p=0.038).  
The grade of hepatic necro-inflammation correlates with the categories of steatohepatitis 
as mild, moderate or severe. It is well known that serum TNF-α levels correlate with 
metabolic associated risk factors such as BMI and percentage body fat. Tsukui et al. 
(2000) reported that exercise and TNF-α rs1800629 independently correlates with 
changes in HbA1c and fasting insulin levels. The finding that CRP levels are significantly 
higher in NASH patients compared to the less severe obese/NAFLD (types 1,2) patient 
groups, while BMI and waist circumference were lower, is ascribed to the fact that the 
Stellenbosch University http://scholar.sun.ac.za
Chapter IV 
   Discussion 
 
103 
 
obese group included only patients with BMI above 30 kg/m2 due to the selecting criteria 
used for this patient subgroup. Furthermore, the finding that each PPARγ C-allele is 
associated with a BMI reduction of 3.45 kg/m2 on average (p=0.020), may be explained 
in the same manner.  
The elevated C-reactive protein levels for each added TNF-α A-allele is contradictive to 
the reduced waist circumference finding with each additive A-allele in the selected 
patient group. Therefore the reduced waist circumference (6 cm less in the presence of 
each risk-associated A-allele) that seems to be associated with the risk-associated TNF-
α rs1800629 A-allele cannot be ascribed to the gene effect but rather to the how the 
patients were selected for this study and other confounders such as smoking shown to 
be associated with reduced BMI and waist circumference. Patients of the same age, 
gender and race who smoke furthermore had on average 20% lower glucose levels than 
non-smokers. This unexpected finding, as well as the observation that a kg/m2 unit 
increase in BMI decreases ALT, AST, glucose, HbA1c, transferrin saturation, total 
cholesterol and triglycerides with between 1-3%, excluded obesity as an independent 
risk factor for progression from fatty liver disease to NASH as previously reported in a 
clinical assessment performed in the parent study (Kruger et al. 2010). In view of the fact 
that NAFLD is a syndrome overlapping with obesity related traits and insulin resistance, 
it nevertheless seems likely that treating or managing both these conditions would 
influence the genetic predisposition to fatty liver disease. In a study performed by 
Timpson et al. (2011) the role of FTO rs9939609 in adiposity supported the causal effect 
of BMI on circulating CRP levels. 
The test of interaction between environmental factors (BMI and waist circumference 
considered a reflection of the diet, physical activity, smoking and alcohol consumption) 
and SNPs FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and PPARγ 
rs1801282 (Pro12Ala, 34 C>G) on clinical and biochemical characteristics in the total 
group of 119 obese, NAFLD types 1,2 and NAFLD types 3,4 (NASH) patients, after 
adjusting for age, gender and race, revealed that physically active subjects were leaner 
compared to the inactive patients. Increased physically activity are therefore likely to 
reduce the influence of genetic factors to develop obesity. The complex relationship 
between physical activity and the degree of genetic influence on BMI and waist 
circumference was in accordance with the Mustelin et al. (2009) study. The average 
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waist circumference of physically inactive NAFLD patients was 12% higher compared to 
the active NAFLD patients (p=0.004). 
Smoking had a significant effect on BMI in relation to the FTO rs9939609 and TNF-α 
rs1800629 SNPs analysed in South African NAFLD patients. For each risk-associated 
FTO rs9939609 A-allele and TNF-α rs1800629 A-allele detected among smokers, BMI 
was significantly reduced by 13% and 27%, respectively, compared with patients with 
two copies of the major SNP alleles (p=0.010). Obesity is related to personality addictive 
disorders such as alcohol dependence (Barry et al. 2009). Poor decision making is a 
core symptom of addictive behaviours such as smoking and alcohol abuse as addicts 
tend to choose the action that brings them immediate relieve of their craving even when 
these actions lead to deleterious outcome. This could explain why individuals who 
smoke have a reduced waist circumference and BMI despite the presence of a genetic 
predisposition for obesity. Instead of eating they smoke to bring immediate reward for 
their emotional state (Davies and Carter, 2009; Bechara and Martin, 2004). When the 
potential allelic effect of FTO rs9939609 was investigated on transferrin saturation levels, 
it was shown that the rate of change was not significant in smokers (lower for each risk 
allele) nor in non-smokers (higher), but the difference between the effects was 
significant. The potential implications of this finding is not clear but needs to be 
evaluated with caution due to small sample size. 
In patients who reported low-moderate alcohol intake, each FTO A-allele increased LDL-
cholesterol by 54%, compared to having inherited no A-allele (p=0.002), while there was 
no allelic effect in those who abstain from alcohol consumption. A similar marginally 
significant effect was observed for reduced HDL-cholesterol (p=0.053), which together 
with total cholesterol (p=0.063) and triglycerides determine LDL-cholesterol levels. A 
study conducted by Zhou et al. (2012) confirmed that FTO rs9939609 positively 
correlates with features of the metabolic syndrome, including hypertension, higher 
fasting insulin, glucose, triglycerides and lower HDL-cholesterol levels. Our findings may 
imply that the deleterious effect of the risk-associated A-allele of the FTO rs9939609 
SNP may become clinically relevant with alcohol intake.  
Increased TNF- levels favour the development of insulin resistance and impaired 
glucose tolerance (Hui et al. 2004). TNF-α is a marker of systemic inflammation during 
cardiovascular events and a risk factor of metabolic syndrome which forms part of a 
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constellation of risk factors contributing to the pathogenesis of NAFLD in South African 
patients (Kruger, 2008). After adjustment for age, smoking and alcohol consumption, AA 
homozygotes (risk-associated genotype) for the TNF-α rs1800629 polymorphism studied 
by Lakka et al. (2006) had higher CRP levels compared to other genotypes and these 
levels decreased with exercise. In this study opposite effects were detected between 
TNF-α rs1800629 and CRP levels when considered in relation to BMI, with decreased 
CRP levels in the presence of the risk-associated A-allele. This finding demonstrates 
that a proven or expected phenotypic effect of low-penetrance genetic risk factors such 
as TNF-α rs1800629 could be masked or overridden by clinical characteristics possibly 
due in part to other, unidentified genetic risk factors that may be more relevant in a 
specific clinical context. While a significant 6% increase in CRP was observed for each 
extra kg/m2 in BMI in the absence of the risk-associated A-allele (GG genotype) as can 
be expected, CRP levels were however reduced by 11% (GA genotype) and 26% (AA 
genotype), respectively, for each extra kg/m2 in BMI in patients with the risk allele, 
compared to patients with the GG genotype (p=0.005). For each extra cm of waist 
circumference, CRP levels were 10% (GA genotype) or 21% (AA genotype) reduced, 
compared to patients with GG, for whom waist circumference did not show a significant 
effect (p=0.003). These findings are clearly contradictor and highlight the complexity of 
utilising genetic information in risk management of complex disorders. For this reason, 
the PSGT approach has been developed in South Africa that takes family history, current 
health status and lifestyle risk factors into account for clinical decision-making (Kotze 
and van Rensburg, 2012).  
The above-mentioned approach is also relevant to the observations made in relation to 
triglyceride levels and PPARγ rs1801282. In patients homozygous for the PPARγ 
rs1801282 risk-associated C allele triglycerides decreased by 3% with each added unit 
of BMI and increased by 6% with each added BMI unit in GG homozygote patients 
(p=0.013). Abstaining from alcohol was not associated with a significant allelic effect of 
PPARγ rs1801282 on insulin, while alcohol drinkers showed an increase of 175% with 
each G-allele (decrease of 175% with each C-allele). Since this finding was based on 
data from 1 drinker (AST 67 units/L) and three non-drinkers (average AST 29 units/L) 
these results as well - as the above-mentioned apparent interactions - should be 
interpreted with caution due to relatively small patient numbers in the subgroups 
available for gene-environment interaction studies in relation to biochemical parameters.  
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Activation of PPARγ receptors using pioglitazone and rosiglitazone (anti-diabetic drugs) 
reduced alcohol consumption according to Stopponi et al. (2011). These findings provide 
new information about the role of PPARγ receptors as a potential candidate treatment for 
alcoholism and warrant further investigation of the above-mentioned insulin-lowering 
effect of alcohol in the presence of the risk-associated  PPARγ rs1801282 C-allele, even 
though the results were obtained in a small number of patients. Further research is 
warranted to determine the benefit of using PPARγ receptors as the target sites for the 
treatment of alcoholism especially in alcoholic fatty liver disease patients (Purohit et al. 
2009). 
4.4 Impact of risk factors incorporated into a genotype risk score on age of onset 
in fatty liver disease patients in relation to NAFLD disease severity. 
While genetic testing could help clinicians to diagnose HH or rare liver diseases that may 
be caused by high penetrance mutations, multiple low penetrance genetic variations 
(e.g. SNPs) influencing phenotypic expression are considered important contributors to 
the overall risk of disease development in NAFLD patients. An individual’s level of risk 
and age of onset of disease depends on a monogenic genetic predisposition, rare 
variants and/or a complex interaction between modifiable environmental factors and 
SNPs in modifier genes (Krawczyk et al. 2010). 
A genotype risk score was calculated for each patient included in this study by counting 
the risk associated FTO rs9939609 A-allele, the TNF-α rs1800629 A-allele, and the 
PPARγ rs1801282 C-allele. A minimum risk score of 0 and a maximum of 6 were 
obtained for each individual. None of the patients in the obese, NAFLD (types 1,2) or 
NASH (NAFLD types 3,4) subgroups were awarded the highest risk score of 6. A similar 
risk score of 2-3 was observed in these patient subgroups. No significant association 
with an increasing risk score was detected between the obese patients, NAFLD types 
1,2 and NASH types 3,4 groups after adjusting for age, gender, race, smoking, alcohol 
consumption and physical activity. When genotype-phenotype association studies are 
performed, careful consideration of possible confounding factors is required to prevent 
the documentation of false associations (Laurie et al. 2010). This possibility was 
considered in relation with the finding that the allelic combination T-G-G was associated 
with a 5.93 kg/m2 increased BMI compared to the T-G-C allelic combination and a 9.09 
kg/m2  increased BMI compared to the risk-associated A-A-C allelic combination 
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adjusted for age, gender, race, smoking, alcohol consumption and physical activity 
(p=0.027). The most likely explanation for unexpected findings like these in the present 
study was the selection criteria applied for the obese group based on BMI, while the 
NAFLD types1-4 patients were included in the study based on liver histology to make the 
diagnosis of NAFLD.  Insulin resistance and inflammation are the key drivers in NAFLD 
disease severity and genetic risk factors underlying these metabolic abnormalities may 
mask or override the effect of the FTO rs9939609 SNP included in this study.  
Histologically confirmed NAFLD patients were, on average, 6 years older at entry into 
the study (also documented as the age of disease diagnosis) than the obese patient 
group (p=0.036). Age of onset of fatty liver disease was on average 5 years younger in 
the presence of each risk-associated TNF-α rs1800629 A-allele (p=0.028) among the 
119 patients included in this study. This age effect was not observed on further 
assessment of the histologically confirmed NAFLD group only, after exclusion of the 
obese group, probably due to reduced statistical power in the smaller sample size. 
Several studies have implicated TNF-α gene variation in the development of NASH. The 
levels of TNF-α was reported higher in steatohepatitis subjects when compared to 
healthy controls (Barbuio et al. 2007; Wang et al. 2011; Musso et al. 2012). When the 
effect of the TNF-α rs1800629 A-allele on age of disease onset was considered in the 
context of FTO rs9939609 and PPARγ rs1801282 as part of a risk score, a 3 year onset 
of fatty liver disease symptoms was observed with each of the three risk-associated 
alleles detected (p=0.008).  
Differences in environmental factors and other variables among study groups 
necessitate the need for adjustment of these factors when performing comparative 
analyses. A frequency of 8.8% for the allelic combination T-A-C was detected in the 
Coloured population while absent in Caucasians, which confirmed the need to consider 
the potential effect of population substructures and ethnic differences when comparing 
allelic distribution of SNPs in relation to phenotypic expression. Differences in alcohol 
consumption and smoking between the study groups were also identified as 
confounders that needed to be adjusted for in comparative studies. The interaction 
between the PPARγ variant and smoking described by Yang et al. (2012) indicated that 
the presence of both factors exhibited a synergistic effect on the development of NAFLD.  
In this study the PPARγ rs1801282 C allele was detected at a frequency of 79% in 
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smokers, compared with 97% in non-smokers, while 17% of patients with the GG 
genotype were smokers and all the non-smokers were either heterozygous or 
homozygous for the risk-associated C-allele. Although the observations of these 
statistical analyses to identify potential confounders have no obvious clinical 
implications, it confirmed the need to adjust for multiple variables in our study population 
during genotype-phenotype correlation studies.  
As mentioned previously the age of onset of fatty liver disease was on average 5 years 
younger in the presence of each risk-associated TNF-α rs1800629 A-allele (p=0.028) 
and 3 years younger when incorporated as part of the genotype risk score tested in the 
total group of 119 patients included in this study. Extended statistical analysis was 
performed to verify these age effects in relation to alcohol intake and smoking. Single 
effects were assessed after adjusting for multiple variables, as well as combined effects 
to determine the potential impact of cumulative risk. The data obtained confirmed that 
each extra TNF-α rs1800629 risk-associated A-allele subtracts on average 5 years from 
age of onset in the patient study group, after adjusting for race, gender and alcohol 
consumption (5.5 years, p=0.015). When these factors were combined to assess 
cumulative risk, the association becomes even more significant (p=0.008). For each 
extra risk allele incorporated in the genotype risk score (0-6) for FTO rs9939609 (intron 1 
T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) 2.6 
years are subtracted, even after adjusting for race, gender and alcohol use (2.6 years, 
p=0.020). When these factors were combined the association was much stronger 
(p=0.009). Alcohol intake or smoking had no independent effect on age of onset of fatty 
liver disease symptoms, which demonstrated the significance of the risk-associated 
TNF-α rs1800629 A-allele and even more so as part of the genotype risk score.  
The association between age of onset of fatty liver disease symptoms and allelic 
combination for FTO rs9939609 (intron 1 T>A), TNF-α rs1800629 (-308 G>A) and 
PPARγ rs1801282 (Pro12Ala, 34 C>G) in NAFLD types1,2, NAFLD types 3,4 (NASH) 
and obese patients was also statistically significant  (p=0.039). The modelled ages in 
relation to all the allelic combinations for FTO rs9939609 (intron 1 T>A), TNF-α 
rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) showed that gender 
had an independent significant effect in the joint model of gender and allelic 
combinations (p=0.023). After the adjustment for allelic combination, females were 5.2 
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years younger at onset compared to male patients.  
While no independent significant association between age of onset of fatty liver disease 
and PPARγ rs1801282 (Pro12Ala, 34 C>G) (p=0.113) was detected, even when 
adjusted for gender, the combination of age and gender was significant (p=0.033). With 
each risk associated PPARγ rs1801282 C-allele age of onset was reduced by 3.7 years. 
An independant effect on age of onset for development of fatty liver disease symptoms 
was not observed for FTO rs9939609 (intron 1 T>A), which corresponds with previous 
exclusion of obesity as a significant risk factor in the NAFLD disease process (Kruger et 
al. 2010). The association between FTO rs9939609 and insulin resistance reported in 
the literature therefore appears to be secondary to obesity as the major phenotype 
associated with the FTO gene effect.  
To date GWAS studies demonstrated increased risk of type 2 diabetes associated with 
SNPs in approximately 40 genes (McCarthy, 2010). Linder et al. (2012) included nine of 
these SNPs selected from the TCF7L2, KCNJ11, HHEX, SLC30A8, WFS1, KCNQ1, 
MTNR1B, FTO and PPARG genes, to develop a weighted genotype risk score. These 
authors found that the diabetes risk genotype score contributed significantly to prediction 
of impaired glucose tolerance and impaired fasting glycemia due to increased genetic 
load. This effect was not present in male, lean and insulin sensitive individuals that may 
indicate a protective role of beneficial environmental factors on the genetic risk (Linder et 
al. 2012). It also seems likely that in these cases the gene effect becomes clinically 
relevant in the presence of a second hit exerted by gender-related risk or insulin 
resistance. When the genotype risk score was reduced to 7 SNPs to reflect mainly a 
disruption of insulin secretion, after omitting the FTO (rs9939609) and PPARG 
(rs1801282) risk-associated alleles, the association with prediabetes was not abolished 
but rather strengthened. This finding raised the possibility that the genetic risk for 
prediabetes is mediated mainly through the genetic variation affecting insulin secretion. 
In the statistical model adjusted for insulin sensitivity, BMI was negatively associated 
with impaired glucose tolerance as a clinical outcome parameter. The association 
between BMI and impaired glucose tolerance was only positive when insulin sensitivity 
was omitted from the covariates. This finding is very relevant to our observation that 
NASH (types 3,4) patients have lower BMI and waist circumference than the less severe 
NAFLD (types 1,2) patients. Linder et al. (2012) suggested that once controlling for 
insulin sensitivity, a higher BMI may become protective against impaired glucose 
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tolerance and that this phenomenon can possibly be explained by a statistical 
dissociation of BMI into metabolically harmful and metabolically non-harmful BMI by 
adjustment for insulin sensitivity. Over-representation of obese individuals with normal 
insulin sensitivity could therefore lead to biased results during association studies. 
Notably, the HOMA-IR levels of the obese patients (0.3) in our study population was 
markedly lower than in NAFLD (types 1,2) (1.0) and NASH (types 3,4) (1.3) patients. 
Since the effect of the 9-SNP score was found to be independent of well-known 
environmental risk factors such as age, body weight and insulin resistance, Linder et al. 
(2012) concluded that early transition from normal glucose tolerance to impaired glucose 
tolerance is significantly affected by genetically determined risk. Data reported by Meigs 
et al. (2008) who genotyped SNPs at 18 diabetes-associated loci in more than 2000 
participants of the Framingham Offspring Study, have furthermore shown that although 
individual per-allele effects are small, individuals with more risk alleles are at greater risk 
than those with fewer alleles irrespective of how many and which genes are considered. 
The most important research question was whether detection of the SNPs included in 
the statistical model allows better prediction of risk than knowledge of common 
phenotypic risk factors alone. Gender-adjusted odds ratio for diabetes was found to be 
1.12 per risk allele and resulted in risk reclassification of, at most, 4% of the subjects 
after further adjustment for age, family history, BMI, fasting glucose level, systolic blood 
pressure, HDL-cholesterol level and triglycerides. The marginal ability of the genotype 
score to discriminate risk when relevant biochemical abnormalities are already present 
support the use of a PSGT approach to determine gene expression, if any, and 
response to treatment in order to monitor the effectiveness of the intervention strategy. 
Notably, lifestyle intervention was found to attenuate the significantly increased risk for 
developing type II diabetes and lower probability to return to normal glucose regulation, 
found to be associated with an extended weighted genotype risk score of 34 SNPs 
(Hivert et al. 2011). This extended genotype risk score was evaluated in more than 2000 
participants from five ethic groups who had been randomised to placebo, metformin, or a 
lifestyle intervention. 
Extended genotype-phenotype association studies are required to identify the most 
important SNPs implicated in insulin resistance and inflammation known to confer 
increased risk for development of multi-factorial diseases such as type 2 diabetes and 
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NAFLD. Assessment in the presence and absence of relevant environmental triggers 
may determine the relative contribution to biochemical abnormalities and disease 
severity and development of effective intervention programs targeted at the cause of the 
disease. Incorporation of an increasing number of clinically validated biomarkers into a 
genotype risk score combined with clinical indicators and lifestyle risk factors may 
therefore facilitate the prevention of cumulative risk underlying the development of 
insulin resistance, type 2 diabetes, NAFLD, CVD and liver fibrosis.  
4.5 Clinical application 
Genomic based personalized medicine has the potential to enhance individualised 
treatment and disease prevention of common chronic diseases such as NAFLD and 
CVD. Genetic testing applications used as a diagnostic tool in clinical practice is rising 
rapidly (Pagon, 2006). However, only a few genome based discoveries have translated 
into evidence-based applications for individualized preventative medicine. According to 
Lenfant, (2003) most clinically derived research findings are “lost in translation”. To 
enhance translational research, a multidisciplinary approach in basic science is needed. 
Due to the limitations of genetic testing recognised early on through extensive research 
performed in the genetically diverse South African population a new pathology supported 
genetic testing (PSGT) approach was developed by Kotze and van Rensburg (2012) to 
facilitate the prevention of cumulative risk in multi-factorial diseases. 
The FTO rs9939609, TNF-α rs1800629 and PPARγ rs1801282 SNPs evaluated in this 
study for their clinical usefulness in patients with NAFLD are well recognised risk factors 
for the development and progression of type 2 diabetes and metabolic syndrome. These 
pathogenic factors include obesity, low-grade chronic inflammation, and insulin 
resistance. The metabolic risk profile of insulin resistant NAFLD patients is greater when 
compared to non-diabetic patients. Hyperglycaemic NAFLD patients have a higher risk 
of developing fibrosis and cirrhosis (Smith and Adams, 2011). Insulin resistance unifies 
NAFLD with metabolic syndrome through the clustering of metabolic related factors such 
as glucose intolerance and/or diabetes, increased triglycerides, high cholesterol and 
obesity. A steatotic liver contributes to the development of insulin resistance, because of 
impaired insulin clearance from the portal vein. The ability to predict complications 
associated with insulin resistance will be valuable to treat and clinically manage NAFLD 
patients. Identification of the underlying disease mechanism is very important as insulin 
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resistance can also occur in patients without overt glucose alterations, where the ability 
of insulin to inhibit glucose is reduced and glucose utilization is stimulated. 
Chronic low-grade systemic inflammation as reflected by elevated serum markers (e.g. 
TNF-α) are continuously present in obese individuals. NASH is the more advanced form 
of liver disease and a marked component of the pro-inflammatory state. Several studies 
have implicated variation in the TNF-α gene in the development of NASH (Manco et al. 
2007; Stechove et al. 2012; Wang et al. 2011). Fatty acids and TNF-α molecules 
stimulate the inhibitory phosphorylation pathway of serine in the insulin receptor. This 
finding correlates with the genetic link of the TNF-α gene with insulin resistance and 
inflammation in the development of NASH. The association of TNF-α with hepatic insulin 
resistance could possibly clarify the connection between insulin resistance and the liver’s 
role in the development of cardiovascular related diseases.  
The susceptibility to develop progressive NASH is influenced by genetic variation as 
genes involved in inflammation, oxidative stress and fibrogenesis have been implicated 
with the severity of liver disease (Aller et al. 2010; Valentini et al. 2002). The heritable 
component of NAFLD and NASH has also been confirmed in this study, especially in 
relation to the TNF-α rs1800629 -308 G>A polymorphism alone or even more so as part 
of a 6-allele risk score. Since the clinical characteristics of NAFLD include obesity and 
insulin resistance it seems probable that treating NAFLD patients with anti-inflammatory 
agents such as pioglitazone may be an attractive treatment option. Phamacogenetic 
studies are warranted to compare the effectiveness of this intervention strategy between 
patients with and without the TNF-α rs1800629 -308 G>A SNP. 
In relation to the PPARγ rs1801282 (Pro12Ala, 34 C>G) SNP, a significant association 
with HbA1c levels were demonstrated in diabetic patients with the minor G-allele treated 
with rosiglitazone, with a significant decrease in HOMA-IR levels compared to those with 
the risk-associated PPARγ C-allele (Kang et al. 2005). It therefore seems likely that 
NAFLD patients with the minor allele will benefit most from this treatment but again, 
pharmacogenetic studies are needed in the South African population to investigate this 
treatment option for a subgroup of patients with insulin resistance further. A variety of 
ligands can bind to PPARγ, including fatty acids, thiazolidinediones and non-steroidal 
anti-inflammatory drugs such as ibuprofen.  
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PPARγ is a thrifty transcription factor gene co-ordinating adipogenesis and glucose 
homeostasis. Variation in the PPARγ gene is associated with insulin sensitivity, 
inflammation and adipogenesis. PPARγ represents an attractive NAFLD candidate gene, 
because both hepatic lipid metabolism and insulin resistance are contributors to the 
pathogenic phenomena of NAFLD (Gawrieh et al. 2012). Moreover, numerous PPARγ 
agonists have been used in therapeutic intervention trails for individuals with NASH, 
emphasizing the role of PPARγ in liver related diseases (Sanyal et al. 2010). When there 
is an imbalance between lipid influx and lipid removal, accumulation of lipids in the liver 
occurs. More than half of the triglycerides found in the liver of NAFLD patients originate 
from plasma albumin bounded-fatty acids and 15% derived directly from the diet 
(Tailleux et al. 2012). Under conditions of insulin resistance the hepatic fatty acid flux 
and uptake are enhanced and contributes to the pathogenesis of type 2 diabetes.  
Over expression of PPARγ is recognised as a feature of the steatotic liver and attributed 
to the activation of lipogenic genes involved in steatotic development (Gavrilova et al. 
2003). Specific targeted deletion of PPARγ in the hepatocytes of mice protected them 
against diet induced hepatic steatosis, suggesting a pro-steatotic role of PPARγ (Morán-
Salvador et al. 2011). In contrast, over expression of PPARγ improved hepatic steatosis 
inflammation and fibrosis in the liver (Wu et al. 2010). The heterogenic effects of PPARγ 
modulating NAFLD features could be due to its action on different metabolic pathways 
and tissues (Tailleux et al. 2012).  
Studies performed on children with NAFLD have shown that children develop the full 
spectrum of NAFLD (Lavine et al. 2004). Obese or overweight children with NAFLD 
typically have elevated fasting serum triglyceride levels. Tominaga et al. (1995) 
conducted a study in Japan with 810 children aged 4-12 years and demonstrated that 
the presence of sonographically detectable NAFLD was 2.6% and its presence 
correlated with obesity. 
To facilitate the prevention of cumulative risk related to low-penetrance mutations such 
as those studied in the FTO, PPARγ and TNF-α genes a pathway approach to validation 
and incorporation of an increasing number of clinically useful SNPs into a risk score is 
needed. Intervention strategies based on a mechanistic understanding of the disease 
and elimination of known modifiable risk factors may facilitate prevention of disease 
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progression from insulin resistance to NASH. Development of innovative approaches to 
risk management of complex multifactorial diseases, which could be applied in a clinical 
context (combining the clinical relevant information, genetic testing and biochemical 
profiles), is becoming increasingly important for both preventative and therapeutic 
interventions. 
4.6 Gene Based Intervention Strategy 
Development of health guidelines by combining evidence-based medical and lifestyle 
advice with genetic information based on the functional effects and associated disease 
mechanisms or pathways affected by genetic variation is an important consideration for 
clinical application. When the knowledge gained in this study is combined with consistent 
information from the literature and a patient’s family history, pathology and 
environmental risk, it may be possible to counteract the deleterious effects of FTO 
rs9939609 intron 1 T>A, TNF-α rs1800629 -308 G>A and PPARγ rs1801282 34 C>G. 
Potential actionable information in relation to these SNPs is provided below, for possible 
future application in a clinical implementation study. 
FTO rs9939609 (intron 1 T>A) 
Since increased expression of FTO was found to be associated with an increased body 
mass (Li et al. 2012), it is reasonable to assume that intervention strategies that may 
reduce gene expression would be beneficial for NAFLD patients to reduce the risk of 
obesity and associated medical conditions. Recent studies have shown that FTO 
expression is regulated by glucose and the availability of essential amino acids (Cheung 
et al. 2012), which may explain why individuals with the FTO rs1558902 variant 
(occurring in the same gene region as FTO rs9939609)had a greater reduction in weight 
and improved fat distribution in response to a high-protein diet. An opposite genetic 
effect was observed on changes in fat distribution in response to a low-protein diet 
(Zhang et al. 2012).  FTO A- allele carriers must also ensure that their fat intake does not 
exceed 30% of total energy, as the increase in BMI associated with the FTO A-allele 
appears to be restricted to individuals with a high fat intake (Frayling et al. 2007). A 
Mediterranean diet may be particularly beneficial for FTO A-allele carriers (Razquin et al. 
2010). Although Kruger et al. (2008) reported that the presence of obesity did not predict 
the presence of more advanced liver disease in South African NAFLD patients, a healthy 
body weight should always be an important clinical goal and failure to detect a gene 
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effect relating to obesity underscores the importance of a combining evidence-based 
clinical health guidelines with genetic information using the PSGT approach.  
Spontaneous cortical activity in lean individuals is increased through insulin, while in 
obese individuals this effect was found to be absent. Cerebrocortical insulin resistance 
prevents normal body weight regulation, because insulin is needed as an adiposity- and 
satiety signal (Tschritter et al. 2007; Shimaoka et al. 2010). The genotype effect on 
cerebrocortical insulin sensitivity is similar to the effect of increased weight; this implies 
that variation in the FTO gene contributes to the pathogenesis of obesity. In this study 
the A-allele of FTO rs9939609 increased LDL-cholesterol on average by 54%, compared 
to having inherited no A-allele (p=0.002). A similar effect was observed in relation to 
decreased for HDL-cholesterol (p=0.053), which together with total cholesterol (p=0.063) 
and triglycerides determine LDL-cholesterol levels. FTO rs9939609 A-allele carriers 
were shown to loose most weight on a low fat hypocaloric diet causing metabolic 
improvements through decreased total and LDL cholesterol and CRP levels observed in  
this genetic subgroup (de Luis et al. 2012). A study conducted by Zhou et al. (2012) 
confirmed that FTO rs9939609 T>A positively correlates with features of the metabolic 
syndrome, including hypertension, higher fasting insulin, glucose, triglycerides and lower 
HDL-cholesterol levels.  
Intervention strategies targeted at components of metabolic syndrome is therefore 
advisable irrespective of mutation status, while avoidance of weight gain should be 
strongly advised in individuals with the FTO A-allele. It was shown that individuals 
meeting exercise recommendations of at least 60 minutes moderate to vigorous physical 
activity per day could overcome the effect of FTO rs9939609 T>A on obesity related 
traits (Ruiz et al. 2010). The importance of exercise was confirmed in this study as the 
average waist circumference of physically inactive NAFLD patients was 12% higher 
compared to the active patients (p=0.004), irrespective of mutation status. The finding 
that FTO has a demethylation function in mRNA expression indicated a novel, reversible 
epigenetic regulatory mechanism (Guifang et al. 2011). 
TNF-α rs1800629 (-308 G>A) 
In patients with the pro-inflammatory TNF-α SNP medical and nutritional therapy needs 
to be targeted at regulation of inflammation. Fat accumulation needs to be avoided as it 
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is accompanied by low-grade systemic inflammation which results in resistance to weight 
loss, which is particularly relevant to NAFLD patients. The data generated in this study 
demonstrated a statistically significant association between the risk-associated TNF-α 
rs1800629 A-allele and CRP levels (p=0.029). This biochemical marker of inflammation 
increased significantly (25.7 mg/l) with each risk-associated A-allele detected among 
fatty liver disease patients. Notably, this association was revealed only after adjusting 
also for alcohol intake due to the significant effect of low-moderate alcohol intake (below 
the level for diagnosis of NAFLD) to reduce CRP levels. Patients who reported low-
moderate alcohol intake had on average 70% reduced CRP levels compared with 
patients who abstain from alcohol drinking (p=0.038) therefore moderate alcohol 
consumption may be beneficial in the context of inflammation; however it must be 
considered in conjunction with other medical and lifestyle factors. Chronic systemic low 
grade inflammation reflected by CRP increases with the degree of obesity and insulin 
resistance, especially if coronary artery disease is also present (Wannamethee et al. 
2004). 
Tsukui et al. (2000) reported that exercise and TNF-α rs1800629 independently 
correlates with changes in HbA1c and fasting insulin levels. It is therefore advisable for 
individuals with TNF-α rs1800629 (-304 G>A) to consume foods with a low glycemic 
index to reduce the risk of obesity, insulin resistance and diabetes (Willet et al. 2002) 
and to include omega-3 fatty acids in the diet on a regular basis, since it has anti-
inflammatory effects (Simopoulos, 2002). Rapidly digested and absorbed carbohydrates 
should also be avoided since it appears to exacerbate the pro-inflammatory process 
especially in overweight individuals prone to insulin resistance (Radulian et al. 2009). 
According to Joffe et al. (2010) the TNF-α rs1800629 (-308 G>A) SNP modifies the 
relationship between dietary fat intake and total cholesterol concentrations in Caucasian 
South African women. When intake of saturated fatty acids are increased, serum total 
cholesterol levels decreased in individuals with the TNF-α  GG genotype and increased 
in individuals with the GA or AA TNF-α genotypes. This confirms a diet-genotype 
interaction which suggests that individuals with the risk associated TNF-α rs1800629 A-
allele are more responsive to changes in dietary fat intake compared with the G-allele 
carriers and would benefit from a diet intervention strategy. Adequate intake of foods 
high in antioxidants especially vitamin E, glutamine (e.g. raw spinach, parsley), arginine 
(e.g. dairy products, meat, peanuts), vitamin C (60mg/day) and vitamin B 
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supplementation (Aeberli et al. 2006; Majewicz et al. 2005) may also be beneficial for 
TNF-α rs1800629 G>A individuals since it enhances immune function and reduces 
inflammation. Several studies have reported higher TNF-α concentrations associated 
with CVD and other diseases such as chronic obstructive pulmonary disease in smokers 
compared to non-smokers (Tappia et al. 1995; Bennet et al. 2006; Jang et al. 2007; 
Gingo et al. 2008). A combined effect for smoking and the TNF-α SNP was not observed 
in our study population where insulin resistance was identified as the most important risk 
factor that may mask less prominent environmental risk factors. Smoking should always 
be discouraged irrespective of genetic test results and demonstration of a significant 
interaction with genetic risk factors would reinforce the importance of smoking cessation.  
PPARγ rs1801282 (Pro12Ala, 34 C>G) 
Given the potential role of PPARγ as a nutrient sensor of fatty acids, dietary fat 
interaction with genetic variation in the gene is likely to contribute to the pathogenesis of 
the metabolic syndrome, insulin resistance and NAFLD. Individuals with the PPARγ 
rs1801282 SNP are considered hyper-responders as they are more sensitive to 
environmental stimuli such as fat intake (Robitaille et al. 2003). Intervention strategies 
targeted at avoidance of weight gain by increased activity and calorie restriction, and the 
use of medication where indicated to lower blood fatty acids would be beneficial for 
individuals with the PPARγ rs1801282 SNP (Bruss et al. 2010; Eakin et al. 2010; Guo et 
al. 2002). Replacement of saturated fat with polyunsaturated and monounsaturated fats 
has a beneficial effect on weight loss. When the dietary polyunsaturated fat to saturated 
fat ratio is low, the mean BMI in G-allele carriers is greater than in individuals with the 
risk-associate C-allele and when the ratio is high the opposite is true (Luan et al. 2002). 
A regular dietary intake of foods rich in omega-3 fatty acids should be encouraged as it 
improves insulin sensitivity, promotes glucose control, and reduces inflammation (Kuda 
et al. 2009; Simopoulos, 2002). Since PPARγ rs1801282 C>G is associated with insulin 
resistance a diet high in plant fats and foods with a low glycemic index (GI≤55) would be 
beneficial to reduce insulin resistance in these individuals (Gilbertson et al. 2003; Fowler, 
2007). The interaction detected between the PPARγ SNP and smoking indicated that 
both factors exhibited a synergistic effect on the development of NAFLD (Yang et al. 
2012). The interaction between these two independent risk factors supports the idea of 
genetic and environmental factors contributing to the development and progression of 
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NAFLD (Day, 2006). NAFLD patients (types 1,2) are at a high risk to progress to NASH 
especially in the presence of relevant genetic and environmental factors such as 
smoking. Simultaneous analysis of the SNPs with associated modifiable risk factors may 
increase the clinical usefulness for improved risk profiling of NAFLD patients.  
Metabolic syndrome was found to be significantly more prevalent in patients with NASH 
(88%) compared to those with a fatty liver alone (53%) (Marchesini et al. 2003). 
Interindividual variability in response to dietary changes is greatly determined by genetic 
and environmental factors. The phenotypic response to diet is affected by genetic factors 
with external factors contributing to the clinical variation observed. To increase the 
clinical usefulness of SNPs the results should be interpreted in the context of clinical 
indicators and lifestyle risk factors (Ordovas and Corella, 2005). Considering all the 
known risk factors relevant to the disease and genes tested would contribute to 
improved health and disease management.  
4.7. Potential modifiers of NAFLD  
When considering the NAFLD disease process, genetic modifiers should be considered 
in the context of relevant environmental factors, clinical co-factors and use of medication. 
Alcohol consumption 
Alcohol abuse is common in the United States where a chronic relapse prevalence of 
8.5% was reported for individuals who participated in a 12 month intervention program 
(Grant et al. 2004). Predictors of future addiction include both genetic (family history of 
alcoholism) and environmental factors. A meta-analysis of 10 000 twin pairs revealed 
that the overall heritability of addictive substances was 40%-70% with alcoholism about 
50% (Goldman et al. 2005). This accentuates that both genetic and environmental 
factors are equally important to fully elucidate the pathogenesis of complex polygenic 
diseases (McCarthy and Hirschhorn, 2008). According to Dunn et al. (2012) the 
prevalence of steatohepatitis in patients with NAFLD decreased with moderate alcohol 
consumption. In the United States as many as 50% of adults regularly consume a 
modest amount of alcohol and within our study patients who reported low-moderate 
alcohol intake had on average 70% reduced CRP levels compared with patients who 
abstain from alcohol drinking. 
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The proposed protective mechanism with moderate alcohol consumption is possibly 
through the action of insulin resistance and it has shown to improve the metabolic risk 
factors for NAFLD (Dixon et al. 2001; Davies et al. 2002; Howard et al. 2004).  In heavy 
drinkers obesity increases the risk of steatosis by twofold (Vernon et al. 2011).   
A meta-analysis of more than 34 prospective studies demonstrated a survival benefit 
with moderate alcohol consumption, especially in diabetic patients. Moderate alcohol 
consumption not only improves the prevalence of steatohepatitis, but also modifies 
cardiovascular risk (Di-Castelnuovo et al. 2006). Data provided by an atherosclerosis 
study showed that moderate alcohol consumption lowered the risk of a cardiovascular 
event by 38% in non-drinkers who began to consume alcohol (10g of alcohol/day) 
(Valmadrid et al. 1999). Even though moderate alcohol consumption is beneficial in 
some settings, even a miniscule amount of alcohol could aggravate diseases or 
conditions such as breast cancer or hepatitis C (Dunn et al. 2012). More research is 
needed regarding the role of moderate alcohol consumption in the prevention or 
treatment of NASH. We could not evaluate the effect of high alcohol consumption in this 
study in relation to disease severity, because patients were pre-selected on the basis of 
alcohol consumption for the non-alcoholic form of fatty liver disease (NAFLD). However 
low to moderate alcohol consumption was higher in the Caucasian NAFLD patients 
(32%) compared to the Coloured NAFLD patients (2%).  
Iron metabolism  
Liver disease progression is influenced by both alcohol consumption and impaired iron 
homeostasis. Hyperferritinemia is frequently observed in both the metabolic syndrome 
and NAFLD patients (Wrede et al. 2006; Zelber-Sagi et al. 2007). The hepatic iron 
overload syndrome characterised by hyperferritinemia unrelated to hemochromatosis is 
frequently associated with various components of the metabolic syndrome and insulin 
resistant pathways (Mendler et al. 1999) Hence the term insulin-resistance associated 
hepatic iron overload syndrome. Mild hepatic iron accumulation in NAFLD involves both 
the hepatocytes and sinusoidal Kupffer cells.  
Low-penetrance HFE gene mutations H63D and C282Y are responsible for the majority 
of hereditary hemochromatosis (HH) cases in the Caucasian population. Since NAFLD 
and HFE mutations are relatively common many studies focused on the association 
between these two conditions. Iron overload and the presence of HFE mutations with the 
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more severe forms of liver disease (NASH) has been established (Fisher, 2011). The 
features of hereditary iron overload include cardiomyopathy, cirrhosis of the liver, 
diabetes and skin pigmentation. The heart may be especially sensitive to the toxic 
effects of iron overload (Sullivan, 1990). Hemochromatosis can easily be treated by 
phlebotomy once diagnosed; therefore this condition is considered a preventable form of 
heart disease amongst other equally important health risks. The risk of cardiovascular 
death in postmenopausal women with at least one copy of the C282Y mutation is 
stronger in women who are hypertensive or current smokers, with a nearly 20-fold 
increased risk when both risk factors are present, compared with non-smokers, non-
hypertensives, and non mutation carriers (Roest et al. 1999). This finding again 
emphasised the importance of multiple risk factor assessment when low-expression 
mutations such as those implicated in multifactorial diseases such as NAFLD are 
analysed. 
A marked increase of pro-inflammatory cytokines such as TNF-α has been observed in 
NAFLD and obese patients. TNF-α is an important regulator of iron homeostasis through 
its stimulatory effects on ferritin formation (Aigner et al. 2008). Iron overload contribute to 
the progression of NAFLD through oxidative stress and fibrogenesis within the liver 
(Tsuchiya et al. 2009). 
The mechanisms involved in hepatic iron accumulation in NAFLD patients have not yet 
been fully elucidated and may include many genetic factors (including HFE mutations), 
iron regulatory pathways (Kupffer cells) and metabolic factors (insulin resistance) 
(Sumida et al. 2009). 
The appropriateness of applying the information generated from this and other studies is 
determined by the individuals risk profile, family history, age of onset of disease and the 
mutations correlated with the disease. Kotze et al. (2009) established the PSGT 
approach for incorporation of low-penetrance functional SNPs that are not sufficient to 
explain the phenotype into an intervention plan for complex diseases such as HH and 
CVD. This approach may in future also be used in patients with NAFLD to identify 
molecular targets for risk reduction within the context of the medical history and relevant 
lifestyle factors. 
 
 
Stellenbosch University http://scholar.sun.ac.za
Chapter IV 
   Discussion 
 
121 
 
Insulin-sensitizers 
Thiazolidinedione (TZD) therapy was evaluated and post treatment histologically showed 
improved steatosis, hepatocellular ballooning, and inflammation with TZD treatment. The 
risk of fibrosis progression was significantly reduced with TZDs treatment (Musso et al. 
2012). Insulin sensitizing agents such as the thiazolidinedione’s, a agonist for the PPAR 
receptors, improved ovarian androgen biosynthesis and ovulatory function (Orio et al. 
2003). Non-steroidal anti-inflammatory drugs (NSAID) have the ability to activate PPARγ 
receptors. Epidemiological studies have shown that NSAID could reduce the risk of 
Alzheimer’s disease by as much as 80%; these effects are attributed to the ability of 
these drugs to stimulate PPARγ activity and inhibit inflammatory processes in the brain 
(Heneka et al. 2011). Metformin has anorexigenic and weight loss properties which 
increases insulin sensitivity. This is an important consideration for diabetic NAFLD 
individuals with the FTO rs9939609 T>A mutation, since the FTO A-allele is significantly 
associated with higher BMI, higher body fat percentage, and higher waist circumference 
(Dina et al. 2007; Zhou et al. 2012b). It also positively correlated with other symptoms of 
the metabolic syndrome, including hypertension, higher fasting insulin, glucose, 
triglycerides and lower HDL-cholesterol levels. Metformin significantly reduces body 
weight, waist circumference and HOMA-IR (Sofer et al. 2011). 
Lipid-lowering drugs 
Statins has been shown to improve ALT and radiological steatosis in hyperlipidaemic 
NAFLD patients and have a cardiovascular benefit (Musso et al. 2012). Ezetimibe 
reduces histological ballooning and fibrosis by connecting non-estrified cholesterol 
accumulation to hepatocyte apoptosis, liver injury and NASH development (Nelson et al. 
2009). The modulation of insulin sensitivity, systemic inflammation, hepatic lipogenesis 
and fibrogenesis could be achieved using angiotensin blockers. Hypertensive NASH, 
telimisartin an angiotensin receptor blocker with PPARγ regulating activity improved 
steatosis, necroinflammation, fibrosis and HOMA-IR (Fabbrini et al. 2010). Combining a 
diet intervention program with lipid-lowering drugs (gene based medical intervention) 
may improve the health outcomes of NAFLD and NASH individuals in some genetically 
predisposed patients. 
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Anti-inflammatories 
The anti-TNF-α agent pentoxifylline improved histological steatosis and lobular 
inflammation in NAFLD individuals (Musso et al. 2012).TNF-α antibody administration is 
beneficial in metabolic inflammation and has been demonstrated to improve steatosis 
(Barbuio et al. 2007). TNF-α expression in NASH/NAFLD patients significantly correlates 
with the degree of fibrosis (Manco et al. 2007; Wong et al. 2006). Ligands of the 
peroxisome proliferator receptor gamma (PPARγ), pioglitazone, are able to suppress 
TNF-α function which positively affected fatty liver disease (Musso et al. 2012).  
For individuals not responding to lifestyle intervention strategies such as the more 
severe form of NAFLD types 3,4 (NASH), pharmacological treatment may be considered 
in conjunction with a lifestyle intervention strategy. Currently no specific pharmacological 
treatments are available. However among the available agents TZDs, statins and 
metformin have consistently been used, but their impact on liver histology is still 
unknown.  
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As a result of this study high throughput genetic assays for the FTO rs9939609 (intron 1 
T>A), TNF-α rs1800629 (-308 G>A) and PPARγ rs1801282 (Pro12Ala, 34 C>G) SNPs 
implicated in obesity, inflammation and insulin resistance was successfully optimised. 
The clinical significance of the rare risk-associated A-allele of TNF-α rs1800629 (-308 
G>A) and common risk-associated C-allele of PPARγ rs1801282 (Pro12Ala, 34 C>G) 
has furthermore been firmly established in South African patients with the hepatic 
manifestation of the metabolic syndrome. The TNF-α rs1800629 and PPARγ rs1801282 
A-C allelic combination underlying inflammation and insulin resistance was the most 
important determinant for earlier development of NAFLD in patients with features of the 
metabolic syndrome. The well-established risk of obesity associated with the A-allele of 
FTO rs9939609 (inton 1 T>A), either independently or as part of the inferred allelic 
combination A-A-C for the FTO (rs9939609, intron 1 T>A), TNF-α (rs1800629, -308 
G>A) and PPARγ (rs1801282, Pro12Ala C>G) SNPs, did not significantly contribute to 
development of NAFLD or progression to NASH in the South African cohort studied. This 
finding provided genetic confirmation of earlier findings by Kruger et al. (2010), which 
excluded obesity as an independent risk factor for progression from NAFLD (types 1,2) 
to NASH (NAFLD types 3,4), prior to genotyping of South African patients that was 
performed for the first time in this study. Although FTO rs9939609 (intron 1 T>A) has 
previously been associated with insulin resistance and type II diabetes, this effect can be 
entirely explained by its impact on BMI and no fatness-independent allelic effects on a 
wide range of inflammatory markers could also be observed in healthy individuals 
(Zimmermann et al. 2011).  
The significant correlation observed between the number of TNF-α rs1800629 A-alleles 
and increasing CRP levels (p=0.029) and the favourable effect of low- to moderate 
alcohol intake on CRP levels in our study population are important observations. This 
information combined with the finding that the average waist circumference of physically 
active NAFLD patients was 12% lower than in physically inactive patients (p=0.004) may 
be incorporated in future preventative strategies based partly on genetic knowledge. 
This study provided evidence at the DNA level that the TNF-α rs1800629 A-allele 
increases the risk of disease progression from NAFLD (types 1,2) to NASH (types 3,4); 
age of onset of fatty liver disease was on average 5 years younger in the presence of 
each risk-associated TNF-α rs1800629 A-allele (p=0.028). Our findings are in agreement 
with earlier RNA expression studies in the parent study, demonstrating differential gene 
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expression between South African NAFLD (types 1,2) and NASH (types 3,4) patients 
(Kruger, 2008).  
 
5.1. Ethical Considerations 
 
The information obtained from genetic testing may not only relate to the tested 
individual, but also his/her close family members. Therefore information should be kept 
strictly confidential and all patients referred for genetic testing should preferably receive 
both both pre- and post-test counselling by registered genetic counsellors. However, this 
is most relevant to genetic testing of high-penetrance mutations to advise on family 
screening for (presymptomatic) disease diagnosis aimed at disease prevention and 
targeted treatment of high-risk individuals.  
Due to the increasing use of genetic testing to direct treatment, it is now accepted 
internationally that because of the small number of registered genetic counsellors and 
the diversity of the types of genetic tests that are available, clinicians will increasingly 
request genetic tests for their patients to guide treatment.  Genetic testing of low-
penetrance mutations is best performed in the context of the family history and/or testing 
of high penetrance mutations where indicated due to biochemical abnormalities or early 
disease onset, to prevent misinterpretation of complex genetic information. The following 
should therefore be explained where relevant to each individual before specimens are 
collected for laboratory testing, possibly as an extension of the CVD multigene test 
(Kotze et al. 2003, Kotze and Thiart 2003), as summarised in the ethically approved 
study protocol: 
 The genetic test will only screen for specific genetic alterations expected to 
provide useful information in relation to treatment/diet intervention.  
 Detection of genetic alterations (positive test) implies that other family members 
may also have the genetic change(s). 
 Failure to detect a specific genetic alteration (negative test result) does not 
exclude undefined gene mutations or other risk factors not tested for. 
 Early detection or pre-clinical diagnosis of treatable or preventable genetic 
diseases is beneficial. 
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 Genetic testing may result in better motivation for lifestyle changes or targeted 
treatment, or possibly anxiety when genetic risk factors are identified in an 
individual without clinical symptoms of a disease. 
 The genetic material is stored for reference purposes or to perform follow-up 
testing and may be stored and included in a genetic database for research 
related to the test requested, unless declined. 
 The genetic material may be tested at different laboratories or using different 
mutation detection methods as part of a quality control process. 
 Identification of genetic alterations in individuals with a family history or clinical 
features of the associated disease will not impact further on insurance, while 
exclusion of a genetic defect in a family member could be beneficial for insurance 
purposes in some instances.  
 A positive genetic test does not mean that the person has a genetic disease or 
will develop the condition, but it can increase the risk of disease in the absence of 
appropriate risk reduction intervention. 
 In the event that genetic testing is performed in families, non-paternity may be 
revealed and it is therefore important that adoption be reported at the time that 
specimens are obtained for genetic testing. 
5.2. Study Limitations 
The control population consisted only of Caucasian samples; no Coloured control 
samples were available in this study for comparative analysis. Blood biochemistry was 
also not done for all the Caucasian control samples. For the general Caucasian control 
population individuals who reported a diagnosis of NAFLD, insulin resistance or diabetes 
were excluded, but the population was not sonorgraphically or histologically confirmed to 
be NAFLD free. Some of the fatty liver patients (obese group with BMI >30 kg/m2) 
identified on ultrasound alone did not fulfil the criteria for a liver biopsy and there are 
some uncertainty regarding their disease diagnosis.  
Not all genetic variations that potentially could contribute to the pathogenesis of NAFLD 
were analysed. Three SNPs were selected for this study to determine the 
appropriateness of the study population for extended SNP analysis to construct an more 
comprehensive genotype score. DNA availability from samples of the parent study was 
insufficient or of poor quality which reduced the sample size for statistical analysis.  
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5.3. Future prospects   
Determination of the genetic basis of differences in response to environmental 
exposures such as alcohol consumption, smoking, physical inactivity, diet and certain 
drugs could provide a valuable adjunct to current clinical practice. Linking genes to 
disease in the context of known environmental triggering or protective factors is 
fundamental for implementation of preventive strategies. Genetic variation in low 
penetrance genes such as FTO (rs9939609 intron 1 T>A), TNF-α (rs1800629 -308 G>A) 
and PPARγ (rs1801282 Pro12Ala C>G) should always be correlated with the 
appropriate clinical and biochemical parameters to assess gene expression and 
response to treatment, while also taking family history and the presence and absence of 
known environmental risk factors affecting the genes into account. Improvement of 
biochemical abnormalities after elimination of modifiable risk factors could provide a 
measure of the effectiveness of the intervention program.  
It is important to identify both genetic and environmental components contributing to 
multi-factorial diseases such as NAFLD, as a single SNP is not sufficient to cause 
disease. Further study is required to further clarify the role of FTO in the relationship 
between obesity and insulin resistance in NAFLD patients.  This should include analysis 
of additional SNPs in the FTO gene as well as the transcription-factor-7-like-2 (TCF7L2) 
gene (also known as TCF4), described as a transcription factor influencing the 
transcription of FTO and several other genes. TCF7L2 binds to the FTO promoter region 
causing the overexpression of FTO (Zhou et al. 2012). TCF7L2 have consistently been 
associated with type 2 diabetes, irrespective of ethnic descent, making it one of the most 
important loci known today to predispose individuals to type 2 diabetes.  
TCF7L2 SNP rs7903146 increases type 2 diabetes susceptibility in the general 
population through β-cell dysfunction and impaired incretin action (Musso et al. 2009). 
This functional SNP modulates postprandial hepatocyte apoptosis, combined with the 
unfavourable adipokine and lipoprotein profile induced by fat ingestion in NASH 
individuals. Although the severity of steatosis and fibrosis seems to be directly 
associated with the TCF7l2 polymorphism, its association with necro-inflammation 
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appears to be mediated by adiponectin and oxidized-LDL. In this context, it is noteworthy 
that PPARγ agonists, currently proposed for the treatment of NAFLD, promote adipocyte 
differentiation by reducing β-cantenin levels and inhibiting TCF activation (Gustafson et 
al. 2006). TCF7L2 predisposes individuals to NAFLD and to metabolic related disorders 
involving β-cell function, hepatic insulin sensitivity, glucose and lipoprotein homeostasis 
(Musso et al. 2009). Prospectively, interventions toward restoring hepatic insulin 
sensitivity and β-cell function may potentially direct more tailored intervention strategies.  
Other genetic determinants for further study in the context of dyslipidaemia contributing 
to NAFLD are the apolipoprotein E (ApoE2 or ApoE4), apolipoprotein C3 (ApoC3) and 
patatin-like phospholipase domain-containing 3 (PNPLA3) genes (He et al. 2010). 
Studies have reported smaller LDL particle size in ApoE2 allele carriers compared to 
larger LDL particle size in ApoE4 individuals (Moreno et al. 2004). Furthermore a strong 
correlation between presence of the I148M SNP in the PNPLA3 gene and elevated 
serum ALT and AST levels with liver inflammation were found. Genetic variation in the 
ApoC3 gene alone, the PNPLA3 gene alone, and the combined risk-associated 
genotypes, accounted for 11.0%, 6.5% and 13.1% of the variance in the risk of NAFLD, 
respectively (Petersen et al. 2010).  
In the last decade several biomarkers have been investigated to noninvasively 
distinguish between NAFLD and its subgroup NASH (Lockman et al. 2010). Recent 
studies have shown that biomarkers associated with NAFLD and liver disease present 
from a young age and may help to discriminate between NAFLD patients at increased 
risk of coronary artery disease as opposed to the development of advanced liver disease 
(NASH) (Valentini et al. 2010). The metabolic syndrome is an independent 
cardiovascular risk marker for diabetes and coronary artery disease (Lee et al. 2007). 
This was substantiated in a study that reported a high prevalence of coronary artery 
disease in South African Africans with the metabolic syndrome and insulin resistance 
(Ntyintyane et al. 2006). According to Shimada et al. (2007), 90% of early stage NASH 
can be predicted by combining HOMA-IR with other biochemical markers such as 
adiponectin and HbA1c. Since NASH may progress to cirrhosis, clinicians assessing 
obese patients must be able to differentiate NASH from simple steatosis. Sorrentino et 
al. (2010) suggested that a higher HOMA-IR level is independently associated with a 
more progressive stage of fibrosis and also an independent predictive factor for fibrosis 
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worsening. HbA1c could possibly be used as a predictive factor or marker for 
postprandial glucose metabolism in NAFLD patients with normal fasting glucose levels 
In addition to standard metabolic indicators, LDL particle size and the aspartate 
aminotransferase to platelet ratio index (APRI) can be valuable biomarkers to distinguish 
between NAFLD patients at increased risk of coronary artery disease or advanced liver 
disease, respectively. APRI was found to be significantly higher in South African NAFLD 
patients with advanced fibrosis compared with patients with no or mild fibrosis (p<0.01) 
(Kruger et al. 2011).  
The development of a more comprehensive risk score that combines both lifestyle (diet, 
exercise score) and genetic (PNPLA3, TCF7L2, APOC3 HFE etc.) factors may be 
beneficial in risk management of patients with NAFLD. However the aforementioned 
genes in conjunction with other biochemical factors needs to be considered in a holistic 
approach do determine the clinical relevance of the risk score in future treatment of 
multi-factorial diseases. The information gathered from the current study may be 
considered for implemented as part of a comprehensive genetic screen for disease 
subtyping, which includes the analysis of gene mutations associated with dyslipidemia, 
iron overload, oxidative stress and inflammation in conjunction with a gene based 
nutritional and pharmacological intervention program. This approach may in future prove 
to improve the sensitivity and specificity of biomarkers such as APRI. To fully integrate 
all the information a systematic approach is needed. The Gkwnomix™ platform aims to 
combine all the relevant information to facilitate the prevention of cumulative risk based 
on disease subtyping to identify pathways for targeted treatment. The clinical, lifestyle 
and biochemical information could be captured in a database that could be used for 
future studies.  
Even though these findings are very promising, its potential application for disease 
prevention and improved clinical management of NAFLD remains to be investigated in 
the diverse South African population. More research is needed in African Black 
populations to develop an appropriate intervention strategy, since ethnicity influence the 
prevalence of NAFLD the disease outcome may differ within this ethnic group. As 
obesity and diabetes mellitus type 2 is becoming more prevalent in South African 
children, it is important to extend this study to children with or at risk of NAFLD as well.  
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While the potential impact of an increasing genotype risk score and allelic combinations 
were assessed on disease progression from obese, NAFLD (types 1, 2) and NASH 
(types 3,4) after adjustment for several variables, development of a model that evaluates 
the cumulative effect of allelic variation in the presence and absence of known 
environmental risk factors such as smoking, alcohol consumption and physical activity 
resided outside the scope of this study. Further studies are therefore warranted to 
include an increasing number of clinically useful SNPs for evaluation as well as 
modifiable environmental risk factors to develop a genotype “activity” score or weighted 
score for more accurate prediction of phenotypic expression. Use of a pathway-based 
approach to analyse the influence of modifiable environmental risk factors in the 
presence of low-penetrance genetic risk factors implicated in insulin resistance as a 
central feature of NAFLD, may eventually enable the development of a risk assessment 
model incorporating multiple variables that collectively are sufficient to cause 
biochemical and metabolic abnormalities underlying disease progression from NAFLD 
(types 1, 2) to NASH. 
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